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THE CERVICITIS STUDY- INTRODUCTION & ACKNOWLEDGEMENTS 
 
The Cervicitis Study upon which this thesis is based, is an original clinical study designed and 
implemented by myself (Chief Investigator) and co-investigator and PhD co-supervisor, Dr 
Pam Konecny. It is the only study of cervicitis in Australian women. 
The idea for the study arose in early 2006 at the Short Street Centre on-site laboratory as Dr 
Konecny and I were discussing the microscope slide of cervicitis in front of us. What was the 
significance of this finding? What should I do about it in relation to my patient? These were 
questions that had troubled me since my early microscopy work in sexual health medicine. A 
quick review of the literature at the time revealed that these were questions commonly 
asked with little consensus to the answers. 
Plans for the Cervicitis Study slowly took shape with a comprehensive literature review and 
discussion with a potential collaborator, Professor William Rawlinson at the Virology 
Research Division, SEALS Laboratory, Prince of Wales Hospital. Together we proposed a 
study utilizing the findings of routine clinical practice and additional use of multiplex PCR 
tests for genitor-urinary infections, in particular the herpes viruses and the mollicutes, 
including Mycoplasma genitalium (MG), that SEALS laboratory was interested in developing 
as in-house tests. As a novice investigator and unpublished clinician, I was not successful at 
attracting NHMRC funding or St George Hospital Research funding for this project, but was 
fortunate enough to be awarded a one-off Novartis-sponsored Sexual Health College 
Scholarship in 2006. 
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My thanks to key collaborators for providing invaluable input to the study design, 
implementation and analysis, in particular Dr Pam Konecny (co-supervisor and colleague) 
who has been a tireless enthusiast, mentor and co-writer with me throughout the study, 
Professor Bob Cumming (supervisor and epidemiologist, University of Sydney) for his 
essential input to the study planning and guidance on the papers and thesis, Frances Garden 
(statistician), the generosity and expertise of Professor William Rawlinson’s Virology 
Research Division (including scientists Christopher McIver, Nicholas Rismanto and Zin Naing) 
at SEALS Laboratory, Prince of Wales Hospital and to William Pauuwe for his expert 
computing and personal support throughout this project. 
Central to the project’s success was the support of the Sexual Health Clinics where I was 
employed as a Registrar and then Staff Specialist during the four-year recruitment period, in 
particular the clinical staff of Short Street Centre at St George Hospital, where most 
recruitment occurred. By funding necessity the Cervicitis Study utilized a sample of women 
already attending the Sexual Health clinics, with minimal deviation in the most part from 
routine clinical practice. This facilitated recruitment and staff involvement. During the 
recruitment period I was posted for 2 years to RPA and Liverpool Sexual Health Clinics, 
initially as a Registrar and then Staff Specialist where recruitment started after Ethics 
Approval, and recruitment continued at the Short Street Service under the supervision of Dr 
Konecny and myself. Recruitment at these other clinics was hampered by the time 
constraints of ethical approval and lesser support for the project.  
Acknowledgement and thanks to the Sydney HIV/AIDS and Related Programme Units (HARP 
Units) and New South Wales Health who are the financial sponsors of this wonderful 
7 
 
network of publically-funded Sexual Health clinical services where this opportunistic 
research occurred.  
Special thanks must also go to the staff and patients of the Short Street clinic, in particular 
Nurse Unit Manager Suzy Wilds, previous Director Dr Chris Carmody, Drs Ruby Uddin and 
Judith Gardiner, nurses Jeanette Ball, Sara Hristov, Wendy Jarrett, Robyn Dever and 
receptionist Helen Rayner who welcomed participants and provided invaluable clerical 
support. Christa McPherson (Scientist, SEALS laboratory, St George Hospital) provided 
quality control on Gram stain slides from all study sites. 
Kevin McGeechan from the University Of Sydney School Of Public Health initially provided 
statistical support for the study, but from 2009 onwards I hired Frances Garden, PhD 
candidate at the University of Sydney, who has provided expert, patient and always timely 
assistance and quality control for my statistical workings with SAS over the project. 
Recruitment for the Cervicitis Study started in July 2006 and completed in February 
2010.The first paper related to the study was published in 2008, Cervicitis: A Review. This 
paper was commissioned for a special STI and AIDS Edition in Current Opinion in Infectious 
diseases. It was my first publication. 
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THESIS STRUCTURE 
This thesis is based on the original clinical study called the Cervicitis Study, of which I was 
the Chief Investigator. 
The Cervicitis Study was a multi-site cross-sectional study of 558 women attending Sexually 
Transmitted Infection (STI) services in Sydney between 2006 and 2010. The thesis is of 
hybrid structure containing 8 chapters plus an Appendix. Three chapters (1,3 &7) contain 
original papers as published in peer-reviewed journals and chapter 4 a pre-publication paper 
(with published version in Appendix). Chapter 6 includes a paper submitted for publication 
currently at ‘under review’ status and chapter 7 contains a draft manuscript in preparation 
for submission for publication.  
The first chapter is in two sections. It contains a literature review written as the Cervicitis 
Study was being planned which was published in early 2008 and a more up to date review of 
literature concerning cervicitis and related matters from 2008-2014. 
Chapter 2 outlines the methods of the Cervicitis Study. Details of the scientific methods are 
contained in the Appendix in the methods paper of McIver et al. I was 6th author on the 
methods paper but made a substantial contribution to it. 
Chapter 3 contains the first paper from interim findings in the Cervicitis Study, which 
discusses the epidemiology of Trichomonas vaginalis and diagnostic considerations. 
Chapter 4 contains the original mollicute paper, again with late interim findings from the 
Cervicitis Study which was abridged to a Short Report format for publication in Sexually 
Transmitted Infections (the published Short Report is included in the Appendix). The initial 
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full paper is included in the thesis for its valuable examination of the mollicute organisms 
and their association with the conditions of cervicitis and bacterial vaginitis. 
 Chapters 5 and 6 contain the final papers of the cervicitis study, using data from the fully 
recruited study of 558 women. These papers address the main study aims. The paper from 
Chapter 5 has been submitted for publication to the peer-reviewed journal Obstetrics and 
Gynecology and the paper from chapter 6 is a draft manuscript in preparation for 
submission for publication.  
Chapter 7 presents a paper related to the Cervicitis Study, published in 2013 which outlines 
the changing epidemiology of heterosexual Neisseria gonorrhoea (NG) noted at our clinical 
service. It is of relevance to help explain the very low rates of NG found during the Cervicitis 
Study and includes a discussion of the overlooked pharyngeal reservoir of this infection in 
women. During study recruitment, rates of cervical NG were very low (prevalence of 1.1%). 
Although in keeping with low rates of heterosexual NG in Sydney during this period, we 
noted a trend of increasing NG rates and reports of increasing acquisition through oral-
genital contact. As these trends occurred around the time of the cervicitis study using the 
same clinic population, the inclusion of the NG study is relevant to offer a wider 
epidemiological understanding on NG in women in this population at this time.  
Chapter 8 is a concluding discussion and includes a guideline for the management of 
cervicitis based on the findings of this study in the context of my literature reviews. 
The appendix has three parts and includes conference and meeting abstracts from the 
Cervicitis Study, participant approach, information and consent forms and finally, copies of 
the five published papers as they appear in journals.  
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THESIS ABSTRACT 
Background 
There is much to clarify about cervicitis including its etiology, significance and optimal 
management. Current management guidelines are inconsistent in their recommendations 
for affected women and their partners, reflecting lack of clarity concerning the etiology and 
best-case definition for cervicitis. The commonly used microscopic Gram stain diagnosis for 
cervicitis of > 30 polymorphonuclear leucocytes/ high-powered field (>30 pmnl/hpf) has 
little practical application in many clinical settings and cervicitis diagnoses based on clinical 
assessments such as ‘mucopurulent discharge’ or ‘yellow discharge’ may have wider utility.  
 
Study Aims 
With a cross-sectional study, explore infectious and non-infectious associations of cervicitis 
using different cervicitis case definitions to determine key etiological exposures and the 
cervicitis definition with best clinical utility. 
With a prospective observational sub-study, assess the effect of presumptive treatment 
with azithromycin 1 G PO of women with cervicitis and non-specific cervicitis (NSC) on the 
outcomes of cervicitis persistence or genital symptoms and to assess benefit on cervicitis 
persistence of additional presumptive male partner treatment with azithromycin 1 G PO. 
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Methods 
558 consecutive consenting women attending three publically-funded STD and HIV services 
in Sydney were enrolled in a cross-sectional study between 2006 and 2010. Infectious and 
non-infectious associations of cervicitis were examined using the cervicitis definition >30 
pmnl/ hpf on cervical Gram stain and these associations were assessed using other 
commonly used cervicitis case definitions (yellow discharge, mucopurulent discharge (MCP). 
Women underwent testing for multiple infections including Chlamydia trachomatis (CT), 
Neisseria gonorrhoea (NG), Mycoplasma genitalium (MG), Mycoplasma hominis (MH), 
Ureaplasma urealyticum (UU), Ureaplasma parvum (UP), HSV1, HSV2, EBV, VZV, CMV, HPV 
and Trichomonas vaginalis (TV). Data was collected from clinical record sheets modified for 
the study, on presence of any genital symptoms and potential non-infectious etiological 
exposures including age group, current smoking, commercial sex work (CSW) and douching 
status, extent of condom use (always/sometimes/never) and number of sexual partners (1, 
>1) in the last three months, timing of last intercourse (</>1 week ago), current use of 
combined oral contraceptive (COC), injectable depo-medroxyprogesterone acetate (DMPA) 
/Progestagen only pill (POP) or Implanon, phase of menstrual cycle (follicular/luteal) and 
stated history of past chlamydia infection and abnormal Pap smear in the preceding two 
years. 
In the treatment sub-study, women diagnosed with cervicitis (definition>30 pmnl/hpf) were 
offered presumptive treatment with azithromycin 1 G PO. For this analysis cervicitis was 
defined as >30 pmnl/hpf on cervical Gram stain with or without known pathogens. NSC was 
defined as the subset of women with >30 pmnl/hpf in the absence of CT, NG, MG or TV. 
Treatment outcomes at follow-up included persistence of cervicitis (>30 pmnl/hpf) or 
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presence of any genital symptoms. Women who tested positive at follow-up for CT, MG, NG 
or TV (incident or persistent infections) were excluded from this analysis. 
Male partners of women with cervicitis were also offered presumptive treatment with 1 G 
azithromycin and study testing.  
 
Results 
Cervicitis defined as >30 pmnl/hpf was present in 268/558 (48.0%), yellow discharge in 
129/540 (23.9%), mucopurulent discharge (MCP) in 102/540 (18.9%) and ectropion (visibility 
of the cervical squamo-columnar junction) in 162/530 (30.6%).  
Prevalence of pathogens at initial enrolment was: CT 5.8% (95%CI 3.8-7.7%), NG 1.1% (95% 
CI 0.2-1.9%), MG 3.8% (95% CI 2.2-5.4%) and TV 3.9% (95% CI 2.2-5.5%). Any genital 
symptoms were present in 59.9%. Cervicitis was strongly associated with the any genital 
symptoms (RR 1.58 (95% CI 1.40-1.78) p<0.0001). 
Interim study papers found PCR testing for TV to be four to five times more effective in 
detecting TV than traditional methods of detection and TV was more common in women of 
culturally and linguistically diverse (CALD) background (p=0.003). MG was found to be 
significantly associated with women being HIV positive (P=0.033) but not with age, vaginal 
discharge, commercial sex work, being of culturally and linguistically diverse background or 
concurrent chlamydia infection. 
CT, MG and TV were significantly associated with increased cervicitis risk on multivariate 
analysis, the strongest associations with the cervicitis definition MCP: CT adjusted Relative 
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Risk (ARR) =2.61 (95% CI 1.57-4.35) p=0.0002, MG ARR =2.25 (95% CI 1.12-4.54) p=0.003, TV 
ARR=2.86 (95% CI 1.61-5.09) p=0.0003. NG (RR=3.66 (95% CI 2.02-6.62) p<0.0001), CMV, 
HPV and HIV increased cervicitis risk on univariate analysis only. Condom use was associated 
with reduced cervicitis risk in univariate analysis and in multivariate analysis by the yellow 
discharge definition (ARR=0.68 (95% CI 0.50-0.92) p=0.013). Positive predictive values (PPV) 
and specificities for significant pathogens were consistently higher for cervicitis ‘tests’ 
yellow discharge and MCP. Exposures not associated with cervicitis included bacterial 
vaginosis, HSV1, HSV2, EBV, candida, Ureaplasma urealyticum, age, smoking, past chlamydia 
infection and hormonal contraceptive & cycle phase. 
Population Attributable Risk% (PAR%) of significant pathogens in the etiology of cervicitis, 
assuming causative effects were as follows: CT 8.5%, NG 3.6%, MG 4.5%, TV 6.7%, yielding a 
total PAR% of the four significant pathogens of only 23.4% in the etiology of cervicitis. 
Presumptive treatment of women with azithromycin 1 G orally showed a non-significant 
reduction in cervicitis persistence in women with cervicitis, RR=0.74 (95% CI 0.46-1.21) 
p=0.235 and in women with NSC, RR=0.60 (95% CI 0.35-1.02) P=0.058. Presumptive 
treatment was associated with a non-significant reduction of symptoms in women with 
cervicitis, RR=0.67 (95% CI 0.44-1.01) p=0.054 and in women with NSC, RR=0.91 (95% CI 
0.46-1.79) p=0.780. Addition of presumptive partner treatment did not reduce cervicitis 
persistence in women with cervicitis, RR=1.18 (95% CI 0.70-2.00) p=0.528 or those with NSC, 
RR= 1.02 (95% CI 0.54-1.90) p=0.961. 
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Conclusions 
There is significantly increased cervicitis risk with CT, MG, NG and TV, however much 
cervicitis remains unexplained. Condom use reduces cervicitis risk. The cervicitis case 
definitions of yellow discharge or mucopurulent discharge have the highest clinical utility 
with consistently higher associations, PPVs and specificities for significant pathogens and 
are more practical than the microscopy definition >30 pmnl/hpf.  
Although we found presumptive azithromycin treatment was associated with a 30% to 40% 
reduction in cervicitis persistence in women with NSC and reduction of symptoms for 
women with cervicitis, these effects did not reach statistical significance. A larger RCT study 
may show more conclusive results. If azithromycin treatment of women with cervicitis and 
NSC is associated with a reduction of the outcomes assessed, our results suggest it is not a 
large effect.  
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CERVICITIS STUDY-AIMS 
Review of the literature when the study started in 2006 revealed that there was still much 
to clarify about the etiology, definition, significance of and best clinical management of 
women with cervicitis. This study was designed to clarify the epidemiology of cervicitis in STI 
clinic populations in Sydney, and provide a clearer picture of the factors associated with 
cervicitis, best case definition and a practical guideline for clinicians on how to manage the 
condition. 
 
STUDY AIMS 
1. With a large multi-site cross-sectional study of women presenting to Sexual Health 
Services, explore infectious and non-infectious exposures putatively associated with 
cervicitis, using the commonly accepted working cervicitis case definition of  >30 
polymorphonuclear leucocytes /high powered field (pmnl/hpf) on cervical Gram stain and 
compare these associations using other commonly used cervicitis case definitions (yellow 
discharge, mucopurulent discharge and ectropion), to determine the cervicitis definition 
with best clinical utility. 
 
2. With a prospective observational sub-study assess the effect of presumptive treatment 
with azithromycin 1 G PO of women with cervicitis (30 pmnl/hpf) and non-specific cervicitis 
(NSC) (women with CT, NG, MG and TV excluded), on the outcomes of cervicitis persistence 
or genital symptoms and to assess benefit on cervicitis persistence of additional 
presumptive male partner treatment with azithromycin 1 G PO. 
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CHAPTER 1 
Literature reviews 
1. Cervicitis: A review  
As published in Current Opinion in Infectious Diseases 2008; 21:49-55. 
 
 
2. Literature review update: 2008-2014-update 
 
 
 
 
 
 
 
24 
 
1. Cervicitis – A Review 
M. Josephine Lusk and Pam Konecny      
Current Opinion in Infectious Diseases 2008; 21:49-55. 
 
ABSTRACT 
Purpose of Review 
Sexually transmitted infections (STIs) impact significantly on global health. Whilst 
Chlamydia, N.gonorrhoea and syphilis have been extensively examined, there remains a 
paucity of knowledge of non-chlamydial and non-gonococcal cervicitis, prevalent but poorly 
characterized condition, with uncertain clinical implications. With increasing application of 
molecular diagnostic methods for the detection of STIs and a growing body of literature on 
cervicitis, a cervicitis review is timely.  
Recent findings 
The number of putative aetiological agents implicated in cervicitis is growing and includes 
Mycoplasma genitalium, Herpes Simplex Virus, Cytomegalovirus, bacterial vaginosis and 
Trichomonas. The potential role of cervicitis in HIV transmission has been highlighted. 
Increasing broad-spectrum antibiotic usage with associated emergence of antimicrobial 
resistance reinforces the need for targeted antibiotic therapies, including cervicitis 
management. 
Summary 
As our understanding of the etiology and significance of cervicitis, particularly non-specific 
cervicitis (NSC) improves, management will be refined. Advances in molecular diagnostic 
testing will facilitate this process but urinary nucleic acid amplification testing (NAAT) should 
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not replace clinical examination while cervicitis prevalence and significance is not yet 
established. A standardized approach to cervicitis research, particularly with consensus of 
case definition, may facilitate outcomes that can be more generally applied in clinical 
practice.  
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INTRODUCTION 
Cervicitis was first recognized as an important clinical entity in 1984 by Brunham [1]. Since 
then much controversy has existed. Interpretation and comparison of published studies is 
hampered by the lack of consensus in the case definition, variability in populations sampled 
and methods used for pathogen detection [2**]. Advances in molecular diagnostics have 
created an opportunity to further clarify cervicitis.  However, while there is an 
understandable desire for rapid, sensitive, potentially clinician-independent testing for 
Chlamydia and gonorrhoea, supplanting speculum-guided cervical specimens with urinary 
nucleic acid amplification technique (NAAT) testing in asymptomatic women attending STI 
clinics [3] may result in lost opportunity for detecting cervicitis before its implications are 
fully realized. It is thus timely to review cervicitis. An extensive literature search was 
conducted using MEDLINE, Embase and Cochrane Library on the topics of cervicitis, 
reproductive health and STIs.  
BACKGROUND 
Cervicitis is a frequently asymptomatic, inflammatory condition of the cervix [4]. It is 
common with rates as high as 30%-45% in some STI clinic populations [1,2,5] and is 
generally considered to be associated with sexually transmissible pathogens. [1,2**4,6,7*]. 
However, Chlamydia and N.gonorrhoea account for less than half of cervicitis cases, with a 
largely undefined aetiology in the remainder [1,2**,8,9], referred to as ‘non-chlamydial, 
non-gonococcal cervicitis’ or non-specific cervicitis (NSC). The clinical significance of the 
finding of NSC, especially in asymptomatic ‘low risk’ women, has been debated [8, 9, 10]. 
Other organisms variably implicated in the pathogenesis of NSC, include Mycoplasma 
genitalium (MG), Mycoplasma hominis (MH), Ureaplasma urealyticum (UU), bacterial 
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vaginosis (BV), herpes simplex virus (HSV), Cytomegalovirus (CMV), Trichomonas vaginalis 
and Adenovirus. This raises concerns about the appropriateness of empirical treatments 
currently used to treat women with cervicitis and their sexual partner(s). Importantly, 
Bradshaw and colleagues [11**], in a recent Australian study of non-specific urethritis 
(NSU), the analogous clinical condition in men, highlighted the role of Adenovirus, HSV-1, 
macrolide-resistant Mycoplasma species and oral sex in NSU, factors yet to be fully 
characterised in NSC.  A lack of consensus on definitive treatments for cervicitis in STI 
Treatment Guidelines [12, 13], reflect these uncertainties with the potential for over-use of 
antibiotics. Furthermore, the psychological impact of empirically treating cervicitis as an STI 
has recently being examined [14*].  
Significance of cervicitis 
Complications of cervicitis include endometritis, pelvic inflammatory disease (PID) and 
adverse outcomes of pregnancy and the newborn. The synergy between genital infection 
and enhancement of HIV transmission is well recognised. There is also literature implicating 
cervical inflammation in the pathogenesis of cervical cancer. 
PID 
Cervicitis may serve as an important marker of subclinical PID. Mucopurulent cervicitis and 
endometritis may be the only signs of PID in some women [4,9,10,15].  Many women with 
tubal factor infertility, ectopic pregnancy or chronic pelvic pain do not give a history of PID, 
but subclinical PID is likely to be an important contributing factor [16,17*]. The reported risk 
of women with lower genital tract infection developing PID ranges from 20-80% depending 
on method used for detection, delay in diagnosis, treatment, co-infection and other host 
factors [reviewed in 17*]. Peipert and colleagues’ analysis of women with pelvic pain in the 
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PEACH study (PID Evaluation and Clinical Health Study) found lower genital tract 
leukorrhoea (>10 leucocytes per high-powered field on microscopic examination of vaginal 
fluid) had a high sensitivity (89%) but low specificity (19%) for predicting histologically 
proven endometritis [18]. Other researchers have confirmed the high PPV of leukorrhoea 
for PID in the high-risk STI settings [19], particularly in the setting of BV [20].  Thus, vaginal 
leucorrhoea may be a useful adjunctive tool in the diagnosis of upper genital tract infection.   
Whilst there is disparate literature concerning chlamydial and gonococcal contribution to 
PID, even less is known about the relationship of NSC to upper genital tract infection.  This is 
an important consideration when 20-30% cases of NSC are refractory to empiric ‘cervicitis’ 
treatment [9]. Furthermore, a recent novel study modelling different management 
algorithms for cervicitis in a hypothetical teen clinic population has emphasised the 
important psychological ramifications associated with diagnosis and empiric treatment of 
cervicitis for women and their partners, verses the PID-prevention benefits where there is a 
low prevalence of Chlamydia [14*].  
Pregnancy 
Chlamydia infection has been associated with a doubling of ectopic pregnancy rates in a 
Norwegian study [21] and while an association of chlamydial infection with pre-term 
delivery is suggested, its role is not yet fully elucidated [17]. Nugent and Hillier’s analysis 
[10] of a large cohort of high-risk pregnant women found that cervicitis was significantly 
associated with the delivery of low birth weight babies (adjusted RR 2.11, 95%CI 1.10-4.04). 
This was despite a low sensitivity (25%) and low PPV (24%) for Chlamydia infection, 
implicating NSC. A recent Chilean study [22] examining the benefit of antibiotic 
administration to women with preterm labor, found that whilst there was no overall benefit 
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on composite neonatal morbidity/mortality outcome, a subgroup of women with NSC 
without amniotic fluid infection and intact membranes derived benefit from antibiotic 
administration with significantly lower frequency of neonatal morbidity and mortality. This 
finding suggests that cervicitis may be a useful clinical marker for women at risk who might 
benefit from antibiotic intervention.  
HIV transmission 
Cervicitis is thought to play an important role in the transmission of HIV infection, by 
increasing susceptibility to HIV infection and increased HIV viral shedding. The association of 
genital ulceration, particularly HSV-related, with increased risk of HIV transmission risk is 
well recognised [23].  A significant correlation between cervical HIV DNA and microscopic 
evidence of cervical inflammation (adjusted OR 8.7) has been demonstrated [24]. 
Mechanisms by which cervicitis may increase HIV-1 shedding include increased viral 
replication in the context of infection or inflammation particularly in the presence of 
elevated pro-inflammatory cytokines, disruption of normal mucosa and increased numbers 
of HIV-infected cells in cervical secretions. Effective treatment of chlamydial or gonococcal 
cervicitis correlated with a greater than six-fold decrease in cervical HIV-1 RNA and with 
normalisation of cervical polymorphonuclear counts, but no reduction in HIV-1 infected cells 
as measured by presence or absence of HIV-1 proviral DNA in one study [25]. Conversely 
and somewhat perplexingly, in the same study, treatment of NSC in these women did not 
significantly reduce HIV-1 viral shedding but did significantly reduce the number of HIV-1 
infected cells.  These data raise intriguing questions about the relationship between HIV-1 
infected cells HIV-1 gene expression and thus HIV transmission risk in different causes of 
cervicitis.  
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Endometritis in HIV-1 positive Kenyan women was associated with a 15-fold increase in HIV 
viral shedding (95% CI 2-120) which is concerning as asymptomatic endometritis may be 
more common in HIV positive women. [26*]. Thus implementation of effective STI 
screening, management and prevention strategies could significantly impact on HIV 
transmission, particularly in resource poor settings.  
HPV and Cervical cancer 
Chronic inflammation has been linked to many epithelial cancers, and thus the role of 
chronic cervicitis as a cofactor in cervical cancer seems plausible [27]. HPV, predominantly 
types 16 and 18, is required for the development of the majority of cervical carcinomas [28]. 
The role of HPV in cervicitis is less clear. Studies have noted a positive association between 
measures of cervical inflammation and squamous intraepithelial lesions (SIL) [28, 29]. A case 
control study of Costa Rican women found that in women infected with oncogenic HPV 
types, the likelihood of developing high grade SIL increased with degree of cervical 
inflammation [29].  Chlamydia, HSV, Trichomonas, bacterial vaginosis and CMV-associated 
cervical inflammation have been reported as potential cofactors in development of cervical 
carcinoma in past predominantly sero-epidemiological based studies. Recent, more 
convincing evidence for a causal link of any of these pathogens is lacking.  Ureaplasma 
urealyticum has been suggested as a possible co-factor in the development of abnormal 
cervical cytology in the presence of HPV [30*]. 
Case Definition of Cervicitis 
The case definition of cervicitis varies widely and is considered by many a clinical diagnosis 
evidenced by cervical ectopy (extension of the columnar epithelium of the endocervix onto 
the visible ectocervix), a ‘friable cervix’, presence of ‘mucopurulent’ or yellow discharge or a 
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combination of these signs. However overt signs of cervicitis may be overlooked given the 
variance in signs considered indicative of cervicitis. The presence of a yellow discharge, 
indicating neutrophil production of myeloperoxidase, has been suggested as a good 
predictor of Chlamydia or N.gonorrhoea infection [1, 4, 15]. However a recent evaluation of 
syndromic management using signs and symptoms of vaginal discharge in women in an 
antenatal setting in Botswana, failed to satisfactorily identify women with Chlamydia or 
gonorrhoea infection [31**]. 
Another approach adopted by clinicians is microscopic analysis of mucous taken from the 
endocervical canal.  Leukocytes are normally present throughout the reproductive tract 
including cervical tissue [32] but are considered pathological when present in high numbers 
(usually >30/high-powered field) [1, 4]. Polymorph assessment of cervical mucous is not 
affected by the phase of the menstrual cycle except for during menstruation when it 
becomes less reliable [1]. The microscopic diagnosis of cervicitis is determined by Gram 
stain of the number of polymorphonuclear leucocytes per high-powered field (PMNL/hpf 
(x1000, oil immersion)) in cervical mucous using different cutoff thresholds, usually >30 
PMNL/hpf [4, 5, 8, 10, 25] but often >10 pmnl/hpf [1, 4, 32].  The validity of each cut off has 
been reviewed [2**, 9] Consensus in the literature appears to favour the former, which has 
greater specificity at the expense of reduced sensitivity.  
The availability of microscopy to facilitate cervicitis diagnosis will be impacted in resource-
poor clinical settings. Microscopy may be open to intra-observer variability and error with 
vaginal epithelial cell contamination of cervical samples and counting polymorphs outside of 
cervical mucous. Studies reporting low positive predictive value (PPV) of microscopic 
cervicitis in detection of Chlamydia and N.gonorrhoea in low STI prevalence settings [8, 10] 
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are based on ability to predict Chlamydia infection detected by culture laboratory methods. 
The PPV of cervical findings could be considerably improved with the use of NAAT methods 
of Chlamydia detection. Additionally, PPVs are often given in terms of Chlamydia and 
N.gonorrhoea detection only and do not consider the increasing array of recently described 
pathogens, such as Mycoplasma spp.  
Therefore, it would seem prudent to diagnose cervicitis using a combination of microscopy 
(>30pmnl/hpf) and at least one of the abovementioned clinical signs. Using these diagnostic 
criteria for cervicitis may improve the PPV for detecting disease. 
Non-infectious Etiology 
It has been suggested that mucopurulent discharge could be caused by exposure of the 
cervical columnar epithelium to non-infectious factors in the vagina, such as smoking, 
douching and combined oral contraception (COC). Earlier large prospective studies found a 
significant association with COC use: Paavonen’s adjusted OR 2.5 (p=0.02) [33] and Castle 
and Hillier’s OR 2.9, (95%CI 1.4-5.9) [29].  Interestingly, however, authors of a subsequent 
large cross sectional study found no such association after adjusting for the presence of 
cervical ectopy [34].  
There is conflicting literature concerning the association between vaginal douching and 
cervicitis, endometritis and PID.  PID was found to be significantly associated with current, 
frequent douching in a formative Seattle study [35]. A similar association with cervical 
Chlamydia infection and douching was observed in a separate large cross sectional study 
[36]. However, in contradiction, no association between douching and gonococcal or 
Chlamydia cervicitis or PID was found recently in a large prospective observational study of 
predominantly African-American women who commonly douche [37]. 
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Although smoking had been previously linked to an increased risk of PID, no link between 
smoking and cervicitis, dysplasia or Chlamydia infection was found, after adjustment for 
confounders, in a UK cross sectional study [38].   
Infectious Etiology 
Of the known infectious agents of cervicitis, Chlamydia and gonorrhoea have been the most 
widely studied. 
Chlamydia trachomatis and Neisseria gonorrhoea 
Chlamydia is the most frequently identified cause of cervicitis with rates of Chlamydia in 
women with cervicitis varying widely in the literature from 11-50% [1,6,17,33] depending on 
population sampled, cervicitis definition and detection methods. However only 10-20% of 
Chlamydia infections may be associated with obvious clinical signs of cervicitis [6]. This may 
be explained in part by infections with a lower quantity of infectious organisms and strain 
variability, including ‘non-fusing variants’ of Chlamydia (about 1.5% of isolates) [39].  
Increasing application of NAAT testing for Chlamydia has resulted in enhanced ability to  
detect this pathogen, but this does not completely account for the concerning continued 
increase in Chlamydia infection [17*].  
Whilst N.gonorrhoea (NG) is known to cause cervicitis, the proportion of cervicitis 
attributable to NG is highly variable, in keeping with the markedly different prevalence of 
NG in different populations.  
Mycoplasma genitalium 
There is strong support for the role of Mycoplasma genitalium (MG) in the aetiology of 
cervicitis [5,40,41,42*,43], endometritis [43,44], PID [42*,45**], genital tract disease in men 
[11**,42*] and more recently in tubal factor infertility [46]. However a recent serological 
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study found a trend but not a significant association of MG with PID and ectopic pregnancy 
[47*]. The organism fulfils Koch’s postulates for pathogenicity and the balance of current 
evidence supports the use of antibiotics if MG is detected [11, 12, 42*, 48**]. A recent 
Danish prevalence study found the likelihood of MG infection in women was associated with 
increasing numbers of recent sexual partners and partners with symptoms [48**]. However, 
the low MG prevalence of 2.3% could not justify routine screening. Similar low prevalence 
rates of MG in asymptomatic women are reported, 6% in a Swedish study [40] and 7% in US 
STD clinic population study [5], where in the latter, MG infection conferred a three-fold 
greater risk of cervicitis. A recent large British study of antenatal women found a prevalence 
of only 0.7% and suggested that MG is not a risk factor for adverse pregnancy outcome in 
healthy women [49]. A higher prevalence of 6.2% in pregnant women in Guinea-Bissau was 
significantly associated with HIV-1 infection but not with adverse pregnancy outcomes [50]. 
Importantly, prevalence rates of MG in symptomatic and high-risk populations appear 
considerably higher, 13-25% [41, 44, 51, 52].  
Mycoplasma hominis  
Mycoplasma hominis (MH) is commonly found in the genital tract of sexually experienced 
females and a role in PID and post-abortal fever [45**] has been suggested. Reports of the 
prevalence of MH in women with cervicitis vary widely between 2.3% in Turkish study and 
26% in a small Wisconsin College population [41].  Nugent and Hillier found MH to be 
significantly associated with cervicitis (RR 2.96 95% CI 1.76-4.99) in a study of high-risk 
pregnant women [10]. It is suggested that MH may exist symbiotically with the mixed 
bacteria of bacterial vaginosis (BV) [45**, 53]. MH serum antibody titres and vaginal 
leucorrhoea have been found to be higher in women with BV, than women without BV [53]. 
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It is difficult to determine the pathogenic role of MH given its frequent association with BV 
[45**].  
Bacterial vaginosis  
Bacterial vaginosis (BV) is found in up to 50% of women with cervicitis [33], and may play a 
role in the etiology [7*, 33, 54].  The association of BV with endometritis, PID and adverse 
pregnancy outcome is increasingly accepted [16, 45**, 55]. Even where a significant 
association between PID and BV was not found, in a large observational cohort of African-
American women, BV was suggested as a marker for women at high risk of PID [56]. The 
authors found that in women with BV, the presence of Chlamydia or N .gonorrhoea was 
associated with a three-fold risk of PID. The strongest risk for PID in the presence of BV was 
carriage of pigmented, anaerobic Gram-negative rods (Porphyromonas, Prevotella, 
Bacteroides). Schwebke’s study found an association between BV and cervicitis and 
between use of metronidazole gel and resolution of cervicitis [54]. A reduction in pro-
inflammatory vaginal cytokines with treatment of BV has been noted in one recent RCT 
involving pregnant women suggesting that BV is associated with inflammatory changes at 
the cervix [57]. Marrazzo’s group investigating risk factors for cervicitis in women with BV 
identified older age, new male or female partner, recent oral sex and absence of H2O2-
producing lactobacilli [7]. The loss of H2O2-producing lactobacilli in conjunction with 
increase in sialidases and glycosidases produced in BV may break down the protective 
cervical mucus barrier [58]. In keeping with this literature, the CDC guidelines recommend 
that BV be treated if found in the presence of cervicitis [12].  
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Ureaplasma urealyticum 
 Ureaplasma urealyticum (UU) is commonly found in the genital tracts of symptomatic and 
asymptomatic men and women, associated with lifetime number of sexual partners. UU is 
suggested as a pathogen associated with cervicitis with OR 2.7, P<0.0133 in study [33], 
adverse pregnancy outcome [45**, 59] and postpartum sepsis [45**]. However there is 
little evidence of its role in PID [45**].  
HSV, CMV and Adenovirus 
HSV-1 and HSV–2 have been associated with cervicitis [4, 6,34]. Cervical HSV shedding is 
thought to be generally asymptomatic. Several studies suggest an association between 
cytomegalovirus (CMV) and cervicitis [6, 34, 60, 61]. CMV accounted for 7.6% of cases of 
cervicitis in one large cross sectional study [34]. Another study of cervical biopsies of HPV-
associated cervical neoplasia identified CMV DNA in 8.7% of specimens [61]. CMV shedding 
has also been found to be significantly greater in HIV-positive than HIV-negative women 
[62].  The development of molecular diagnostic techniques, particularly multiplex 
polymerase chain reaction (mPCRs) will aid in the detection of these viruses, which are also 
associated with significant congenital infection [63]. Adenovirus has been implicated in NGU 
in males [11**], and it is thought to have a role in cervicitis [64] but it is not well defined and 
an area of potential interest. 
Trichomonas & Candidiasis 
Trichomonas is associated with cervical inflammation [2,33,65*,66*] and  increased risk of 
HIV transmission [65]. Its reported contribution to the aetiology of cervicitis is highly 
variable reflecting local prevalence, and it is considered to be frequently under-diagnosed 
due to the relatively low sensitivity of wet-mount microscopy. New methods for 
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Trichomonas detection, specifically NAAT testing and the new rapid ‘Point-of-Care’ (POC) 
bedside immunochromographic tests could help clarify local prevalences [66*]. Very little is 
published on cervicitis and yeast, but a negative association with cervicitis has been 
suggested [33]. 
Management of cervicitis 
In Australasia, standard empiric treatment for cervicitis is azithromycin for affected women 
and their sexual partners [13]. As the local heterosexual prevalence of gonorrhoea is very 
low [3], concurrent treatment for gonorrhoea is not routinely given empirically. 
Azithromycin failure in 28% of men with MG-related urethritis has been reported and 
occurred more frequently when the MG originated from South East Asia, where there is 
emerging macrolide resistance [11**,67**]. This has important treatment implications 
when MG is associated with cervicitis.  There are reports of improved clearance rates of MG 
with extended courses of azithromycin and moxifloxacin [42, 67**].  . 
Persistent cervicitis, despite ‘standard’ empirical treatment is not infrequently encountered 
(personal observation) and reported by others [6, 8, 12]. The natural history of cervicitis is 
not defined, nor is the benefit of further treatment for unresponsive cases and their 
partners. Most STI guidelines suggest gynaecological review to exclude underlying pathology 
such as malignancy or the consideration of chemical irritant or idiopathic causes. Ablative 
therapy of the cervix has been used to treat chronic cervicitis [68], but there is a paucity of 
literature concerning the rationale and effectiveness of this intervention, which presumably 
relates to the association between ectopy and cervicitis. Returning to the concept that 
cervicitis may be an indicator of silent PID, STI guidelines could perhaps give consideration 
to recommending PID treatments for persistent cases of cervicitis. The management of PID 
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has recently been reviewed and emphasis placed on achieving high rates of clinical as well 
as microbiological cures [69].  
CONCLUSION 
In conclusion, cervicitis remains a condition yet to be fully characterised. It is common, often 
asymptomatic and may be associated with significant adverse outcomes for women. 
Research in NSC is a particular area of need.  Wide variations of case definition, study 
populations and methods for pathogen isolation, hinder the ability to draw conclusions on 
the aetiology, natural history and best management of cervicitis on a population basis. 
Certainly the evidence suggests it is a multifactorial condition. We suggest future research 
should combine a microscopic definition of >30 pmnl/hpf, the more frequently cited 
criterion, with at least one of the accepted clinical signs such as yellow mucopus. 
Urinary-based NAAT methods of STI testing have revolutionized the process of STI testing, 
but ironically without internal genital examination, the diagnosis of cervicitis cannot be 
made. With the streamlining of clinical services and in some practices, replacement of 
genital examination with urinary NAAT testing particularly for asymptomatic screening, we 
risk overlooking significant pathology in women with ‘negative STI screening tests’.  In the 
meantime further research is needed to elucidate the contribution of new putative 
aetiological agents, such as MG and BV and their antibiotic susceptibility patterns and non-
infectious factors implicated in the aetiology of cervicitis, in order to improve diagnosis and 
management of this condition and thus ultimately improve health outcomes for women and 
their partners.   
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2 Literature review update: Cervicitis 2008-2014 
The following literature review is an update of papers examining the epidemiology and 
treatment of cervicitis and related topics, since the publication of the article ‘Cervicitis: A 
review’ Lusk and Konecny. Current Opinion in Infectious Diseases 2008; 21:49-55. This 
review paper has been successfully received with 46 citations to date including citation in 
the 2010 CDC STD Guidelines for the management of cervicitis. 
In the field of cervicitis little progress has been made in the last 6 years in clarifying the 
etiology, optimum management and clinical relevance of the finding of cervicitis. 
Undoubtedly, with self-collected vaginal and urine samples, there is less need to examine 
women so fewer clinicians actually make the diagnosis of cervicitis. However, given its 
association with upper genital tract infection 1,2, preterm birth 3 HIV transmission 4 and 
symptoms in many women, it remains an important area for further research. 
The two most important recent contributions to the field have been a large US cross- 
sectional study by Gaydos in 2009 5  and a 2013 randomized control trial (RCT) of treatment 
outcomes for cervicitis of unknown etiology 6. Gaydos’s study in a Baltimore STD service of 
324 women examined the prevalence and associations of Chlamydia trachomatis (CT), 
Neisseria gonorrhoea (NG), Trichomonas vaginalis (TV) and Mycoplasma genitalium (MG) 
with cervicitis (definition cervical discharge or mucopurulent discharge or cervical friability). 
They found only MG to be associated with cervicitis in multivariate analysis (AOR= 2.5, 
p=0.002) and a high cervicitis prevalence of 41%. STDs were highly prevalent in this 
population: CT 11.1%, NG 4.6%, TV 15.3% and MG 19.2 %. Interestingly, factors not found to 
be associated with cervicitis included CT (AOR 1.81 (95% CI 0.79-4.14) p=0.16), NG (AOR 
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1.01 (95% CI 0.29-3.53) p=0.99, TV (AOR =1.74 (95% CI 0.92-3.31) p=0.09, bacterial vaginosis 
(BV) (AOR =1.51 (95% CI 0.95-2.41) p=0.08, and age. Some of these factors, in particular CT 
and TV may have been significant if sample size had been larger. This paper was 
accompanied by an editorial 7 by Manhart on MG. Our Cervicitis Study was similarly 
designed to the Gaydos study but larger with more comprehensive examination of a 
number of other variables and examination of associations using several commonly 
accepted cervicitis definitions, including microscopic Gram stain diagnosis 30 
polymorphonuclear leucocytes /high powered field (30pmnl/hpf), yellow discharge and 
mucopurulent discharge.  
Taylor’s cervicitis treatment paper 6 was published in 2013 in STD with an Editorial 
Commentary from Wiesenfeld 8. This study was a multicenter RCT attempting to examine 
the treatment outcome of cervicitis of unknown etiology (women with CT, NG, MG, TV, 
symptomatic BV, active HSV excluded). Unfortunately the study proved too ambitious with 
recruitment of only 53 women with cervicitis of unknown etiology and closed early with 33 
women completing the study. Women with ‘cervicitis of unknown etiology’ (cervicitis 
definition used was mucopus and/or easily induced bleeding and >30 pmnl/hpf) were 
randomized to placebo or treatment with Azithromycin 1G plus cefixime 400mg, with 
follow-up at 2 and 8 weeks. Clinical cure and failure rates of treatment were not significantly 
different in the 2 arms at 8 weeks.  
Taylor also published a 2014 review on cervicitis 9 highlighting the lack of consensus case 
definition for cervicitis, un-explained etiology for a large proportion of cases and lack of 
current evidence to support presumptive treatment of cervicitis. A UK survey of Sexual 
Health physicians questioned about cervicitis 10 also demonstrated a lack of consensus in 
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diagnosis and management, and concluded that diagnosis by microscopy should be 
abandoned. 
Cervicitis, Subclinical PID and PID 
Despite the lack of studies focusing on the etiology and significance of cervicitis itself there 
have been some excellent papers on PID, subclinical PID and associated adverse 
reproductive outcomes. This is of relevance to the understanding of cervicitis given that 
lower genital tract inflammation (cervicitis or leucorrhoea) is a sensitive indicator of 
endometritis or subclinical pelvic infection 1,11. As for cervicitis, studies of PID are limited by 
the inconsistent diagnostic criteria used for this diagnosis. 
In a prospective observational treatment trial of 418 women with or at high risk of CT or NG 
or with BV, but without clinical PID, Wiesenfeld and Hillier’s group 12 identified a 40% 
reduction in pregnancy rate at median follow-up time of 2.8 years (HR=0.6 (95 % CI 0.4-0.8)) 
in women with subclinical PID (indicated on endometrial biopsy) despite presumptive 
treatment for CT, NG and BV. Women with proven CT or NG, in the absence of subclinical 
PID, had no reduction in fertility. BV in the absence of subclinical PID also did not affect 
pregnancy rates. They concluded that subclinical PID decreases fertility despite presumptive 
treatment for STDs and that current treatments for seemingly uncomplicated cervical CT 
and NG might be inadequate for preventing the long-term outcome of infertility. This study 
adds support to the argument for presumptive treatment of cervicitis including non-specific 
cervicitis.(NOT SURE!!) 
Another recent study in 298 women with confirmed endometritis utilizing data from the 
PEACH study 13 investigated the effect of delayed treatment (>14 days symptoms) to cover 
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CT, MG and NG endometritis, on reproductive outcomes. In the entire cohort they found 
non-significant increases in infertility, recurrent PID and chronic pelvic pain in those women 
delaying treatment. Results relating to single pathogens were not significant due to small 
numbers. Treatment was more commonly delayed in women with CT and MG, probably due 
to fewer symptoms.  
There have been three interesting recent papers on Chlamydia and PID. A widely cited 2010 
BMJ RCT (The POPI, Prevention Of Pelvic Infection Study) by Oakeshott and colleagues 14 of 
2500 young sexually active female university students in the UK, offered baseline self-
collected vaginal swab for chlamydia with immediate testing and treatment if required in 
the intervention group and for the control group, sample storage and analysis after one year 
(with the caveat that controls could seek testing and treatment in the interim, which 22% of 
controls wisely did). The ethics of this study seem marginal, and the authors pointed out 
that it was at the limits of acceptability. The follow-up outcome was incident PID over 1 year 
largely based on patient account and some medical records. There was a non-significant 
reduction in PID amongst women immediately screened and treated, (RR 0.65 (95% CI 0.34-
1.22) over those with deferred analysis and treatment of baseline samples, with similar 
baseline chlamydia rates in the two groups. Most women with PID were negative for 
chlamydia at baseline (79%) and they concluded that a single screen for chlamydia was not 
effective in high-risk women, suggesting more frequent screening for this group to pick up 
incident infection. A weakness of this study was failure to take into account other PID-
related infections such as NG and MG.  
Another UK study examining PID 15 used data from the UK General Practice Research 
Database (covers 5.5 % of the population) examining numbers of diagnostic coding for 
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definite, probable and possible PID diagnoses in General Practice between 2000 and 2008. 
They found the rate of definite/probable PID decreased by 10.4% per year, most 
pronounced in women 16-19 years, with rates of possible PID increasing. Some of the 
findings could be explained by symptomatic people seeking care preferentially in 
Genitourinary (GUM) Clinics (given the easier access with the 48-hours-wait target 
introduced to GUM services in 2004 and more PID diagnoses reported in this setting) and 
trends of less specific diagnoses being made by GPs with the obvious limitations of relying 
on such coding for reliable PID diagnosis. The most likely explanation for reducing PID rates 
was cited as the substantial increase in chlamydia testing and diagnosis over this decade, 
particularly in younger women. 
More generally, Haggerty and colleagues 16 produced a 2010 review of 24 papers on the risk 
of sequelae after chlamydia infection. They found no prospective studies directly assessing 
risk of long-term reproductive sequelae after untreated chlamydia infection (reflecting the 
difficulty of conducting such studies). They concluded that in high-risk settings 2-5% of 
untreated women with chlamydia infection developed PID within the first 2 weeks between 
testing positive and being treated but rate of progression to PID in asymptomatic women 
was lower. Despite our knowledge of the adverse outcomes associated with delayed or 
untreated PID, a 2011 study of adherence to US CDC guidelines for PID treatment in the US 
Emergency departments revealed a dismal 30 % adherence to guidelines 17.  
Haggerty also reviewed PID management in 2007 18. The dual regimen doxycycline/ 
metronidazole has been found to have  poor clinical and microbiological cure rates, one UK 
observational study finding a cure rate of 55%, this increasing to 72% with the additional of 
ceftriaxone 19. Doxycycline has poor cover for streptococci, E coli, anaerobes and NG and 
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since PID is thought to be a poly-microbial infection, broad cover is required. Another 
excellent discussion on PID appeared in 2010, by Soper 20, which reminded us that 
symptoms of PID are not always the traditional pain and fever and can be more subtle such 
as abnormal discharge, cycle change, heavy menstruation and urinary symptoms, but the 
diagnosis is clinched by signs of lower genital tract infection in conjunction with pelvic organ 
tenderness. Best outpatient treatment was suggested as broad-spectrum cephalosporin plus 
doxycycline or azithromycin. A UK study 21 comparing the efficacy of azithromycin 
monotherapy against azithromycin/ metronidazole combination for treatment of PID 
(mostly diagnosed by laparoscopy) found a 97% clinical cure rate and clearance of 
pathogens with azithromycin alone (but didn’t include testing for MG or TV) and 96% cure 
with azithromycin /metronidazole regimen. However it was not clear from this study which 
azithromycin regimen was most optimal (one trial used 500mg IV then 250 mg orally for 6 
days a second trial used IV Azithromycin for 2 days then oral for 5 days) and involvement 
from Pfizer was not accompanied by a conflict of interest declaration. Additionally details on 
what constituted a ‘cure’ were unclear in this study. Azithromycin provides good cover for 
CT, NG and anaerobes and is a single dose, well tolerated treatment with a 68-hour half-life 
and accordingly seems to be an essential part of any PID treatment regimen. 
Current Guidelines in Australia for outpatient management of PID mostly recommend 
azithromycin stat plus 14 days of doxycycline and metronidazole BD, plus ceftriaxone 500 
mg IMI if severe or NG isolated /suspected. 
TV and HIV. Naturally, much research of the last decade has focused on the role of STIs in 
enhancement of HIV transmission. A 2012 large STI prevalence study in asymptomatic HIV 
positive men and women in South Africa examined prevalence and associated risk factors 
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for cervicitis and urethritis-associated pathogens, finding pathogens more prevalent 
amongst women and TV to be the most prevalent pathogen overall (7.6%). The authors 
recommended STI screening in HIV positive men and women, given the large burden of 
asymptomatic STIs in this population 22. Although not common in urban Australia, TV is 
important because of its prevalence worldwide, often with an asymptomatic presence 23,24, 
relatively overlooked pathogenic role and likely association with HIV transmission. 
McClelland summarized nicely, the role of TV in a 2008 Editorial 25 alongside Van Der Pol’s 
large definitive case control study demonstrating the significant association between the 
presence of TV infection and increased risk of HIV acquisition in a general population of 
African women (AOR 2.74 95% CI 1.25-6.00) 26. This and the high prevalence of TV in HIV-
endemic areas implicate TV as a major contributor to heterosexual HIV transmission and 
McClelland suggested that the control of TV presents a relatively easy opportunity to reduce 
HIV transmission. 
Our findings concerning the under-diagnosis of TV with wet mount preparation compared to 
PCR testing 27, were corroborated in a US study of high risk women 24, also finding a four to 
five fold increase in TV case detection using PCR detection methods rather than traditional 
detection methods and finding many women with TV to be asymptomatic. They 
recommended more widespread TV PCR screening inclusion in high-risk populations. 
However there has been little recent investigation of the association of TV with cervicitis. A 
2013 cross-sectional study in Peruvian CSWs 28 did not accurately assess the role of TV, 
focusing on BV and there were no statistically significant findings. 
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BV and Cervicitis, PID and HIV transmission 
The relationship between cervicitis and BV remains controversial, with few recent papers 
examining this association and most studies examining the role of BV in genital tract 
inflammation and PID. A detailed Chinese paper 29 using PCR analysis of the microflora in BV 
in women with and without cervicitis, found that lactobacilli were significantly reduced in 
both conditions but did not find evidence of direct involvement of BV with cervicitis. The 
2009 Gaydos cross-sectional study 5 found an association between BV and cervicitis 
(ARR=1.51 (95 % CI 0.95-2.41) p=0.08) but it was not statistically significant. 
The relationship between BV and PID is much more solid 30, demonstrated  in a multicenter 
US study of over 1100 women comparing incident PID rates over 3 years in women with and 
without BV, where they found carriage of  BV-associated microorganisms significantly 
increased PID risk (ARR 2.03(95% CI 1.16-3.53)). This risk was particularly increased for 
women with a new sexual partner. In a longitudinal study over 1 year of 3620 women, 
Schwebke’s group 31 demonstrated BV was associated with a significantly increased risk 
(adjusted hazard ratio (AHR) 1.73 (95% CI 1.42-2.11) for acquisition of TV, NG and/or CT 
infection, with similar estimates for isolated TV, NG and CT infections.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
There has also been mounting evidence of the role of BV as an STI 32 with a Melbourne 
based study finding BV absent in truly sexually inexperienced women 33 and US study of 335 
women who have sex with women 34 finding BV to be associated with sexual practices that 
efficiently transmit vaginal fluid (sharing toys and lubricant use). A 2008 review and meta-
analysis 35 of 43 studies looking at associations between sexual risk factors and BV found a 
summary estimate of BV and new/ multiple male partners was 1.6 (95% CI 1.5-1.8), BV and 
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female partners 2.0 (95% CI 1.7-2.3) and condom use 0.8 (0.8-0.9), suggesting that BV has an 
epidemiological profile similar to that of an STI. 
The association between BV and enhanced HIV acquisition seems well established, as 
summarized in a 2008 meta-analysis of 23 HIV incidence studies, which found BV to be 
associated with increased HIV acquisition (RR 1.6, 95% CI 1.2-2.1) and 21 HIV prevalence 
studies showing a positive association 36. There was also a large 2008 African study of 4531 
women which found that women with BV (Hazard ratio (HR) 2.5 (95% CI 1.68-3.72) or yeast 
(HR 2.97 (95% CI 1.67-5.28) were more likely to acquire HIV 37. 
MG and Cervicitis, PID and STD co-infection 
MG is increasingly recognized as a genital tract pathogen, with a consistent picture 
emerging of similar or greater prevalence 7,38-42 and pathogenicity to CT, and associations 
with upper and lower genital tract inflammation in women, risk of preterm birth 43, NSU in 
men and enhanced risk of HIV transmission. Haggerty reviewed MG and PID 44, finding 
strong evidence for its role and suggested MG as an important contributor to treatment 
failure for PID, suggesting the need for MG antibiotic cover to be included in PID treatment 
regimens. This is important given that MG testing is not available in many settings and co-
infection with other STIs, in particular chlamydia is being increasingly reported, as is 
resistance of MG to azithromycin. In contrast, a side study from the POPI study analyzed PID 
incidence after baseline MG infection in a large group of UK students and concluded that 
MG was not likely to be a significant risk factor for PID (RR 2.35 (95% CI 0.74-7.46) p=0.14), 
but this study had a number of limitations as mentioned above, and the prevalence of MG 
was much lower (3.3%) than that reported in many developing world studies 45. Manhart’s 
59 
 
review 46 of MG and cervicitis (14 studies) and MG and PID (9 studies) in 2011 concluded 
MG’s role in both conditions to be conflicting. Odds ratios for association between MG and 
cervicitis ranged from 1.2 to 5.7, but were often un-adjusted, and almost half the studies 
reported no association. Of the six studies using MG PCR to investigate association with PID, 
ORs ranged from 4.6-6.3 in five studies, supporting the association. 
There has only been one study 47 with weak support of MG as a cause of ectopic pregnancy, 
finding antibodies to MG (and CT) associated with risk of ectopic pregnancy, OR 1.6 (95% CI 
0.6-4.0).  
MG is variably reported to be associated with CT infection, symptoms and with cervicitis. A 
US study of 381 mainly Afro-American women in an STD service 48 with very high STD rates, 
found MG co-infections in 30% of women with NG, 25% of women with CT and 20 % of 
women with TV. MG as a sole infection was associated with age <22 years (AOR 2.53(1.25-
5.12) and cervicitis (AOR 2.11(1.04-4.26). Vaginal swab specimens had superior MG 
detection rates compared to endocervical swab specimens. In a US study of 331 high-risk 
adolescents from a hospital- based teen health center (again with very high STD prevalence 
rates), Huppert et al 39  found MG to be significantly associated with CT co-infection (OR 2.3 
95% CI 1.4-4.4) but not with TV, NG, cervicitis (defined as mucopurulent discharge or 
cervical friability) or symptoms. Another US study involving quarterly visits for two years of 
383 adolescent women in a primary care setting and 117 of their male partners 49 also found 
MG significantly associated with CT co-infection (AOR 1.89 (95% CI 1.07-3.34) P=0.029) but 
not with NG, TV or symptoms. Male partners of MG-positive women were more likely to 
have MG than male partners of women not infected (P<0.02), supporting sexual 
transmission. They found 25% of male partners of MG positive women to be infected 
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compared to our figure of 40% (un-reported data, see Abstract 2010, Appendix, Part 1).  In 
Hitti’s large case-control study of MG in Peruvian sex workers 43, MG was associated with CT 
co-infection (<0.001) and importantly preterm birth (AOR 2.5 (95% CI 1.2-5.0) P=0.014). 
Closer to home, a NZ study of women under 25 years having terminations of pregnancy 
found MG was not significantly associated with CT co-infection 40. Additionally our 2010 
interim findings paper 38 found a significant relationship between MG and cervicitis (ARR 
1.24 (95% CI 1.04-1.48 p=0.02) and between MG and HIV (p=0.03) but not with CT (p=0.44) 
or vaginal discharge (p=0.32). 
MG and HIV 
There have been several papers arising from a hormonal contraceptive and HIV acquisition 
study of women in Uganda and Zimbabwe. This study also looked at various STIs and their 
contributions to HIV transmission, including a nested case-control study 50 which found a 
two-fold increase in HIV acquisition risk in women who had MG immediately prior to their 
HIV diagnosis (AOR 2.41(95% CI 1.01-5.80) p=0.05. They also found HSV2 and NG to be 
strongly associated with HIV acquisition. The same authors also published a meta-analysis of 
19 studies in AIDS 2009 51 on the association of MG with HIV and found an overall OR of 2.01 
(95% CI 1.44-2.79). Manhart has written prolifically on the topic of MG and HIV. Most 
interesting was an original study in 2008 of 303 HIV positive Kenyan women, finding a high 
MG prevalence (17%) and a three-fold increase in risk of cervical HIV shedding (AOR 2.9 
(95% CI 1.1-7.6) p=0.03) in women with high cervical MG organism load. Low cervical MG 
organism load and cervicitis were not associated with cervical HIV shedding. MG was much 
more prevalent than CT (7%) or NG (10%) 41. 
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 Manhart and McClelland 52 wrote a perceptive editorial accompanying a paper by 
Vandepitte et al on the natural history of MG infection in Ugandan CSW 42. The editorial 
recommended priority review of antibiotic regimens currently used in syndromic 
management in Africa, given the high prevalence of both MG and HIV in these areas and 
increasing reports of MG resistance to azithromycin. The natural history study 42 involved 
MG testing of samples from a previous cohort study of 1027 CSW. Prevalence of MG was 
14%. At three months 55% had spontaneously cleared infection, 83% within 6 months and 
93 % within 1 year, however 39 % became re-infected. HIV positive women cleared MG 
more slowly than HIV negative women and clearance was slower with CD4 counts <350. 
Women had antibiotics during the study to treat other STIs, but were not specifically treated 
at the time for MG with azithromycin. This paper includes a detailed discussion of the 
antibiotic resistance mechanisms of MG.  
MG treatment 
The body of literature dealing with MG treatment is growing. MG resistance has been 
reported and investigated since 2005 by Bradshaw 53, Jensen 54, Bjornelius 55 and Jernberg 
56. The Melbourne study 53 recruited males with NSU and females with cervicitis/PID and 
contacts of MG and found MG prevalence in these groups 11% and 10% respectively. 
Azithromycin 1 G was effective in eradicating MG in 84%. Jensen 54 isolated the mutation 
responsible for MG azithromycin resistance and in analysis of nine specimens of men with 
NGU obtained before and after azithromycin treatment, found only two initially had the 
mutation, suggesting single dose azithromycin treatment induced this resistance mutation. 
A Japanese group also suggested a possible increased resistance with a 1 G azithromycin 
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dose 57. This obviously has implications for the current widespread use of azithromycin 1 G 
therapy for cervicitis and NSU.   
A longer five day treatment regimen of azithromycin 500mg on day one followed by four 
days of 250 mg proved to be 100% effective for MG eradication in women and 96% effective 
(95% CI 85-99%) in men, in a 2008 Scandinavian study of 155 men and 60 women with MG, 
recruited from six STI services in 2002-2004 55. A single 1 G dose of azithromycin was 
effective in 85% (95% CI 69-94%) in men and 88% (95% CI 64-99%) in women. A 
consideration here though is the relatively small numbers of women especially, and the fact 
that people given extended azithromycin therapy had already been given and failed 
doxycycline treatment. As a result of this study, the extended 5 day course of azithromycin 
was adopted in Scandinavia for treatment of MG. It would be good to see a larger study of 
the efficacy of this regimen, as it is preferable to widespread moxifloxacin use. A somewhat 
different result was found in a 2008 retrospective survey of treatment efficacy in 10,109 STI 
patients in Oslo 2005-2006 56 which examined the microbiological cure rates of several 
different regimens for MG treatment, and found the following eradication rates: 
azithromycin 1 G (79%), azithromycin 1 G repeated after five to seven days (74%), 
azithromycin 500mg then 250 mg for further four days (78%), ofloxacin 200mg BD for 10 
days (56%) and moxifloxacin 400mg daily for seven days (100%). Only the first 2 regimens 
were used first line over the observed period. If the five day regimen was used 2nd or 3rd 
line, the cure rate dropped to 34%, with the suggestion that these patients were likely 
already resistant to azithromycin. MG prevalence was 4.5%. Although retrospective, this 
was a huge sample and this country’s health policies facilitated high follow-up rates. The 
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findings did concur that a five day azithromycin regimen is an effective first line treatment 
for MG, although in this study, no more so that a single 1G dose of azithromycin. 
 Manhart reviewed MG treatment in 2011 46, concluding that single dose or five day 
azithromycin treatments were probably of similar efficacy and was cautious about the small 
number and observational nature of the data supporting moxifloxacin use. Accordingly she 
recommended prudent use of moxifloxacin only for 2nd line treatment of resistant 
cervicitis/PID or NGU with proven MG infection persisting after test of cure at four weeks. 
There are also reports of moxifloxacin resistance appearing 58. 
An exciting new development was described in a large French study 59 evaluating the clinical 
performance of the Bio-Rad Dx CT/NG/MG multiplex assay in urogenital samples in 
comparison with the Roche COBAS® TaqMan® CT assay for CT and an in-house TaqMan PCR 
assay for MG. They found very high sensitivity and specificity of the multiplex, 
recommending this assay as suitable in urogenital specimens of symptomatic and 
asymptomatic men and women. 
A discussion of the potential role of cytokines in cervicitis appears in the main findings paper 
(chapter 5). Finally a search of the literature does not yield any studies examining the 
potential effects of trauma of sex, toxic effect of semen per se or timing of last intercourse 
as factors associated with cervicitis. 
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METHODS 
 
The Cervicitis Study was designed from mid-2006 to 2008 and commenced recruitment at 
the Short Street Centre in July 2008. This study had to be of an opportunistic nature, 
utilizing my role as a Senior Registrar and then Staff Specialist at Sexual Health Services in 
Sydney and relied upon the supervision and mentorship of my colleague and PhD co-
supervisor Dr Pam Konecny. Part of my job description was to be a researcher, so this fitted 
in as part of my employment. Whilst posted to other clinics I maintained a supervisory and 
support presence at the Short Street Centre. This clinic is a small but very dynamic service 
dedicated to the support of research with just over six full time staff members, attached to 
the St George Hospital. It forms part of a network of publically funded-Sexual Health 
Services in New South Wales.  
All the STI clinics sites used for this study provide STI and HIV services by triage to patients 
from ‘priority populations’ defined in the 2006-2009 NSW Sexually Transmissible Infections 
Strategy 1, symptomatic patients, STI contacts and those referred from primary care and 
hospital specialists. They operate in areas with a high proportion (40%) of patients from 
culturally and linguistically diverse cultural backgrounds. 
As a novice researcher, the only funding I secured was a one-off research scholarship 
through the Sexual Health College in 2006 (sponsored by Novartis) which helped towards 
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the cost of multiplex laboratory testing during the study and to cover my statistical 
expenses. Collaboration with Prof. William Rawlinson’s Virology Research Laboratory was 
critical to give us access to the multiplex PCR tests and limited number of HPV testing kits 
used for comprehensive pathogen detection. 
By necessity the protocol for the study had to follow standard clinical practice in the clinics, 
in order to fit in with everyday workflow and not financially impact upon the clinic budget. 
Thus the study was observational in its design. This facilitated staff involvement and clinic 
support and importantly meant decline rates for the study were low because there was 
minimal intervention or disruption for participants. 
The study aims were as follows: 
1. With a multi-site cross-sectional study of women presenting to Sexual Health 
Services, explore infectious and non-infectious exposures putatively associated with 
cervicitis on literature review 2, using the commonly accepted working cervicitis case 
definition of  >30 polymorphonuclear leucocytes /high-powered field (pmnl/hpf) on 
cervical Gram stain and compare these associations using other commonly used 
cervicitis case definitions (yellow discharge, mucopurulent discharge and ectropion), 
to determine the cervicitis definition with best clinical utility. 
2. With an observational prospective sub-study assess the effect of presumptive 
treatment with azithromycin 1 G PO of women with cervicitis (30 pmnl/hpf) and non-
specific cervicitis (NSC), on the outcomes of cervicitis persistence or genital 
symptoms and assess benefit on cervicitis persistence of additional presumptive 
male partner treatment with azithromycin 1 G PO. 
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We initially intended to include recruitment from a gynaecology service as well as STI clinics, 
but logistics proved too difficult and recruitment was confined to the services where I was 
working during the recruitment period, primarily Short Street Centre, and secondary sites 
Royal Prince Alfred (RPA) Hospital Sexual Health (April-November 2008) and Liverpool 
Sexual Health clinics (November-December 2008). Ethics approval delays and local clinical 
service restrictions limited recruitment in these secondary sites to 89 women, with 83% of 
participants being recruited at the primary site Short Street Centre.  
The study protocol is also described in the papers from Chapters 3-6 and the Laboratory 
methods for the dedicated study PCR tests are described in McIver’s paper, included in the 
Thesis appendix 3.  
Selection of Study Subjects 
The study enrolled 558 women between July 2006 and February 2010. All recruiting 
clinicians underwent standardized on-site training in diagnostic microbiology, study protocol 
and sample collection. Inclusion criteria included consecutive consenting women over 18 
years requiring vaginal examination based on presenting complaint or requesting 
examination. During the study it was clinic policy for clinicians to collect speculum samples 
on most women for screening or investigation of symptoms, with patient self-collected 
samples less commonly offered. (Re-enrolment was permitted if more than six months had 
elapsed since initial enrolment and a new sexual partner reported.) Exclusion criteria 
included PID, menstruation, pregnancy, no vaginal sex in prior three months, antibiotic use 
in prior month, sexual assault, Intrauterine contraceptive device (IUCD) or cervical surgery in 
prior 3 months. The exclusion criteria were chosen to exclude women with conditions where 
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the cervical environment may have been altered (recent antibiotic use, surgery, pregnancy, 
menstruation, IUCD pelvic infection). Women who had not had vaginal sex for 3 months 
were excluded, as they were less likely to have infection present. 
There were 1327 consecutive women approached with 630 (47.5%) eligible and 697 (52.5%) 
ineligible. Of 630 eligible women 558 (88.6%) were enrolled (including 21 enrolled twice) 
and 72 (11.4%) declined. A log was kept of reasons for not enrolling and declines. Most 
common reasons for ineligibility were: not requiring examination (36.7%), recent antibiotic 
use (13.5%) and menstruation/ pregnancy (12.8%).  
Data collection and laboratory methods 
The cervix was visualized using a sterile speculum and excess exudate removed using a non-
sterile cotton swab before taking four endocervical sterile cotton swabs (Copan California). 
The first endocervical swab was taken for Gram stain to define women as having cervicitis or 
not by the working definition >30 pmnl in 3 non-adjacent high-powered fields and for NG 
culture on selective media (lysed horse blood agar containing vancomycin, colistin, nystatin 
and trimethoprim (VCNT)). A second endocervical swab was collected for Chlamydia 
trachomatis (CT) / Neisseria gonorrhea (NG) PCR testing (Amplicor CT/NG Test (Roche)). NG 
positivity was defined by positive culture +/- PCR test result. NG Culture was routinely 
performed in the clinic at the time, with PCR results carrying less reliability in the low 
prevalence setting. The third endocervical swab was taken for multiplex PCRs 3 for MG, M 
hominis (MH), Ureaplasma urealyticum (UU), Ureaplasma parvum (UP), HSV1, HSV2, EBV, 
VZV, CMV and TV. A 4th endocervical swab was also taken to store for any future testing as 
required. Swabs three and four were transported in viral 2SP viral transport medium (0.5 ml 
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sucrose phosphate + vancomycin maintenance buffer) and batch tested non real-time. All 
samples were processed at the research laboratory within 48 hours of being taken. 
A high vaginal swab was taken for Gram stain and candida culture and wet preparation for 
TV if clinically suspicious (see chapter 3). Bacterial vaginosis (BV) was defined on Gram stain 
using Nugent’s criteria. Laboratory scientists were blinded to clinical information. 
From June 2008 onwards, women at the Short Street site were also asked to submit an 
additional first-void urine sample to be tested in tandem. Results for a pathogen were taken 
to be positive if they were positive on endocervical testing, urine testing or both from this 
time onwards. Comparison of the pathogen detection from endocervical and urine sample 
testing will be the topic of a future publication. 
Gram stain slides from consultations were verified for diagnosis of cervicitis and BV at a later 
time by a laboratory scientist blinded to clinician findings (Christa McPherson at St George 
Hospital SEALS Microbiology). All discrepant slides were re-examined and consensus Gram 
stain cervicitis diagnosis reached. The cervicitis diagnosis >30 pmnl/hpf was robust, 87.2% of 
clinician Gram stain slides being examined by the laboratory scientist and high agreement 
between clinician and laboratory diagnosis of cervicitis or not (kappa 0.79 (95% CI 0.74-0.84) 
Testing for high risk Human Papilloma Virus (HPV) subtypes 16, 18, 31, 33, 35, 39, 45, 51, 56, 
58, 59, 68 (Human Genetic Signatures High Risk HPV Detection Kit, Sydney, Australia) was 
performed in a subset (n=191) of women 4, as we had access to a limited number of kits 
from the manufacturers. This test was in the process of being TGA- approved at the time of 
the study. HPV was included based on biological plausibility of a potential role in 
inflammation of the cervix and literature support and is discussed further in Chapter 5. 
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Clinical and history information was collected from clinical history sheets, modified for the 
purposes of the study. Yellow discharge was recorded if this was seen on examination of the 
cervix (yellow staining of a white cotton swab) or a woman complained of yellow discharge. 
Mucopurulent discharge (MCP) (subjective clinician observation of purulent looking cervical 
secretions) and ectropion (visibility of the squamocolumnar junction) were recorded if this 
was the noted on the cervix by the examining clinician.  
Data was collected on presence of any genital symptoms and potential non-infectious 
etiological exposures including age group, current smoking, commercial sex work (CSW) and 
douching status, extent of condom use (always/sometimes/never) and number of sexual 
partners (1, >1) in the last three months, timing of last intercourse within the last week or 
>1 week ago, current use of combined oral contraceptive (COC), injectable depo-
medroxyprogesterone acetate (DMPA) /Progestagen only pill (POP) or Implanon, phase of 
menstrual cycle (follicular/luteal) and stated history of past chlamydia infection and 
abnormal Pap smear in the preceding two years. 
Male partners of women diagnosed with cervicitis were also offered testing with standard 
clinic tests of chlamydia and gonorrhoea plus by consent, dedicated study multiplex PCR 
tests, all from a first void urine sample. Samples were collected from 52 male partners.  
The Treatment Sub-study  
All women diagnosed with cervicitis were offered presumptive treatment with azithromycin 
1 G PO stat on the day of assessment and follow-up at 6 to 8 weeks for re-testing for CT/NG, 
study multiplex PCRs and assessment for persisting cervicitis and persistence of any genital 
symptoms. If NG or TV were diagnosed at initial assessment by on-site microscopy, women 
78 
 
were treated accordingly with ceftriaxone 500mg IM or tinidazole 2G PO respectively and 
not offered presumptive azithromycin.  
In keeping with clinic practice at the time women were not actively recalled unless they 
required a test of cure or treatment for an identified pathogen. Time to follow-up of some 
women with positive study multiplex results was delayed due to batch testing but all CT/NG 
results were acted upon real time. 
Cervicitis was defined as >30 pmnl/hpf with or without known pathogens. NSC was defined 
as >30 pmnl/hpf in the absence of CT, MG, NG or TV (pathogens found to be significantly 
associated with cervicitis from the Cervicitis Study and literature review). Women with 
positive results for CT, MG, NG or TV (ie persistent or interim incident infection) at follow-up 
were excluded from the follow-up analysis. 
Follow-up outcomes were defined as persistence of cervicitis by the same cervicitis 
definition, >30pmnl/hpf on cervical Gram stain or report of any genital symptoms. All 
participants diagnosed with STIs during the study were contacted and offered treatment 
and follow-up as required according to clinic guidelines. 
Male partners of women with cervicitis were also offered presumptive treatment with 1 G 
azithromycin and study testing if they attended, with discussion concerning the lack of a 
firm guideline in this area. Women diagnosed with cervicitis were advised of the uncertainty 
of benefit of presumptive treatment for themselves and presumptive partner treatment. 
Women who returned for follow-up were asked if they had taken the azithromycin 
treatment supplied as directed and if their sexual partner(s) had taken this same treatment 
(‘partner treatment’). 
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Statistical methods and databases 
I collected all clinical data from patient notes onto temporary clinical datasheets, and then 
entered this into a clinical Excel database with some clerical assistance from Helen Rayner at 
the Short Street Centre. I then manually transferred data from the laboratory database into 
a final combined database for analysis in SAS. 
Associations of infectious and non-infectious exposures with cervicitis (the ‘disease’) were 
estimated using relative risks (RR) and χ2 testing. As this was a cross-sectional study and the 
outcome of cervicitis very common, RRs were calculated rather than odds ratios as the most 
valid measure of association. Relative risks were estimated by log-binomial regression. 
Multivariate analysis involved forward selection of covariates using exposures from the 
univariate analysis with p < 0.05. Sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) of the ‘test’ (different cervicitis definitions >30 pmnl/hpf, 
yellow discharge, mucopurulent discharge) for the significant pathogens, were calculated 
using 2x2 tables.  
Sample size calculations indicated an ideal and logistically possible sample size of 600 
women and this was powered (80%, p<0.05) to detect RR of 3.0 (assuming cervicitis 
prevalence of 20% and pathogen prevalence 5%) or RR 2.4, assuming  pathogen prevalence 
of 10%. A review of findings at sample size of 558 indicated that relative risks were static 
and that sample size was sufficient for the primary study aim. Thus, at this point recruitment 
was halted. 
For the treatment sub-study analysis, differences between baseline characteristics of 
women with cervicitis who were followed up or not, and of women with cervicitis followed 
80 
 
up who had azithromycin treatment or not, were assessed using χ2 tests. The effect of 
presumptive treatment of women with cervicitis and the additional effect of partner 
treatment were estimated using relative risks (RR) and 95% confidence intervals (CI).  All 
calculations were performed with SAS version 9.3 (SAS Institute, Cary, NC USA).   
ETHICAL APPROVALS  
Ethics approval for the three clinical sites was granted by the South Eastern Sydney and 
Illawarra Area Health Service Human Research Ethics Committee (Short Street Clinic) and 
the Sydney South West Area Heath Service Ethics Review Committee (RPA and Liverpool 
clinics). Copies of study participant approach, information and consent forms are included at 
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FOREWORD 
 
This chapter comprises the second publication from the Cervicitis Study and was published 
in Sexually Transmitted Infections in early 2010, but appeared initially online November 
2009 and received the ‘Editor’s Choice’ award. 
This paper presents interim findings from the Cervicitis Study from the data of 356 women 
and highlighted the discrepancy in Trichomonas vaginalis case detection between the 
traditional diagnostic method of discretionary wet mount preparation verses PCR detection 
method, which was found to be four to five fold more effective in detecting Trichomonas 
vaginalis. We also found a significant association between cervicitis and TV and found TV to 
be significantly more common in women with culturally and linguistically diverse cultural 
backgrounds.  
TV has tended to be the forgotten STI, particularly in urban environments in developed 
countries. This paper aimed to raise the profile of TV in the urban Australian setting given 
the important potential impacts of this infection upon adverse health outcomes in women 
including preterm birth and enhanced risk of HIV transmission, not forgetting troublesome 
symptoms for many. 
We suggest that TV is likely to be under-diagnosed presently, which could pose a threat to 
the re-emergence of this infection and accordingly recommended development of 
commercially available PCR tests for TV and wider uptake of these tests. 
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Trichomonas vaginalis: under-diagnosis in urban Australia could 
facilitate re-emergence 
M. Josephine Lusk, Zin Naing, Ben Rayner, Nikolas Rismanto, Christopher J. McIver, Robert 
G.  Cumming, Kevin McGeechan, William D. Rawlinson and Pam Konecny  
Sexually Transmitted Infections 2010;86(3):227-30 
 
ABSTRACT:  
Objectives: Trichomonas vaginalis (TV) has a low profile in urban sexually transmitted 
infection (STI) clinics in many developed countries. The objective of this study was to 
determine true prevalence of TV in an Australian urban sexual health setting using sensitive 
molecular diagnostic techniques.  
Methods: A cross-sectional study investigating the etiology of cervicitis in women attending 
two urban sexual health clinics in Sydney, Australia, enrolled 356 consecutive eligible 
women from 2006-2008.  The diagnostic yield from the standard clinical practice of 
discretionary high vaginal wet preparation microscopy in women with suspicious vaginal 
discharge was compared with universal use of nested polymerase chain reaction (PCR) for 
TV of cervical samples.  
Results:  TV was detected by PCR in 17/356 women (4.8%, 95% Confidence Interval (CI) 2.8-
7.5%), whereas only 4 cases (1.1%, 95% CI 0.3-2.8%) were detected by discretionary wet 
preparation microscopy. Eleven of the 17 women (p=0.003) were of culturally and 
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linguistically diverse (CALD) background. Additionally, cervicitis was found to be significantly 
associated with TV, RR 1.66(1.14-2.42), p=0.034  
Conclusions: Traditional TV detection methods underestimate TV prevalence in urban 
Australia. The TV prevalence of 4.8 % by PCR testing in this study exceeds previously 
reported urban Australian TV rates of <1%. An increase in trichomoniasis-associated adverse 
reproductive outcomes and enhanced HIV transmission poses a salient public health threat. 
Accordingly TV warrants a higher profile in urban STI clinic settings in developed countries 
and we suggest priority be given to development of standardized molecular TV detection 
techniques and that these become part of routine STI testing.   
 
Key Messages 
 We report a higher than previously reported prevalence of Trichomonas vaginalis 
(TV) of 4.8 % by PCR methods in an urban Australian STI clinic setting. 
 TV is likely under-diagnosed in urban STI clinic settings using only traditional 
methods of detection. This may presage re-emergence with important Public Health 
consequences. 
 We find TV is significantly associated with women of culturally and linguistically 
diverse (CALD) background, and cervicitis is significantly associated with TV (RR 1.66, 
p=0.034). 
 TV warrants a higher profile. Priority should be given to the development of 
standardized molecular TV detection techniques for inclusion in routine STI testing.  
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INTRODUCTION 
Trichomonas vaginalis (TV) is a sexually transmitted infection (STI) causing significant 
morbidity worldwide. Trichomonads are highly site-specific protozoan parasites. In women, 
TV infects the lower urogenital tract, causing superficial vaginal and cervical ulceration. 
Typical symptoms include frothy yellow discharge, itch, odour, dyspareunia and occasionally 
vaginal bleeding. Infection of the urethra and para-urethral glands causes dysuria and 
frequency 1. However, at least one third of infected women may be asymptomatic 2. 
Trichomoniasis has been associated with premature rupture of membranes 3, pelvic 
inflammatory disease (PID) 4 cervicitis 5,6  and enhanced risk of HIV transmission 7. Men may 
present with balanitis, urethral discharge or dysuria, but again, high rates of asymptomatic 
carriage have been reported. A recent US STI clinic study detected TV in 72% of male 
partners of infected females and of these men, 77% were asymptomatic 8. The duration of 
TV infection in women may be prolonged for up to 3-5 years but only about four months in 
men 9. The natural history of TV infection is not well defined. 
Trichomoniasis is the most common curable sexually transmitted infection. In 1999, WHO 
estimated 174 million new cases per year, more than double the number of Chlamydia 
trachomatis cases and treble the cases of gonorrhoea. The high TV prevalence worldwide is 
concentrated in developing countries and socioeconomically disadvantaged groups, with a 
dramatic decline in TV rates in some developed countries in the past few decades 10. TV 
prevalence in urban Australia is reportedly low based upon routine wet preparation 
diagnostic method 9,10 Australian rates of TV peaked in the 1950s at 20-30% and rapidly 
declined through the 1960s and 1970s to below 1% in 1990 10. This has been attributed to 
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the combination of widespread use of the Nitroimidazoles, and increased surveillance 
through Papanicolaou smears 9,10. This decline and the fact that TV is not a notifiable disease 
in Australia have led to the present situation where testing for TV has assumed a very low 
priority in urban Australian settings. An audit of commercial sex workers (CSW) undergoing 
regular STI screening at a sexual health clinic in Melbourne in 2003 reported a very low 
incidence of TV at 0.11 per 100 person months 11. By contrast, TV prevalence in indigenous 
Australian women, in remote Northern Territory, was high at 25% in a self-sampling PCR 
method based study 12. Prevalence of TV by PCR amongst US women of reproductive age 
was recently found to be 3.1%, with an even lower prevalence of 1.3% in the sub-group of 
non-Hispanic white women 13.  
We are conducting a prospective study investigating the prevalence and etiology of cervicitis 
using molecular diagnostic techniques in women attending two urban STI clinics in Sydney, 
Australia. In this paper we report the prevalence of TV by PCR testing against traditional 
methods of detection, and compare our findings to previous data from other Australian 
urban STI clinics. 
METHODS 
This study was conducted in two urban Sydney STI clinics from July 2006-December 2008. 
Ethics approval was granted by the South Eastern Sydney and Illawarra Area Health Service 
Human Research Ethics Committee and the Sydney South West Area Heath Service Ethics 
Review Committee (Royal Prince Alfred Hospital Zone). 
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Subject selection 
Women were eligible for this study if they were 18 years or older, had been sexually active 
in the previous three months and required an internal examination. The parent cervicitis 
study protocol excluded women if they had been previously enrolled, had clinical pelvic 
inflammatory disease (PID), had received antibiotics or undergone gynaecological 
intervention in the previous month, had an intrauterine contraceptive device, were 
currently menstruating or pregnant, attending about sexual assault or unsuitable for 
enrolment due to psychosocial ill health or comprehension difficulties. Of a total of 957 
consecutive first attendances, 561 women (58.6%) were ineligible 40 (4.2%) declined and 
356 (37.2%) were enrolled. Most common reasons for ineligibility included examination not 
required (30.7%), antibiotics in previous month (14.2%), pregnancy (8.6%) and no sex in 
previous 3 months (8.3%). Women with clinical PID comprised 3.1% of ineligible women. 
This report is an interim analysis of 356 consecutive first attendances of women enrolled in 
the parent cervicitis study. 
Sampling procedure 
 A sterile speculum was used to visualize the vagina and cervix. Gram stain was performed 
on all cervical and high vaginal swabs (HVS). Due to the nature of the parent study, HVS for 
wet preparation microscopy was discretionary based upon clinical suspicion of TV infection, 
in keeping with usual clinical practice, and so not performed for all women. The endocervix 
was sampled in all women, with a sterile cotton swab (Copan, CA, USA) for Gram stain and 
bacterial agents. An additional endocervical sterile cotton swab was taken and placed in 
viral transport medium 199 (GIBCO Invitrogen, NY, USA) and stored at -70oC for subsequent 
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PCR testing for TV by the method described below.  Swabs from all women were tested for 
TV by PCR. 
Cervicitis was defined as >30 polymorphonuclear cells per high-powered field (pmnl/hpf) in 
at least 3 non-adjacent fields of cervical mucus on Gram stain of the first endocervical swab. 
Bacterial vaginosis (BV) was defined by Nugent score from Gram stain of the HVS. 
Nucleic acid extraction and PCR amplification   
Swabs were suspended in 500µl of viral transport medium (above) before extraction of the 
total nucleic acid using a robotic extraction machine (MagNaPure LC, Roche, Germany) 
applying the Total NA protocol according to the manufacturer’s instructions (Roche, 
Germany).  Extracts were stored at 4oC before testing within 48 hours of collection. 
Detection of TV was performed using a nested PCR. Briefly, the first round reaction 
comprised 10l of template in a 50l of PCR reaction mixture containing 9l of Nuclease-
free water, 25l of 2x iScript reaction mix (BioRad, Australia), 0.5μM each primer: TricV-OF 
(5’ CTATTGTCGAACATTGGTCTTACCCTC 3’) and TricV-OR (5’ TCTGTGCCGTCTTCAAGTATGCCC 
3’) 14,15 and 1l of iScript RT enzyme (BioRad, Australia). (This commercial master mix is used 
in our laboratory for the amplification of both RNA and DNA templates). Cycling conditions 
were 50C for 30 min; denaturation at 95C for 15 min, then 35 cycles of 94C for 45 secs, 
57C for 45 secs, and 72C one min; a final extension of 7 min at 72C; and a 4C hold. A 
second round reaction comprised of 2l first-round product included in a 50l reaction 
mixture containing 18l of nuclease-free water, 25l of Amplitaq gold PCR Master Mix 
(Applied Biosystems), and 0.5μM each primer: TricV-IF (5’ CTCAGTTCGCAAAGGCAGTCCTTGA 
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3’) and TricV-IR (5’ GCTTGGAGAGGACATGAACTTCGGA 3’) 14. Cycling conditions included 
denaturation and activation at 95C for 5 min, 33 cycles of:  94C for 20 secs, 57C for 20 
secs, 72C for 20 secs; a final extension at 72C for 10 min and a 4C hold. PCR products of 
206 bp were expected for Trichomonas vaginalis positives and were visualised by gel 
electrophoresis.   
Using positive controls from either culture-proven or molecularly proven sources, sensitivity 
was assessed by measuring the limit of detection (102 copies per reaction) of plasmid 
constructs of the target sites as previously described 14 and is estimated to be between 95 to 
98%. The specificity was determined as follows: confirmation by probe hybridization 
following the PCR amplification, and DNA sequencing was performed on PCR products of the 
first 10 TV positive samples from the study. Nucleotide BLAST on NCBI site (for all 10 
samples) confirmed that all DNA sequences produced from sequencing were Trichomonas 
vaginalis. The results from above methods confirmed the assay has 100% specificity. 
 
Analysis 
 We report the prevalence with 95% confidence intervals of TV by traditional methods and 
PCR methods. Population characteristics of women with and without TV were compared 
using Chi-square testing. P values < 0.05 were considered statistically significant. Data were 
analyzed with SAS software, SAS Institute Inc. USA. 
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RESULTS 
Prevalence of TV by PCR testing was 17/356 (4.8%, 95% CI 2.8-7.5%).  Clinical suspicion 
prompting discretionary wet mount preparation microscopy identified TV in only 4/356 
women (1.1%, 95% CI 0.3-2.8%). PCR identified a higher percentage of women with TV 
(p=0.0003). 
Of the 17 women positive for TV by PCR testing, only 11 had wet preparation microscopy 
performed. Use of discretionary wet preparation was not significantly different in women 
with and without TV by PCR (p= 0.498).  Detection by Papanicolaou smear occurred in only 2 
of the 11 pap smears done in women with TV. The mean age of the women with TV, 33.2 
years, was not significantly different from the mean age of women without TV, 30.7 years 
(p=0.221) (Table 1). 
Significantly, 11/ 17 women with TV (p=0.003) were of culturally and linguistically diverse 
(CALD) background and identified consorts from populations of higher TV prevalence 
overseas (Africa, China, Sri Lanka, South America, Lebanon, Black American). Three women 
identified rural or ‘bush’ Australian contacts. Five women were commercial sex workers 
(CSW). No cases of TV were indigenous women. Six cases had bacterial vaginosis (BV) and 
three had concurrent STIs (two with Chlamydia and one with HIV and active genital herpes). 
Dysuria was significantly associated with women with TV (p= 0.014). Prevalence of cervicitis 
in women without TV was 39%, compared to 65% (11/17) in women with TV, giving a RR of 
cervicitis in the presence of TV of 1.66 (95% CI 1.14, 2.42) P=0.034  
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TABLE 1.Characteristics of women with and without Trichomonas vaginalis by PCR 
Characteristic Women with TV 
n=17 
Women without TV 
n=339 
P value
* 
Mean age (yrs) 33.4 30.7  0.221 
CALD 
1 
11 (65%) 104(31%) 0.003 
Condoms always 4 (24%) 75 (22%) 0.892 
>1 partner last 3 mth 6 (35%) 95 (28%) 0.516 
CSW 5 (29%) 58 (17%) 0.195 
Concomitant STI 
2 
2 (12%) 24 (7%) 0.397 
Signs & symptoms    
Dysuria 7 (41%) 59 (17 %) 0.014 
Vaginal discharge 11(65%) 143 (42%) 0.067 
Bacterial vaginosis 
3 
6 (35%) 79 (23 %) 0.258 
 
*p values <0.05 statistically significant at the 95% confidence level. 
1. CALD (culturally and linguistically diverse) defined as women identifying at clinic 
registration as preferring a language other than English, speaking a language other than 
English at home, or identifying non English Ethnic background. 
2. Concomitant Chlamydia or Gonorrhoea 
3. Defined by Nugent’s score on Gram stain of high vaginal swab. 
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DISCUSSION 
Our data show that traditional methods of detection greatly under estimate the prevalence 
of Trichomonas vaginalis. We report a TV prevalence of 4.8% by PCR testing whereas clinical 
suspicion prompting discretionary wet preparation microscopy identified TV in only 4/356 
women (1.1%) in the same study population. The lower case detection rate by discretionary 
use of wet preparation microscopy (and Pap smear) observed here reflect the inadequacy of 
relying solely upon these methods for detecting TV.  Wet mount microscopy has sensitivity 
as low as 52% 16 depending on specimen handling, skill of the microscopist and TV organism 
load in specimen.  Additionally, wet preparation microscopy is not routinely performed even 
in many STI clinic settings and laboratories 8,17. 
These TV prevalence rates by PCR are higher than previously reported rates of <1% in other 
urban Australian STI clinic studies, sampling CSWs using traditional diagnostic methods 10, 11. 
This difference could signal a true rise in TV prevalence or be attributed to the more 
sensitive PCR diagnostic techniques employed here as well as sampling a less clinically 
homogeneous, highly screened population than those represented in previous literature 9,11. 
Women recruited to the study were a convenience sample which was biased towards 
symptomatic women in an STI service; factors that likely contributed to the high prevalence 
of both Trichomans vaginalis and cervicitis. 
 However due to the relatively low population prevalence of TV, the positive predictive 
value of these PCR findings may be reduced. On the other hand these PCR data may 
potentially underestimate the true prevalence due to the strict inclusion criteria of the 
parent study protocol and retrospective PCR testing of stored, frozen and thawed 
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specimens. Cervical specimens were used for this study, but performance of cervical and 
vaginal specimens for TV PCR testing has been shown to be comparable 18.  
An important finding in our study was the high proportion (11/17, P= 0.003) of women with 
TV who were of CALD backgrounds. Urban society in Australia, as in many other 
industrialized countries, is very culturally diverse with a highly mobile population. 
Accordingly sexual networks, particularly of migrant and first generation Australians often 
include consorts who come from or travel to populations with higher TV prevalence. We 
found the symptom of dysuria to be significantly associated with women with TV, 
highlighting the need for clinicians to consider the possibility of TV especially in the absence 
of other causes of dysuria. We did not find an association between TV and bacterial 
vaginosis although others have 8. BV may mask the presence of TV. Standard BV treatment 
with nitroimidazoles will effectively eradicate co-existent TV infection however partners of 
women with concomitant BV and TV will remain untreated, potentially facilitating the 
persistence and spread of TV. 
 Cervicitis was associated with TV (RR 1.66, p=0.034) supporting the role of TV in the 
etiology of cervicitis. Non-gonococcal, non-chlamydial cervicitis, or non-specific cervicitis 
(NSC) comprises a major proportion of reported cervicitis 5,6 and TV has been recently 
recognized as an etiological agent in this condition 5. Molecular testing for TV in STI 
populations is likely to shed further light on the etiology of NSC in women, a current area of 
research need.  
Co-infection with another STI, including TV, remains a significant risk factor for HIV 
acquisition 7. Women increasingly carry the burden of the HIV epidemic in many developing 
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and westernized countries 19. As many screening programs are targeting younger women, 
older groups of sexually active women where TV predominates 9 may be overlooked, 
potentially contributing to the TV reservoir in the community. The recent rise in gonorrhoea 
in women in some industrialized nations and noted in our own region 20 may indicate 
relaxation of safer sex practices, possibly presaging a rise in STIs with re-establishment in 
these sexually active populations and increased opportunity for HIV transmission.  
If not specifically sought, TV will not be detected. Presently sensitive, standardized detection 
methods for TV are seldom commercially available, relying on in-house laboratory molecular 
methods. This coupled with the low profile of TV has led to infrequent uptake of any testing 
for TV in many clinical settings. Our findings suggest that when sensitive diagnostic tests are 
routinely or selectively applied TV may be found to be more prevalent than previously 
thought. These concerns echo those of others 2,7-9,16,21  that priority be given to developing 
standardized, sensitive, cost-effective techniques for TV detection. 
In summary, we report a higher than previously reported prevalence of TV, by PCR testing, 
in an urban Australian STI clinic population. We suggest the current low profile of TV and the 
variable application of insensitive tests for case detection, have led to under-diagnosis of TV.  
In turn this could facilitate a re–emergence of TV particularly in culturally diverse urban 
populations. Trichomoniasis has the potential to impact significantly on reproductive health 
of women and increase HIV transmission. Accordingly TV warrants a higher profile in urban 
settings in developed countries. With this demonstration of higher than expected TV 
prevalence, a call is justified for the development and application of standardized PCR TV 
detection techniques to facilitate case-finding, surveillance and continued control of this STI.  
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CHAPTER 4 
 
Mycoplasma genitalium is strongly associated with 
cervicitis and Mycoplasma hominis with bacterial 
vaginosis in an urban Australian STI clinic population 
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FOREWORD 
This chapter presents a paper based on Cervicitis Study interim findings from 527 women, 
being the original paper submitted to the journal Sexually Transmitted Infections, which was 
shortened to a Short Report format for publication, focusing on the findings concerning MG. 
The Short Report appears in the Appendix of the thesis as published in Sexually Transmitted 
Infections in 2011. 
One of the initial curiosities of the Cervicitis Study was to explore the group of bacteria 
called the mollicutes, which include the organisms Mycoplasma genitalium (MG), 
Mycoplasma hominis (MH), Ureaplasma urealyticum (UU) and Ureaplasma parvum (UP). 
MG has become the organism of most interest, emerging as important genital tract 
pathogen but UU has also been implicated as a genital tract pathogen with more evidence 
of its role in men. Both MH and UU have been implicated in cervicitis and bacterial 
vaginosis. The significance of UP is not defined. 
The collaborating Scientists developed a multiplex PCR test for the four mollicutes, which 
was used in this study (see McIver’s method paper Part 3, Appendix). 
This paper was designed to examine the role of these commonly found genital tract agents, 
and to clarify their associations with the common conditions of cervicitis and bacterial 
vaginosis. It presents material on the association of the mollicutes with BV that is currently 
unpublished elsewhere. 
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Mycoplasma genitalium is strongly associated with cervicitis and 
Mycoplasma hominis with bacterial vaginosis in an urban 
Australian STI clinic population 
 
ABSTRACT  
Objectives: To elucidate the prevalence and associations of the genital mollicutes, 
Mycoplasma genitalium (MG), Mycoplasma hominis (MH), Ureaplasma urealyticum (UU) 
and Ureaplasam parvum (UP) with cervicitis and bacterial vaginosis (BV) and to characterize 
the clinical associations of MG in a Sydney STI clinic population. 
 
Methods: 527 women were enrolled in a cross-sectional study at two Sydney Australian 
Sexually Transmitted Infection (STI) services. Genital mollicutes were detected by multiplex 
PCR testing of cervical swabs and associations with cervicitis and bacterial vaginosis (BV) 
analysed. 
 
 Results: MG was found in 4.0% of women, MH in 17.1%, UU in 14.1% and UP in 51.8%.  MG 
was the only mollicute associated with cervicitis (RR 1.85, 95% CI 1.52-2.26, P<0.0001). MG 
was significantly associated with women being HIV positive (P=0.033) but not with age, 
vaginal discharge, commercial sex work, being of culturally and linguistically diverse 
background or concurrent chlamydia infection. Two of the 21 women with MG had ectopic 
pregnancies. MH was significantly associated with BV. Women with MH were almost four 
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times more likely to have BV than women without MH (RR 3.61 (95% CI 2.80-4.65) 
P<0.0001). None of the other genital mollicutes were significantly associated with the 
presence of BV. 
 
 Conclusions: We recommend wider application of PCR testing for Mycoplasma genitalium 
in STI services in high-risk women, particularly those with cervicitis or HIV infection. Further 
longitudinal studies of the impact of MG infection upon female reproductive health are 
needed. 
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INTRODUCTION 
Substantial evidence implicating Mycoplasma genitalium (MG) as a genital tract pathogen 
has emerged in the last decade. However the potentially pathogenic roles of the other 
genital mollicutes, Mycoplasma hominis (MH), Ureaplasma urealyticum (UU) and 
Ureaplasma parvum (UP) are less well characterized. The consequences of any mollicute 
infection for female reproductive health require clarification. 
The mycoplasmas and ureaplasmas belong to the class of mollicutes. There are 16 species 
detected in humans, of which seven are primarily found in the urogenital tract 1, the four of 
most interest being MG, MH, UU, UP.  Occasionally these may be found in the oropharynx 
due to orogenital contact and transient colonization of the neonate may occur during 
passage through the birth canal. However, establishment of the mollicutes in the urogenital 
tract occurs after sexual debut.   
Of the genital mollicutes, MG has been most strongly implicated as a sexually transmitted 
infection (STI) with associations with cervicitis 2-6, endometritis 7, pelvic inflammatory 
disease (PID) 8, non-gonococcal urethritis 9, tubal factor Infertility 10 and preterm birth 11. 
Cervicitis is common particularly in STI clinic populations and has been shown to be 
associated with endometritis, pelvic inflammatory disease (PID) 12, adverse pregnancy 
outcomes 13 and enhanced transmission of HIV infection 14. However less than half of 
cervicitis cases are associated with chlamydia or gonorrhoea; the remainder are termed 
non-specific cervicitis (NSC). Aetiological organisms implicated in NSC include Trichomonas 
vaginalis, Herpes viruses, MG, MH and UU 15. 
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There appear to be relationships between the genital mollicutes and bacterial vaginosis 
(BV). Mycoplasma hominis has been associated with BV 1,16,17 but the roles of the other 
mollicutes in BV are unclear 1,18. The pathogenic potential of BV and enhanced HIV 
transmission associated with BV, have been recently recognized 19.  However the pathogenic 
mechanisms of the genital mollicutes are to date, variably characterized 1 and the clinician is 
faced with the uncertainty of the significance of detecting a mollicute in the female genital 
tract. Thus elucidation of their disparate roles as commensals or STI pathogens is of 
importance. 
Using a cross sectional study of 527 attendees of three Australian STI services, we 
determined the prevalence of the genital mollicutes MG, MH, UU and UP and their 
associations with the conditions of cervicitis and BV and examined the clinical correlates of 
MG infection.  
METHODS: 
A cross-sectional study was undertaken in three urban Sydney STI clinics from 30 June 2006 
to 31st January 2010. Ethics approval was granted by the South Eastern Sydney and Illawarra 
Area Health Service Human Research Ethics Committee and the Sydney South West Area 
Heath Service Ethics Review Committee (Royal Prince Alfred Hospital Zone). 
Participant selection 
527 consecutive eligible consenting women were enrolled with 83% recruited from a 
primary study site. Inclusion criteria were women 18 years or older, sexually active in the 
previous three months and requiring or requesting an internal examination. Exclusion 
criteria were clinical PID, antibiotics or gynaecological intervention in the previous month, 
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an intrauterine contraceptive device, current menstruation or pregnancy, attendance 
concerning sexual assault or unsuitability due to psychosocial ill health.   
Of 570 eligible women 527 consented (92.5%). Of women who were ineligible (889), the 
most common reasons were internal examination not required (33.2%), antibiotics in the 
previous month (12.6%), pregnancy (9.2%), not sexually active (7.9%) and sexual assault 
(6.0%). Thirty one women (3.5%) were excluded due to clinical PID. 
Sampling procedure 
The study required two cervical swabs in addition to routine clinic tests. Seven clinicians 
trained in study protocol recruited women to the study. A sterile speculum was used to 
visualize the vagina and cervix. A high vaginal swab (HVS) was taken for Gram stain and wet 
preparation. The endocervix was sampled in all women, with a sterile cotton swab (Copan, 
CA, USA) for routine gonorrhoea and chlamydia testing. An additional endocervical sterile 
cotton swab was taken and placed in viral transport medium 199 (GIBCO Invitrogen, NY, 
USA) and stored at -70oC for subsequent study PCR testing. Gram stain was performed on all 
cervical and HVS and these were examined real-time in the clinic laboratory for the 
presence of cervicitis, bacterial vaginosis, yeast and T vaginalis. Cervicitis was defined as >30 
polymorphonuclear leucocytes per high-powered field (pmnl/hpf) in at least three non-
adjacent fields of cervical mucus on Gram stain. Bacterial vaginosis was defined by Nugent 
score from Gram stain of the HVS. A single laboratory scientist blinded to clinical diagnosis 
later assessed clinicians’ cervical and vaginal Gram stains for diagnostic accuracy. 
Nucleic acid extraction and PCR amplification 
Nucleic acid extraction from swab specimens (suspended in 500 µl of viral transport 
medium) was carried out using a robotic extraction machine (MagNaPure LC, Roche, 
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Germany) applying the Total NA protocol according to the manufacturer's instructions 
(Roche, Germany). Specimens were extracted within 48 hours of receipt, then stored and 
subsequently tested in batches. 
Detection of mollicute species MG, MH, UU and UP was performed using a single-round 
multiplex PCR (mPCR) (VDL06) 20 followed by PCR enzyme-linked immunosorbent assay 
(ELISA).  VDL06 mPCR reaction comprised 10l of template in a 50l of PCR reaction mixture 
containing 14.8l of Nuclease-free water, 14l of 2x iScript reaction mix (BioRad, Australia), 
0.4μM of each primer (Table 1), 0.2µl digoxigenin-11-dUTP (Roche, Germany), and 1l of 
iScript RT enzyme (BioRad, Australia). (This is a commercial master mix used in our 
laboratory for the amplification of both RNA and DNA templates). Cycling conditions were 
50C for 30 min; denaturation at 95C for 15 min, then 50 cycles of 94C for 30 secs, 57C 
for 45 secs, and 72C one min; a final extension of 7 min at 72C; and a 4C hold. PCR 
products were visualized by gel electrophoresis, and the amplicons were identified by probe 
hybridization (Table 1) using the PCR ELISA assay (digoxigenin detection, Roche, Germany). 
Positive controls from either culture-proven or PCR proven sources were used as PCR 
controls. 
Sensitivity of VDL06 mPCR was assessed by measuring the limit of detection (103 copies per 
reaction) of plasmid constructs of the target sites as previously described 20 and is estimated 
to be between 95 to 98%. The specificity was determined by DNA sequencing on PCR 
products of the first 10 positive samples of each MG, MH, UU and UP from the study. 
Nucleotide BLAST on NCBI site (for all 40 samples) confirmed that all DNA sequences 
produced from sequencing were of correct mollicutes species. The results from DNA 
sequencing confirmed the assay has 100% specificity. 
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Table 1. Primers and probes used in identification of mollicute species (VDL06 mPCR) 
 
Organism Probe name Probe sequence 5’ -> 3’ 
Mycoplasma genitalium Mgen-P3-Am Probe bTCGGAGCGATCCCTTCGGT 
Mycoplasma hominis Mhom-P10-Am Probe bGACACTAGCAAACTAGAGTT 
Ureaplasma parvum UPPROBE1 bCTGAGCTATGACATTAGGAGTTACC 
Ureaplasma urealyticum UUPROBE1 bCTGAATTCAATGTTGCAATACATCAGCTGA 
 
Statistical methods 
The prevalence and exact 95% confidence intervals (CI) of mollicutes and bacterial vaginosis 
in the study sample were calculated. The associations of mollicutes with BV and cervicitis 
were estimated using relative risks (RR), 95% confidence intervals and the associated P 
value. As this was a cross-sectional study and the outcomes of cervicitis and bacterial 
vaginosis were both common, we calculated RR rather than odds ratios as the most valid 
measure of association. Comparisons between woman with and without MG were made 
using chi-squared tests and t-tests. All analyses were performed with SAS version 9.2 (SAS 
Organism Primer name Size  Promer sequence 5’ -> 3’ Target gene 
Mycoplasma 
genitalium/hominis 
My-ins 520 OF GTA ATA CAT AGG TCG CAA GCG TTA TC 
16S tRNA gene MGSO-2-Bi 520 OR CAC CAT CTG TCA CTC TGT TAA CCT C 
Ureaplasma 
parvum 
UMS-170 396 OF GTA TTT GCA ATC TTT ATA TGT TTT CG 
Multiple Banded 
Antigen Gene 
 
  
UMA222  OR GTA AGT GCA GCA TTA AAT TCA ATG 
Ureaplasma 
urealyticum 
  
UMS-170 476 OF GTA TTT GCA ATC TTT ATA TGT TTT CG 
UMA263   OR TTT GTT GTT GCG TTT TCT G 
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Institute, Cary, NC USA). The Genmod procedure was used to enable analysis of RR using 
SAS. 
RESULTS 
Of women enrolled, 40.6% presented as asymptomatic and 59.4% had symptoms. MG was 
found in 4.0 % of women, MH in 17.1%, UU in 14.1% and UP in 51.8% of women (Table 2). 
MG was the only mollicute found to be associated with cervicitis (RR 1.85 95% CI 1.52-2.26, 
p<0.0001). The prevalence of BV was 25.5% and BV was not associated with cervicitis. 
Examining the relationship between the genital mollicutes and BV (Table 2), women with 
MH were almost four times more likely to have BV than women without MH (RR 3.61 95% CI 
2.80-4.65, p<0.0001). None of the other genital mollicutes were significantly associated with 
BV. 
Correlates of MG infection were examined (Table 3).  MG was significantly associated with 
cervicitis (p<0.0001) and with women being HIV positive (p=0.033). There was no 
association between MG and age, vaginal discharge, commercial sex work (CSW), being 
culturally and linguistically diverse (CALD) or concurrent chlamydia infection (prevalence 
5.7% in our study sample). It was noted that two of the 21 women with MG had ectopic 
pregnancies near the time of recruitment.  
Mollicutes were found in 346/527 (65.7%) women and of these women 95/346 (27.5%) had 
more than one mollicute detected (Table 4). Of the mollicutes, UP occurred significantly 
more often (p<0.0001) as a single mollicute infection (72% of UP infections). 
The prevalence of cervicitis was 47.7%. Agreement between the clinician and laboratory 
scientists’ Gram stain diagnosis of cervicitis was high at 85.4% (95% CI 80.1-90.0). 
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Table 2. Prevalence and associations of Mollicutes with cervicitis and BV 
Bacterial 
Exposure 
Prevalence (%) (95%CI) RR of cervicitis 
 
p value RR of BV p value 
M genitalium 21/527     4.0%  (2.5-6.0) 1.85 (1.52-2.26) <0.0001 1.11 (0.56- 2.22) 0.764 
M Hominis 90/527     17.1% (14.0-20.6) 1.00  (0.79-1.27) 0.993 3.61 (2.80-4.65) <0.0001 
U. Urealyticum 74/527     14.1% (11.2-17.3) 0.96  (0.73-1.25) 0.747 1.38 (0.96-1.97) 0.080 
U parvum 273/527    51.8%(47.4-56.1) 1.09  (0.91-1.31) 0.342 0.85 (0.64-1.14) 0.278 
Bacterial 
vaginosis 
134/527   25.5%  (21.9-29.4) 1.01 (0.83-1.24) 0.889   
 
 
Table 3. Characteristics of women with and without MG 
 
 Women with MG 
(n=21) 
Women without 
MG(n=506) 
P value
* 
Mean age (yrs) 28.1 30.4 0.279 
Vaginal discharge§ 11 210 0.322 
Cervicitis ¥ 18 234 <.0001 
concurrent Chlamydia 2 28 0.443 
Commercial sex work 3 92 0.666 
CALD ᵵ  7 164 0.945 
HIV positivity 2 11 0.033 
Ectopic pregnancy 3 Unknown  
 
*P value from a t-test for age and chi-squared tests for all other variables. 
§  Symptom of vaginal discharge 
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¥  Cervicitis defined >30 polymorphonuclear leucocytes per high-powered field (pmnl/hpf) 
in at least 3 non-adjacent fields of cervical mucus on Gram stain 
ᵵ  CALD (culturally and linguistically diverse) defined as women indicating they speak a 
language other than English at home, or prefer to speak a language other than English, or 
identify a specific ethnic background that is non-English . 
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Table 4. Mollicute co-infections  
Mollicute(s) 
detected 
Number of 
women 
(n=527)  
% of total 
women 
Proportion of Mollicutes  as 
singe infection 
MG only 6 1.1 6/21         (28.6%) 
MH only 19 3.6 19/90       (21.1%) 
UP only 197 37.4 197/273   (72.2%) 
UU only 29 5.5 29/74       (39.2%) 
MG+MH 2 0.4  
MG+UP 6 1.1  
MG+UU 2 0.4  
MG+UP+UU 2 0.4  
MG+MH+UU 1 0.2  
MH+UP 42 8.0  
MH+UU 14 2.6  
MH+UP+UU 10 1.9  
UP+UU 14 2.7  
MG+MH+UP+UU 2 0.4  
Negative 181 34.3  
Total 527 100%  
MG - M. Genitalium, MH - M. Hominis, UP - U. Parvum, UU - U. urealyticum 
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DISCUSSION  
In this study a prevalence of MG of 4.0% was detected.  This is similar to other populations: 
6.0% in a Swedish STI population 4,5 7.0% in a Seattle STI population 3 and 4.5% in a 
Norwegian STI clinic setting 21. More locally, a study of under-25 year old women 
undergoing abortions in New Zealand found a MG prevalence of 8.7% 22. The prevalence of 
MG in this study is approaching that of Chlamydia, which has been noted in other STI clinic 
populations 4,5,23. Additionally 4.0 % MG prevalence is likely to be an underestimate in this 
population due to the strict inclusion criteria of the study. 
While the prevalence of cervicitis by the case definition used was very high (47.7%), this is 
similar to other high-risk STI clinic populations 2,21. The strong agreement (85.4%) between 
the clinician and laboratory scientists’ Gram stain diagnosis of cervicitis suggests that we 
used a robust and reproducible case-definition 
MG was found to be to be significantly associated with cervicitis. None of the other genital 
mollicutes or bacterial vaginosis were associated with cervicitis (Table 2). As noted by 
Manhart 24 the evidence supporting the role of MG in cervicitis is conflicting.  Studies 
supporting this association 2-5 have used variable definitions of cervicitis and methods of MG 
detection and some use archived specimens 3. There is little information on the potential 
associations between the Ureaplasmas and cervicitis.  
When the relationships between the genital mollicutes and BV were analysed, women with 
MH were almost four times more likely to have BV than women without MH. (Table 2) This 
supports the purported role of MH as a marker for BV 1,17 but the extent to which MH is a 
pathogen in itself remains ill-defined 16. Although we found a strong MH-BV association, 27 
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of the 90 women (30%) with MH did not have concurrent BV, and our measurements for 
MH were qualitative rather than quantitative. Rosenstein’s group found that in higher grade 
BV, numbers of MH organisms increased dramatically 17. In our study, there was no 
association of UU or MG with BV, which has been observed previously 1,18. However, others 
have reported associations of MG with BV 25 and of UU with BV 17. This study found UP to be 
very common (52%). Although not found to be associated with cervicitis or BV, UP was 
significantly more likely to occur as a single mollicute infection (72.2%) in contrast to the 
other mollicutes which were more likely to coexist with other mollicutes (p<0.0001). (Table 
4) This raises the question of whether UP may have a protective probiotic effect with 
respect to infections with other mollicutes, although there is no literature supporting this. 
(The presence of UP did not significantly affect the associations of MG, Chlamydia 
trachomatis, Trichomonas vaginalis or Neisseria gonorrhoea with cervicitis (working not 
shown)). 
We examined correlates of MG infection (Table 3) and found MG to be significantly 
associated with women being HIV positive. The main study clinic serves as a referral centre 
for HIV positive women; hence the HIV prevalence found in this study (2.5%) is higher than 
the background HIV prevalence in this population (0.1-0.2 %) 26. This association of MG with 
HIV positivity has also been noted in a study of Nairobi STI clinic attendees with salpingitis 27 
in a study of West African sex workers 6 and more recently in a prospective study of MSM in 
Brighton, UK 23. As HIV shedding is associated with high MG organism burden 28, it is 
possible MG has the potential to be a significant contributor to heterosexual and 
homosexual HIV transmission. We did not find MG to be associated with concurrent 
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chlamydia infection, which is consistent with other studies 22,25 but recently Chlamydia co-
infection was found to be associated in a large study of preterm birth in Peru 11. 
 Interestingly, we found two of the women with MG had ectopic pregnancies (both early 
undiagnosed pregnancies at the time of recruitment) and another woman gave a history of 
an ectopic pregnancy in the year prior to diagnosis of MG. There is some evidence to 
support the association of ectopic pregnancy and MG 1. Jurstrand’s group in a serological 
study of archived samples 29 found no significant association with ectopic pregnancy, but a 
tendency to an association in younger women. A large UK community based study of low 
risk pregnant women 25 was unable to assess an association between MG and adverse 
pregnancy outcome, perhaps due to very low MG prevalence. Similarly, a large study of 
pregnant women in Guinea-Bissau 30 did not show any association of MG with adverse 
pregnancy outcome. Neither the British or African study examined ectopic pregnancy 
outcome. This observation in our data is quite striking; however we did not collect 
information on ectopic pregnancy in all study participants and so are unable to evaluate the 
significance of this finding at this point.  Given the disastrous reproductive outcome of a 
tubal pregnancy, high MG prevalence found in some populations of pregnant women 22 and 
lack of research in this area, the potential association between MG and ectopic pregnancy 
warrants further investigation. 
In summary, we present important prevalence data and clarification of the associations of 
the genital mollicutes with the common female genital tract conditions of cervicitis and BV. 
We found MG to be the only mollicute significantly associated with cervicitis and only MH to 
be associated with BV. MG was also found more frequently in HIV positive women and our 
data suggest a possible association between MG and ectopic pregnancy. In conclusion, we 
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recommend wider application of PCR testing for Mycoplasma genitalium in STI services and 
the development of a commercially available test, for use in high-risk women, particularly 
those with cervicitis or HIV infection. The longer-term impact of MG infection on 
reproductive health warrants further investigation. 
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CHAPTER 5 
 
Cervicitis: Can we move to a consensus case definition? 
Infectious and non-infectious associations and clinical utility 
of commonly used case definitions for cervicitis. 
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FOREWORD 
This paper is the final summary paper for the Cervicitis Study and encompasses the first 
study aim using data from the full recruitment of 558 women. All infectious and non-
infectious exposures putatively associated with cervicitis from review of the literature are 
included in this comprehensive analysis including multivariate analysis. These associations 
are also compared using other commonly used case definitions for cervicitis including  
yellow discharge, mucopurulent discharge and ectropion, in an attempt to provide guidence 
for a consensus case definition for cervicitis. 
We found a consistent pattern of higher positive predictive values (PPV) and specificities for 
the significant pathogens, using the case definitions yellow discharge and mucopurulent 
discharge. This demostration of better utility of these case definitions concurs with recent 
literature suggesting the traditional definition by microscopy of >30 pmnl/hpf lacks 
prediction of pathogens and is impractical. Importantly it is not available in most clinical 
practice and  overcalls disease. 
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Cervicitis: Can we move to a consensus case definition? Infectious 
and non-infectious associations and clinical utility of commonly 
used case definitions for cervicitis. 
M Josephine Lusk, Frances L Garden, William D Rawlinson, Zin W Naing, Robert G Cumming, 
Pam Konecny 
 
ABSTRACT  
Objective 
To investigate associations and case definition with best utility for cervicitis. 
Methods 
558 women enrolled in a cross-sectional study examining infectious and non-infectious 
associations of cervicitis using the cervicitis definition >30 pmnl/hpf on cervical Gram stain. 
All women underwent testing for multiple pathogens. These associations were assessed 
using other cervicitis definitions (yellow discharge, mucopurulent discharge (MCP)) to 
identify the definition with best clinical utility. 
Results 
Chlamydia trachomatis (CT), Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) 
were significantly associated with increased cervicitis risk by multivariate analysis, the 
strongest associations with the definition MCP: CT Adjusted Relative Risk (ARR) = 2.61 (95% 
CI 1.57-4.35) p=0.0002, MG ARR =2.25 (95% CI 1.12-4.54) p=0.003, TV ARR = 2.86 (95% CI 
1.61-5.09) p=0.0003.  NG (RR= 3.66 (95% CI 2.02-6.62) p<0.0001), CMV, HPV and HIV were 
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associated with increased cervicitis risk on univariate analysis only. Condom use reduced 
cervicitis risk on multivariate analysis (ARR=0.68 (95% CI 0.50-0.92) p=0.013). Positive 
predictive values (PPV) and specificities for significant pathogens were higher for cervicitis 
‘tests’ yellow discharge and MCP. Exposures not associated with cervicitis included bacterial 
vaginosis, HSV1, HSV2, EBV, candida, Ureaplasma urealyticum, age, smoking, past chlamydia 
infection, hormonal contraceptive and cycle phase. 
Conclusion 
There is significantly increased cervicitis risk with CT, NG, MG and TV, however much 
cervicitis remains unexplained. Condom use reduces cervicitis risk. The cervicitis case 
definitions of yellow discharge or mucopurulent discharge have the highest clinical utility 
with consistently higher associations, PPV and specificities for significant pathogens and are 
more practical than the microscopy definition >30 pmnl/hpf. 
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INTRODUCTION    
Thirty years on from its debut there is still much to clarify about cervicitis including its 
etiology, significance and optimal management. Cervicitis is clinically important being 
associated with pelvic inflammatory disease (PID) 1,2 preterm birth 3 and enhanced risk of 
HIV transmission 4. Chlamydia trachomatis (CT) and Neisseria gonorrhea (NG) are 
consistently associated with cervicitis 5,6 but Mycoplasma genitalium (MG) 7,8 and 
Trichomonas vaginalis (TV) 5,7,9 less so. Most diagnoses of cervicitis occur in the absence of 
these pathogens and are referred to as non-chlamydial non-gonococcal cervicitis 5, non-
specific cervicitis 4 or cervicitis of unknown etiology 10. Lack of consensus regarding cervicitis 
case definition currently limits interpretation of studies and accordingly estimates of the 
cervicitis prevalence and its associations vary widely depending on definition used and 
population studied 5,6. 
With the increasing trend of self-collected vaginal or urine samples and molecular diagnostic 
testing, vaginal examination is less frequently performed with fewer clinicians making the 
diagnosis of cervicitis. The commonly used microscopic Gram stain diagnosis of > 30 
polymorphonuclear leucocytes /high-powered field (>30 pmnl/hpf) has little practical 
application in many clinical settings, particularly primary care, but remains popular in 
Sexually Transmitted Disease (STD) clinics. Cervicitis diagnoses based on non-microscopic 
clinical assessments such as ‘mucopurulent discharge’ or ‘yellow discharge’ may have wider 
utility 6,11-13. This research responds to the call for further clarification of the etiology and 
best-case definition for the diagnosis of cervicitis 5,11,12. 
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This study aimed to explore infectious and non-infectious associations of cervicitis using the 
working cervicitis case definition >30 pmnl/hpf on cervical Gram stain, for exposures 
putatively associated with cervicitis from current literature review 6. These associations 
were examined using other commonly accepted cervicitis case definitions (yellow discharge, 
mucopurulent discharge and ectropion) in order to determine the cervicitis definition with 
best clinical utility. 
MATERIALS AND METHODS 
The study protocol is described previously 9,14. In brief a cross sectional study in three 
publically-funded STD clinics in Sydney, enrolled 558 women between July 2006 and 
February 2010. These clinics provide STD and HIV services by triage to patients from ‘priority 
populations’ defined in the 2006-2009 NSW Sexually Transmissible Infections Strategy 15, 
symptomatic patients, STD contacts and those referred from primary care and hospital 
specialists. They operate in catchments with a high proportion (40%) of patients from 
culturally and linguistically diverse cultural backgrounds.  
All recruiting clinicians underwent standardized on-site training in diagnostic microbiology. 
Inclusion criteria included consecutive consenting women over 18 years requiring vaginal 
examination based on presenting complaint or requesting examination. During the study it 
was clinic policy for clinicians to collect speculum samples, with patient self-collected 
samples less commonly offered. (Re-enrolment was permitted if more than six months had 
elapsed since initial enrolment and a new sexual partner reported). Exclusion criteria 
included PID, menstruation, pregnancy, no vaginal sex in prior three months, antibiotic use 
in prior month, sexual assault, IUCD or cervical surgery in prior 3 months.  
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Sampling and laboratory methods 
The cervix was visualized using a sterile speculum and excess exudate removed using a non-
sterile cotton swab before taking three endocervical sterile cotton swabs (Copan California). 
The first endocervical swab was taken for Gram stain to define women as having cervicitis or 
not by the working definition >30 pmnl in 3 non-adjacent high-powered fields and for NG 
culture on selective media (lysed horse blood agar containing vancomycin, colistin, nystatin 
and trimethoprim (VCNT)). A second endocervical swab was collected for CT/NG PCR testing 
(Amplicor CT/NG Test (Roche)) according to usual clinic practice. NG positivity was defined 
by positive culture +/- PCR test result. NG Culture was routinely performed in the clinic at 
the time, with PCR results carrying less reliability in the low prevalence setting. The third 
endocervical swab was taken for multiplex PCRs 14 for MG, M hominis (MH), Ureaplasma 
urealyticum (UU), Ureaplasma parvum (UP), HSV1, HSV2, EBV, VZV, CMV and TV. A high 
vaginal swab was taken for Gram stain and candida culture and wet preparation for TV if 
clinically suspicious 9. Bacterial vaginosis (BV) was defined on Gram stain using Nugent’s 
criteria. 
A laboratory scientist blinded to clinician findings verified gram stain slides for diagnosis of 
cervicitis and BV at a later time.  All discrepant slides were reexamined and consensus Gram 
stain cervicitis diagnosis reached. Testing for high risk Human Papilloma Virus (HPV) 
subtypes 16,18,31,33,35,39,45,51,56,58,59,68 (Human Genetic Signatures High Risk HPV 
Detection Kit, Sydney, Australia) was performed in a subset (n=191) of women 16. All women 
diagnosed with STDs during the study were treated according to clinic guidelines. 
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Yellow discharge was recorded if this was seen on examination of the cervix (cervical 
discharge yellow colour on a white cotton swab) or the woman complained of yellow 
discharge. Mucopurulent discharge (MCP) (subjective clinician observation of purulent 
looking cervical secretions) and ectropion (visibility of the squamocolumnar junction) were 
recorded if this was the noted on the cervix by the examining clinician.  
Data was collected from clinical history sheets modified for the study, on presence of any 
genital symptoms and potential non-infectious etiological exposures. These included age 
group, current smoking, commercial sex work (CSW) and douching status, extent of condom 
use (never or sometimes/always) and number of sexual partners (1, >1) in the last three 
months, current use of combined oral contraceptive (COC), injectable depo-
medroxyprogesterone acetate (DMPA) /Progestagen only pill (POP) or Implanon, phase of 
menstrual cycle (follicular/luteal) and stated history of past chlamydia infection and 
abnormal Pap smear in the preceding two years. 
Statistical methods 
Associations of infectious and non-infectious exposures with cervicitis (the ‘disease’) were 
estimated using relative risks (RR) and χ2 testing. As this was a cross-sectional study and the 
outcome of cervicitis very common, RRs were calculated rather than odds ratios as the most 
valid measure of association. Relative risks were estimated by log-binomial regression. 
Multivariate analysis involved forward selection of covariates using exposures from the 
univariate analysis with p < 0.05. Sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) of the ‘test’ (different cervicitis definitions >30 pmnl/hpf, 
yellow discharge, mucopurulent discharge) for the significant pathogens, were calculated 
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using 2x2 tables. The Laboratory Excel database was maintained by ZWN and MJL entered 
all clinical data and combined the two databases manually. The study was powered (80%, 
p<0.05) to detect RR of 3.0 (assuming cervicitis prevalence of 20% and pathogen prevalence 
5%) or RR 2.4, assuming pathogen prevalence of 10%. All calculations were performed with 
SAS version 9.3 (SAS Institute, Cary, NC USA).   
Ethics approval for the three clinical sites was granted by the South Eastern Sydney and 
Illawarra Area Health Service Human Research Ethics Committee and the Sydney South 
West Area Health Service Ethics Review Committee. 
RESULTS  
There were 1327 consecutive women approached with 630 (47.5%) eligible and 697 (52.5%) 
ineligible. Of 630 eligible women 558 (88.6%) were enrolled (including 21 enrolled twice) 
and 72 (11.4%) declined. Most common reasons for ineligibility were: not requiring 
examination (36.7%), recent antibiotic use (13.5%), menstruation/ pregnancy (12.8%).  
Cervicitis defined as >30 pmnl/hpf was present in 268/558 (48.0%), yellow discharge in 
129/540 (23.9%), mucopurulent discharge (MCP) in 102/540 (18.9%) and ectropion in 
162/530 (30.6%). The cervicitis diagnosis >30 pmnl/hpf was robust, 87.2% of clinician Gram 
stain slides being examined by a laboratory scientist and high agreement between clinician 
and laboratory diagnosis of cervicitis or not (kappa 0.79 (95% CI 0.74-0.84). 
Prevalence of pathogens at enrolment was: CT 5.8% (95% Confidence Interval (CI) 3.8-7.7%), 
NG 1.1% (95% CI 0.2-1.9%), MG 3.8% (95% CI 2.2-5.4%) and TV 3.9% (95% CI 2.2-5.5%). Any 
genital symptoms were present in 59.9%. Cervicitis was strongly associated with the any 
genital symptoms (RR 1.58 (95% CI 1.40-1.78) p<0.0001). 
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Prevalence of infectious and non-infectious exposures and their associations with cervicitis, 
by different cervicitis case definitions are shown in Table 1 and 2 respectively. In univariate 
analysis using the cervicitis definition >30pmnl/hpf, cervicitis risk was significantly increased 
for CT (RR=1.47 (95% CI 1.14-1.89) p=0.003), NG (RR=2.06 (95% CI 1.89-2.25) p=0.012), MG 
(RR=1.84 (95% CI 1.51-2.23) p<0.0001), TV (RR=1.41 (95% CI 1.03-1.93) p=0.033), CMV 
(RR=1.36 (95% CI 1.02-1.82) p=0.038) and High Risk HPV genotype (RR=1.88 (95% CI 1.34-
2.62) P=0.0002).  
Notably the RR of cervicitis increased for most of these exposures using the cervicitis case 
definitions yellow discharge and MCP, being highest for MCP: CT (RR= 2.39 (95% CI 1.52-
3.78) p= 0.0002), NG (RR= 3.66 (95% CI 2.02-6.62) p<0.0001), MG (RR=2.37 (95% CI 1.40-
4.02) p=0.001), TV (RR=2.39 (95% CI 1.41-4.06) p=0.001), CMV (RR 2.00 (95% CI 1.17-3.40) 
p=0.011). 
Presence of HIV infection was associated with increased cervicitis risk only by the MCP 
definition (RR 2.10 (95% CI 1.03-4.27) p=0.041) and interestingly also with ectropion 
(RR=2.05 (95% CI 1.31-3.22) p=0.002). Use of condoms ‘sometimes or always’ was 
associated with a significant reduction in cervicitis risk by case definition >30 pmnl/hpf 
(RR=0.82 (95% CI 0.68-0.98) p=0.027) and yellow discharge definition (RR=0.71 (95% CI 0.52-
0.96) p=0.027) and also a reduction in symptoms (RR=0.82 (95% CI 0.71-0.95) p=0.006). 
Current CSW was associated with reduced cervicitis risk by yellow discharge definition only 
(RR=0.58 (95% CI 0.35-0.96) p=0.035) and douching an increase (RR=1.57 (95% CI 1.05-2.34) 
p=0.028). Douching was uncommon (11.2%). 
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Reporting sexual intercourse in the last week was associated with decreased cervicitis risk 
only by the MCP definition (RR 0.63 (95% CI 0.44-0.90) p=0.012 and reporting >1 partner in 
the previous 3 months was also associated with a reduction in cervicitis, only by the yellow 
discharge definition (RR=0.57 (95% CI 0.40-0.83) p=0.003). 
None of the exposures BV (and MH), UU, UP, HSV1, HSV2, EBV, VZV, candida, age less than 
25 years, smoking, COC, DMPA /POP/Implanon, menstrual phase, stated history of ever 
having chlamydia or abnormal Pap smear in the last two years, were associated with 
cervicitis by any case definitions in univariate analysis. BV was strongly associated with MH 
(RR=3.7 (95% CI 2.90-4.73) p<0.0001) but not with any of the other mollicutes MG, UP or 
UU.  
Multivariate analysis (Table 3) of significant exposures with different cervicitis case 
definitions, found only CT, MG and TV to be significantly associated with increased cervicitis 
risk. (NG could not be modelled due to small data numbers, but achieved the highest 
unadjusted RR). The highest RR for cervicitis were again seen for the case definition MCP: CT 
Adjusted relative risk (ARR) = 2.61 (95% CI 1.57-4.35) p=0.0002, MG ARR =2.25 (95% CI 1.12-
4.54) p=0.003 and TV ARR = 2.86 (95% CI 1.61-5.09) p=0.0003. Using the working cervicitis 
definition of 30pmnl/hpf, only CT (ARR =1.30 (95% CI 1.01-1.68) p=0.045) and MG (ARR= 
1.55 (95% CI 1.24-1.95) p=0.0002) were associated with increased cervicitis risk. Use of 
condoms sometimes/ always was associated with reduced cervicitis risk by the >30 
pmnl/hpf (ARR=0.86 (95% CI 0.74-0.99) p=0.047) and yellow discharge cervicitis definitions 
only (ARR = 0.68 (95% CI 0.50-0.92) p=0.013). CMV was not significantly associated with 
cervicitis by any case definition. 
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Table 4 outlines the sensitivities, specificities, PPV and NPV of different cervicitis case 
definitions (‘tests’) for the significant pathogens MG, CT, NG and TV. This shows the 
strongest PPV and specificities for all significant pathogens were consistently higher for the 
cervicitis ‘tests’ yellow discharge and MCP. 
Population Attributable Risk% (PAR%) of significant pathogens in the etiology of cervicitis, 
assuming causative effects, were calculated using ARR for the case definition MCP from 
table 3 and unadjusted RR for NG, and are as follows: CT 8.5%, NG 3.6%, MG 4.5%, TV 6.7%, 
yielding a total PAR% of the four significant pathogens of 23.4% in the etiology of cervicitis. 
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Table 1  
Univariate Analysis. Exposure prevalence and unadjusted relative risk (RR) of cervicitis by 
different case definitions (30 pmnl/hpf, yellow discharge and mucopurulent discharge 
(MCP), ectropion and presence of symptoms) for infectious exposures 
Variable 
 
 
 
n Prev 
% 
RR Cx 
>30 
pmnl  
95% CI p  RR 
yellow 
d/c 
p  RR 
MCP 
 
p RR 
ectrop 
p RR 
Sympt 
p 
          MG 
 
552 3.8 1.84 1.51-2.23 <.0001 2.10 0.002 2.37 .0013 1.24 0.445 0.96 0.820 
          MH 
 
552 16.9 0.99 0.78-1.25 0.94 1.18 0.387 1.40 0.103 0.82 0.284 1.28 .0011 
          UU 
 
550 14.0 0.95 0.73-1.23 0.685 0.99 0.875 1.04 0.886 1.04 0.844 1.05 0.591 
          UP 
 
552 52.4 1.14 0.95-1.36 0.158 1.00 0.999 1.04 0.826 0.94 0.617 1.03 0.657 
          CT 
 
555 5.8 1.47 1.14-1.89 .003 1.84 .0073 2.39 0.0002 1.76 0.003 0.83 0.295 
          NG 
 
554 1.1 2.06 1.89-2.25 .012 3.60 <.0001 3.66 <.0001 0.54 0.501 1.4 0.072 
          TV 
 
545 3.9 1.41 1.03-1.93 0.033 2.06 0.0029 2.39 0.0012 0.98 0.956 1.21 0.187 
          HPV 
 
191 8.4 1.88 1.34-2.62 .0002 1.91 0.108 2.33 0.078 1.45 0.230 1.22 0.271 
          CMV 
 
542 5.2 1.36 1.02-1.82 0.038 1.71 0.030 2.00 0.011 1.57 0.036 1.22 0.118 
          BV 
 
555 25.4 1.02 0.83-1.24 0.855 1.00 0.995 1.21 0.323 1.11 0.465 1.32 <.0001 
          HSV1 
 
542 1.3 0.90 0.38-2.13 0.809 1.82 0.177 1.53 0.485 0.93 0.910 1.21 0.439 
          HSV2 
 
543 2.0 0.95 0.49-1.82 0.864 - - - - 0.59 0.416 0.61 0.212 
          EBV 
 
542 4.8 0.97 0.63-1.48 0.881 0.97 0.929 1.24 0.056 1.61 0.028 0.97 0.858 
          VZV 
 
542 2.2 0.70 0.31-1.56 0.377 0.70 0.576 - - 0.27 0.170 0.70 0.293 
     Candida 
 
555 18.9 1.10 0.89-1.36 0.366 1.02 0.929 1.03 0.887 0.69 0.061 1.45 <.0001 
          HIV 
 
554 2.5 1.11 0.60-2.04 0.740 1.64 0.170 2.10 0.041 2.05 0.002 0.47 0.076 
 
Blank entries where RR could not be calculated 
n varies according to data numbers for that variable 
Neisseria gonorrhea (NG),Chlamydia trachomatis (CT), Trichomonas vaginalis (TV) Mycoplasma genitalium 
(MG), Mycoplasma hominis (MH), Ureaplasma urealyticum (UU), Ureaplasma parvum(UP), High Risk Human 
Papilloma Virus (HPV)  herpes simplex virus type 1 (HSV1), herpes simplex virus type 2 (HSV2), Epstein Barr 
virus (EBV) ,varicella zoster virus (VZV), cytomegalovirus (CMV), human immunodeficiency virus (HIV), bacterial 
vaginosis (BV)
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Table 2 
Univariate analysis. Exposure prevalence and unadjusted relative risk (RR) of cervicitis by 
different case definitions (30 pmnl/hpf, yellow discharge and mucopurulent discharge 
(MCP), ectropion and presence of any genital symptoms) for non-infectious exposures 
Variable 
 
 
 
n Prev 
% 
RR Cx 
>30 
pmnl  
95% CI p RR 
yellow 
d/c 
p RR 
MCP 
 
p RR 
ectrop 
p RR 
Sym
p 
p 
Age group 
<25yrs 
558 30.8 1.15 0.97-1.38 0.115 0.92 0.606 1.18 0.383 1.50 0.002 1.03 0.700 
Smoke 
 
549 41.7 0.97 0.81-1.17 0.775 1.01 0.679 0.93 0.698 0.76 0.049 - - 
CSW 
 
553 17.5 0.83 0.65-1.08 0.158 0.58 0.035 0.89 0.629 0.71 0.092 0.81 0.053 
douche 492 11.2 1.02 0.77-1.36 
 
0.884 1.57 0.028 1.51 0.085 0.88 0.622 1.07 0.511 
aCondom 
sometime
s/always 
 
528 65.9 0.82 0.68-0.98 0.027 0.71 0.027 0.94 0.747 1.21 0.200 0.82 0.006 
Partner>1
b 
545 35.2 0.87 0.72-1.06 0.162 0.57 0.003 0.87 0.470 0.71 0.021 0.96 0.608 
Last sex<1 
week ago 
 
542 52.6 0.90 0.75-1.07 0.215 0.76 0.083 0.63 0.012 0.90 0.433 0.91 0.188 
COC 
 
550 28.2 1.11 0.92-1.33 0.292 0.88 0.491 0.74 0.171 1.76 <.0001 0.89 0.154 
Cycle 
phase 2 
 
426 60.1 0.85 0.69-1.04 0.109 0.80 0.216 0.88 0.502 0.99 0.965 1.03 0.678 
POP 
/DMPA/ 
implanon 
 
545 5.9 0.97 0.66-1.42 0.890 1.23 0.478 0.84 0.678 0.83 0.600 0.99 0.972 
Hx CT 
 
384 13.8 0.91 0.67-1.23 0.532 1.40 0.124 1.15 0.603 1.26 0.263 0.96 0.725 
Abnormal 
pap within 
last 2 yrs 
487 12.9 0.95 0.72-1.27 0.735 0.83 0.494 0.79 0.462 1.58 0.008 0.97 0.794 
 
n varies according to data numbers for that variable 
a 
condoms used “sometimes/always” in the last 3 months 
b 
partner >1 means more than one partner in the last 3 months 
commercial sex worker (CSW),combined oral contraceptive (COC), depo-medroxyprogesterone acetate 
(DMPA), progestogen only pill (POP) /Implanon
TM 
,Hx chlamydia is reported history of chlamydia ever 
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Table 3 
Multivariate analysis. Adjusted relative risk (ARR) of cervicitis by different case definitions 
(30pmnl/hpf, yellow discharge and mucopurulent discharge (MCP)) for significant infectious 
and non-infectious exposures 
Variable 30 pmnl/ 
hpf 
 
95% CI  Yellow 
d/c 
95% CI  MCP  
 
95% CI  
 
 
ARR  p ARR  p ARR  p 
MG 
 
1.55 1.24-1.95 0.0002 2.13 1.27-3.55 0.004 2.25 1.12-4.54 0.003 
CT 
 
1.30 1.01-1.68 0.045 1.81 1.12-2.92 0.015 2.61 1.57-4.35 0.0002 
TV 
 
1.34 0.96-1.87 0.086 2.30 1.40-3.78 0.001 2.86 1.61-5.09 0.0003 
CMV 
 
1.16 0.89-1.50 0.275 1.50 0.89-2.51 0.128 1.22 0.65-2.29 0.528 
Condoms sometimes 
/alwaysa 
0.86 0.74-0.99 0.047 0.68 0.50-0.92 0.013 0.98 0.67-1.42 0.898 
(HIV)b 
 
      1.68 0.74-3.80 0.216 
 
Multivariate model includes exposures with p < 0.05 from univariate analysis using the cervicitis case definition 
30 pmnl/hpf.  NG excluded from model as data too sparse. HPV excluded as n=191  
Neisseria gonorrhea (NG), Chlamydia trachomatis (CT), Trichomonas vaginalis (TV) Mycoplasma genitalium 
(MG) 
a
condoms used “sometimes/always” in the last 3 months 
b
HIV included in model for MCP as unadjusted RR of cervicitis with HIV significant by this case definition. 
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Table 4   
Sensitivities, specificities, negative predictive values (NPV) and positive predictive value 
(PPV) of different cervicitis case definitions (‘tests’) 30 pmnl/hpf, yellow discharge,  
mucopurulent discharge (MCP) for the significant infectious exposures MG, CT, NG and TV 
Variable Cx case Defn (test) 
 
Sens (%) Spec (%) ppv (%) npv (%) 
MG 30 pmnl 86 54 7 99 
 Yellow discharge 48 77 8 97 
 MCP  43 82 9 97 
CT 30pmnl 69 54 8 97 
 Yellow discharge 42 77 10 96 
 MCP  42 82 13 96 
NG 30 pmnl 100 53 2 100 
 Yellow discharge 83 77 4 100 
 MCP  67 82 4 100 
TV 30 pmnl 67 53 5 98 
 Yellow discharge 48 77 8 97 
 MCP  43 82 9 97 
 
Neisseria gonorrhea (NG), Chlamydia trachomatis (CT), Trichomonas vaginalis (TV) Mycoplasma genitalium 
(MG) 
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DISCUSSION 
 
Cervicitis is very common and frequently symptomatic, necessitating better understanding 
of its etiology. Infectious exposures significantly associated with increased cervicitis risk in 
multivariate analysis were CT, NG, MG and TV, with all these associations being strongest 
for the cervicitis case definition MCP. Use of condoms sometimes/ always reduced cervicitis 
risk. Infectious exposures not associated with cervicitis included HSV1, HSV2, EBV, BV, MH, 
UU, UP and candida. Non-infectious exposures not associated with cervicitis included age 
less than 25, smoking, COC, DMPA /POP/Implanon use, reported history of CT or abnormal 
Pap smear in the preceding two years and menstrual phase.  
Our results concerning HSV and BV are contrary to others 17,18 but Gaydos et al 7 also 
recently found BV was not associated with cervicitis. Our finding of MH being the only 
mollicute associated with BV has also been noted previously 19. Both BV and MH have been 
implicated in PID 20 so their association with cervicitis might be expected. 
After adjusting for other significant exposures CMV was not significantly associated with 
cervicitis by any case definition, supporting its role as a bystander rather than cause of 
cervicitis 17, despite an important role in neonatal infection 21. The cervical CMV prevalence 
of 5.2% is remarkably similar to the CMV IgM positivity rate of 5.5% found in a local study of 
pregnant women 21. 
Infection with HIV was associated with cervicitis using the MCP cervicitis definition but was 
not significant when adjusted for STDs. This is an important potential association given that 
STDs enhance HIV shedding from the cervix contributing to horizontal and vertical HIV 
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transmission. In earlier studies 22 we demonstrated a significant association between MG 
and HIV, as well as MG and cervicitis. Manhart et al 23 described increased HIV shedding in 
women with high cervical MG burden; it may be that MG-associated cervicitis in particular is 
an important HIV transmission driver.    
Cervical infection with High-Risk HPV was associated with increased cervicitis risk by the 
>30pmnl/hpf definition only in univariate analysis. This is a biologically plausible association 
6. Cervical inflammation has previously been suggested as a possible co-factor in the 
development of high grade cervical lesions in women with oncogenic HPV, with uncertain 
temporality to this association24. We were limited to 191 High-Risk HPV testing kits, but with 
more data this might have been a stronger finding and worth exploring further.  
A curious finding was >1 partner being associated with a reduction in cervicitis by the yellow 
discharge definition (RR=0.57 (95% CI 0.40-0.83) p=0.003). A possible explanation besides 
chance, was that women with more partners might use condoms more, but there was no 
significant interaction between number of partners and condoms use (p=0.426). Also, 
unexplained was the finding that sex in the previous week reduced cervicitis risk, but this 
was only for the MCP definition, and has not been implicated as a factor previously. 
A case definition for cervicitis with the best clinical utility is one easily made in primary care 
with good PPV for pathogens that does not over diagnose ‘disease’ 12. Using the definition of 
>30 pmnl/hpf , 48% of women had cervicitis, a very high rate of ‘disease’ with incumbent 
ramifications for individuals and couples with the diagnosis of an ‘STD’ and potential for 
antibiotic overuse. Because most women diagnosed with cervicitis will routinely have 
testing for at least CT and NG with the opportunity for recall for treatment, the specificity of 
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a bedside ‘test’ for cervicitis is probably of greater importance than the sensitivity. Our data 
show that the MCP ‘test’ for cervicitis (and yellow discharge ‘test’) show consistently higher 
ARR, PPV and specificities than the traditional cervicitis ‘test’ of 30 pmnl/hpf, for the 
significant pathogens CT, NG, MG and TV, but lower sensitivities. Importantly cervicitis or 
‘disease’ was diagnosed in only 18.9% of women using the MCP case definition. Marrazzo et 
al 12 also found cervical signs such as mucopus to have better PPV for pathogens chlamydia 
or gonorrhea than >30 pmnl/hpf, particularly in women under 25. Our findings suggest the 
case definition >30 pmnl/hpf over-calls disease and lacks prediction of pathogens. It follows 
that MCP or yellow discharge are the cervicitis case definitions with better all-round clinical 
utility. NPV for significant pathogens were high for all cervicitis ’tests’, reflecting low 
pathogen prevalence in this population. 
As rapid point of care (POC) tests become more available, such a test to predict disease 
would be a welcome development in the first-line management of women with vaginal 
symptoms, given these complaints are often poorly managed initially 25. Vaginal leucocytes 
predict endometritis 2 and so act as a useful triage system, particularly in the presence of BV 
and other STDs (CT and NG) 26. A blind vaginal swab with a rapid POC test for both 
leucocytes and pH could provide an effective, immediate and less invasive way of predicting 
serious infection and guiding immediate management than a speculum examination. MCP 
cervicitis or raised vaginal leucocytes both provide us with ‘tests’ at the bedside with 
reassuringly high NPV and specificities for pathogens in the absence of ultimate solution of 
cheap reliable POC multiplex tests for CT, NG, MG and TV. 
In our STD population, using the most predictive cervicitis definition of MCP, the PAR% of 
the significant pathogens CT NG, MG and TV (assuming causative roles), might still only 
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account for 23.4% of cervicitis. However as PAR% is prevalence driven, this figure would 
increase with higher pathogen prevalence and highly triaged situations. 
Given this result it is reasonable to postulate that factors other than infective agents play a 
role in cervicitis 5. A very extensive range of potential pathogens were considered in this 
study, but the low cumulative PAR % of the significant pathogens leave about 75 % of 
cervicitis unexplained in this setting and not necessarily synonymous with pathogen 
infection. We have however demonstrated some important negative findings, particularly 
concerning the potential roles of BV, MH, UU and HSV. With expanding knowledge of the 
microbiome, in particular the vaginal microbiome, other pathogens may be uncovered, 
much as MG has emerged as a pathogen in the last 15 years. 
Inflammatory cytokines have been implicated in cervical inflammation 5. Pro-inflammatory 
cytokines and cervical monocyte activation have been associated with ectopy and menstrual 
cycle phase in healthy women 27 which may afford protection to the female genital tract 
under these conditions, but ironically enhance HIV acquisition risk. Higher RANTES and 
lower secretory leukocyte protease inhibitor (SLPI) were associated with HIV transmission in 
a large study of African women (seen in DMPA users, possibly contributing to increased HIV 
transmission risk in this group), but the study did not examine cervicitis associations 2 8. 
Elevated Interleukin 10 has been described in women with non-ulcerative STDs and BV 29 
and also proposed as a possible mechanism for increased susceptibility to HIV. A small 
Japanese study of pregnant women 30 found significantly elevated levels of IL-8, IL6, 
lactoferrin and µ-DF in cervicitis. A recent small Indian study 31 found elevated levels of 
interlekin-1β, tumor necrosis factor-α and interleukin 6 to be significantly associated with 
cervicitis, but they did not control for infections with CT, NG, HSV or MG, thereby limiting 
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the significance of their findings. Whether these inflammatory markers contribute to or are 
simply present in cervicitis is not clear. 
There is also the possibility that ‘cervical inflammation’ or cervicitis may be part of a normal 
continuum in some women. Little is known about the natural history of cervicitis. The three 
different definitions of cervicitis used in this study yielded widely differing cervicitis 
prevalence, from 48% (30 PMNL) down to 18.9% from mucopurulent discharge. Such 
divergent results suggest inaccuracies and uncertainties with the criteria used to define a 
condition, labelled as pathological by many, but as a poorly explained enigma by others. This 
study has tried to address the merits of the different definitions widely used and propose a 
best working definition for cervicitis. Only from this point, can the management of this 
condition be clarified. 
Study strengths and limitations   
This study was cross sectional with limited inference on causality, but sample size was large 
and appropriately powered (80% p<0.05) to detect pathogen RR of 2.5 to 3.0. We included 
in the study all relevant infectious and non-infectious exposures. Clinical practice directed 
examination of a convenience sample of all symptomatic women and some asymptomatic 
women, so enrolment was biased towards symptomatic women (60%) likely contributing to 
high cervicitis rates, by all definitions. Recruitment occurred at three related STD clinics but 
83% at the primary clinic (Short Street Centre) using a small group of clinicians with 
advantages for consistency but also potential biases. HPV data on all women would have 
been optimal but funding precluded this. 
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In summary we have demonstrated significantly increased cervicitis risk with CT, NG, MG 
and TV however much cervicitis remains unexplained. We recommend the cervicitis case 
definitions with best clinical utility are yellow discharge or mucopurulent discharge, which 
have consistently higher associations, PPV and specificities for significant pathogens than 
the traditional case definition >30 pmnl/hpf. We hope this study further supports a 
consensus case definition for cervicitis.     
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FOREWORD 
This paper presents the findings of an observational treatment study which was a sub-study 
of the Cervicitis Study. It aimed to investigate the benefit of presumptive treatment of 
women with cervicitis and non-specific cervicitis (NSC) with azithromycin 1 G orally and 
determine if there is any benefit of addition of presumptive azithromycin treatment of male 
partners. At the time the Cervicitis Study was planned it was common practice to 
presumptively treat women diagnosed with cervicitis with azithromycin. Support for this 
practice waned as it has become more apparent that only a small proportion of cervicitis 
occurs in the presence of chlamydia  infection and although azithromycin covers chlamydia 
and a large proportion of Mycoplasma genitalium (MG) infection, there is growing evidence 
of azithromycin resistance to MG. 
Cervicitis was defined as >30 pmnl/hpf with or without known pathogens. NSC was defined 
as cervicitis (>30 pmnl/hpf) occurring in the absence of the pathogens CT, MG, NG or TV. 
This assumed findings from the main Cervicitis Study paper (chapter 5) that these pathogens 
are significantly associated with cervicitis.  
The outcomes examined in this study were the persistance of cervicitis (30 pmnl/hpf) or the 
presence of any genital symptoms. Analysis of follow-up outcomes in women excluded any 
women who were diagnosed as having one of the pathogens CT, MG, NG or TV at follow-up 
visit. Although we found presumptive azithromycin treatment was associated with a 30% to 
40% reduction in cervicitis persistence in women with NSC and a similar reduction of 
symptoms for women with cervicitis, these effects did not reach statistical significance. A 
larger RCT study may show more conclusive results. If azithromycin treatment of women 
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with cervicitis and NSC is associated with a reduction of the outcomes assessed, our results 
suggest it is not a large effect.  
Study limitations 
The findings of this study have significant limitations primarily because it was not a 
randomized controlled trial (RCT), follow-up numbers were very small (particularly the non-
treatment group) and there was a long and variable time to follow-up for many women. In a 
more formalized and resourced study, routine follow-up of women at four to six weeks 
would be desirable to more reliably link treatment with effect on follow-up outcomes. This 
study was an observation of the results of clinical practice (a ‘real life’ observational study) 
and suffers the limitations of this; however it represents a solid effort to answer questions 
about presumptive treatment.  
In the context of the literature reviews it seems likely that cervicitis predicts upper genital 
tract infection and the long-term sequalae associated with this and so it is possible that 
azithromycin treatment in women with cervicitis and NSC could have benefits in the 
reduction of sequelae of subclinical PID. These are more difficult treatment outcomes to 
assess but may be more important than the outcomes assessed in this study. 
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Cervicitis: A prospective observational study of empiric treatment 
with azithromycin in women with cervicitis and non-specific 
cervicitis and their male partners, in Sydney STD clinic populations. 
M Josephine Lusk, Frances L Garden, Robert G Cumming, Pam Konecny 
ABSTRACT  
Background and Aim  
Cervicitis management guidelines reflect its uncertain etiology with unclear benefit of 
presumptive azithromycin treatment of women and their partners. The aim of this 
prospective observational study in women attending three STD services in Sydney 2006-
2010 was to assess the effect of presumptive azithromycin 1 G orally for women with 
cervicitis and non-specific cervicitis (NSC) and effect of additional partner presumptive 
treatment.  
Methods 
Cervicitis was defined as >30 pmnl/hpf with or without known pathogens. NSC was defined 
as >30 pmnl/hpf in the absence of Chlamydia trachomatis (CT), Mycoplasma genitalium 
(MG), Neisseria gonorrhea (NG) or Trichomonas vaginalis (TV). Testing for CT, MG and TV 
was by PCR and NG by PCR and culture. The follow-up outcomes were persistence of 
cervicitis or persistent of any genital symptoms. Women with positive tests for CT, MG, NG 
or TV at follow-up (incident or persistent infection) were excluded from the follow-up 
analysis. Effect on the outcomes was also assessed after additional reported presumptive 
partner treatment with azithromycin 1G. 
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Results:  
558 women were enrolled. Prevalence of pathogens at enrolment of all women was: CT 
5.8%, NG 1.1%, MG 3.8%, TV 3.9%. Cervicitis prevalence at enrolment was 268/558 (48.0%). 
Of these women, 131 (48.9%) returned for follow-up and after exclusion of women with 
positive pathogens at follow-up or missing data, 125 women with cervicitis and 89 women 
with NSC could be included in the follow-up analysis.  
Presumptive treatment of women with azithromycin 1 G orally showed a non-significant 
reduction in cervicitis persistence in women with cervicitis, RR=0.74 (95% CI 0.46-1.21) 
p=0.235 and in women with NSC, RR=0.60 (95% CI 0.35-1.02) P=0.058. Presumptive 
treatment was associated with a non-significant reduction of symptoms in women with 
cervicitis, RR=0.67 (95% CI 0.44-1.01) p=0.054 and in women with NSC, RR=0.91 (95% CI 
0.46-1.79) p= 0.780. Addition of presumptive partner treatment did not reduce cervicitis 
persistence in women with cervicitis, RR=1.18 (95% CI 0.70-2.00) p=0.528 or those with NSC, 
RR= 1.02 (95% CI 0.54-1.90) p=0.961. 
 Conclusions: Although not reaching statistical significance, our findings suggest 
presumptive azithromycin treatment of women with NSC may be associated with reduced 
cervicitis persistence and a reduction of symptoms in women with cervicitis. We did not find 
a benefit of partner presumptive treatment. A larger study, ideally a RCT may show 
significant benefit of presumptive treatment of women particularly in higher STD prevalence 
populations.  
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INTRODUCTION   
Cervicitis is associated with clinical disease such as pelvic inflammatory disease (PID), 
endometritis and preterm birth 1-4 and increased risk of HIV transmission 5. It is common and 
often asymptomatic but many women have troubling symptoms which require a clinician’s 
action. Accordingly it remains relevant to pursue better understanding of how to manage 
cervicitis at the time of initial consultation. 
Lower genital tract complaints in women are extremely common and often inaccurately 
diagnosed and presumptively treated in the first instance 6. This has the disadvantages of 
antibiotic overuse, cost and increased potential for reinfection if clear diagnoses are never 
made and partners not concurrently treated. Management guidelines for cervicitis reflect 
the uncertainty of the etiology of cervicitis and are inconsistent in their recommendations 
for management. The 2010 CDC guidelines 7 recommend presumptive treatment of 
cervicitis with azithromycin 1 G stat for women less than 25 years of age, those reporting 
new or frequent partner change and unprotected sex, HIV positive women and women 
unlikely to return for follow-up. The addition of presumptive treatment for Neisseria 
gonorrhea (NG) is suggested in populations of >5% NG prevalence and partner management 
is informed by pathogen isolation. Interestingly the management of the analogous condition 
in males, non-specific urethritis (NGU), is much more clearly defined with the 
recommendation of presumptive treatment of affected men and their female partners, 
assuming high Chlamydia trachomatis (CT) infection rates. Many guidelines for cervicitis are 
not so prescriptive and questions remain as to whether there is benefit in presumptive 
treatment of women with cervicitis and presumptive treatment of their male sexual 
partners 8-11.  
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The aim of this prospective observational study was to assess the effect of presumptive 
treatment with azithromycin 1 G PO of women with cervicitis and non-specific cervicitis 
(NSC), on the outcome of cervicitis persistence or genital symptoms and to assess if there 
was a benefit on cervicitis persistence of additional presumptive male partner treatment 
with azithromycin 1 G PO. 
METHODS 
Recruitment and Laboratory methods 
This was an observational treatment-outcome sub-study within a larger study examining 
infectious and non-infectious exposures associated with cervicitis and utility of commonly 
used definitions of cervicitis (submitted elsewhere for publication). The methods have been 
previously described 12,13: in brief a cross-sectional study in three STD services in Sydney 
enrolled 558 consecutive consenting women from July 2006 to February 2010. These 
services are publically-funded STD and HIV management clinics serving suburban 
populations of average socio-economic status including a large proportion (40%) of 
culturally and linguistically diverse people.  
Women over 18 years consecutively attending the clinics, requiring vaginal examination 
based on presenting complaint or requesting examination, were approached for the study. 
The exclusion criteria were PID, menstruation, pregnancy, no vaginal sex in the prior 3 
months, antibiotic use in the prior month, sexual assault, IUCD or cervical surgery in the 
prior 3 months. Women were diagnosed as having cervicitis or not by the assessment of a 
cervical swab Gram stain using the definition >30 polymorphonucleocytes/ high-powered 
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field (pmnl/hpf) in 3 non-adjacent fields, with this diagnosis verified at a later time by a 
laboratory scientist blinded to clinician findings. 
For the purposes of analysis cervicitis was defined as the finding of >30 pmnl/hpf on cervical 
Gram stain with or without known pathogens. NSC was defined as the subset of women 
with >30 pmnl/hpf in the absence of Chlamydia trachomatis (CT), Mycoplasma genitalium 
(MG), Neisseria gonorrhea (NG) or Trichomonas vaginalis (TV). Women with positive results 
for CT, MG, NG or TV (ie persistent or interim incident infection) at follow-up, were excluded 
from the follow-up analysis. 
Women were tested real time for CT and NG by PCR (Amplicor CT/NG PCR test (Roche)), NG 
by culture (on selective media of lysed horse blood agar containing vancomycin, colistin,  
nystatin and trimethoprim (VCNT)), bacterial vaginosis  (Amsel’s Criteria) and candida 
(culture). They had non-real time testing for a number of other infectious agents putatively 
associated with cervicitis, using dedicated study multiplex PCRs 13 for Mycoplasma 
genitalium (MG), M hominis (MH), Ureaplasma urealyticum (UU), Ureaplasma  parvum (UP), 
HSV1, HSV2, EBV, VZV, CMV and Trichomonas vaginalis (TV). NG status was considered 
positive if a positive PCR result was confirmed by culture. 
Clinical data was collected during patient clinical consultations by a group of trained clinic 
doctors and nurses using clinical history sheets modified for the purposes of the study. 
Variables included age, presence of any genital symptoms, current commercial sex work 
(CSW), current smoking, current douching status, condom use (always/sometimes/never) 
and number of sexual partners (1, >1) in the last 3 months. 
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Treatment and follow-up 
All women diagnosed with cervicitis were offered presumptive treatment with azithromycin 
1 G PO stat on the day of enrolment but if NG or TV were diagnosed by on-site microscopy, 
women were treated accordingly with ceftriaxone 500mg IM or tinidazole 2G PO 
respectively and not offered presumptive azithromycin. Women with cervicitis were 
encouraged to return for follow-up in 6 to 8 weeks’ time but were not actively recalled 
unless they required a test of cure or treatment for a pathogen identified from non-real 
time study test results. Time to follow-up of some women with positive study multiplex 
results was delayed due to batch testing but all routine tests for CT and NG were acted upon 
in real time.  
Follow-up outcomes were defined as persistence of cervicitis by the same cervicitis 
definition >30pmnl/hpf on cervical Gram stain or report of any genital symptoms. 
Women taking presumptive azithromycin treatment were given a contact information slip 
for their male partners offering male partners presumptive treatment and study testing. 
Women diagnosed with cervicitis were advised of the uncertainty of benefit of presumptive 
treatment for themselves and presumptive partner treatment. Women who returned for 
follow-up were asked if they had taken the azithromycin treatment supplied as directed and 
if their sexual partner(s) had taken this same treatment (‘partner treatment’). 
Statistical analysis 
Differences between baseline characteristics of women with cervicitis who were followed 
up or not, and of women with cervicitis followed up who had azithromycin treatment or not, 
were assessed using χ2 tests. The effect of presumptive treatment of women with cervicitis 
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and the additional effect of partner treatment were estimated using relative risks (RR) and 
95% confidence intervals (CI). Significant associations were those for which the p-value was 
<0.05. All calculations were performed with SAS version 9.3 (SAS Institute, Cary, NC USA). 
Ethics approval was granted by the South Eastern Sydney and Illawarra Area Health Service 
Human Research Ethics Committee and the Sydney South West Area Heath Service Ethics 
Review Committee. 
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Figure 1- Study map        
 
       1327 consecutive women approached 
            
   
 
   630 women eligible    697 women ineligible 
 
 
    
558 women enrolled (88.6%)   72 women declined (11.4%) 
 
 
   268 women diagnosed with cervicitis (48%) 
 
 
                         125 women with all cervicitis                            89 women with non-specific cervicitis 
follow-up                          follow-up (CT, NG, MG, TV  excluded) 
 
 
114 women treated with azithromycin              82 women treated with azithromycin  
11 women not treated              7 women not treated 
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RESULTS  
Of 1327 consecutive women approached, 630 were eligible and 558 enrolled (88.6%). 
72/630 (11.4%) of eligible women declined participation. Of women enrolled 268/558 
(48.0%) were diagnosed with cervicitis.  
Of the 268 women with cervicitis, 131 (48.9%) returned for follow-up, and after exclusion of 
women with positive pathogens at follow-up and missing data, 125 women with cervicitis 
and 89 women with NSC could be included in the follow-up analysis (Figure 1). (Three 
women in the cervicitis group had infections at follow-up (two with CT and one with MG) 
and none in the NSC group). Presumptive treatment with azithromycin 1 G orally was taken 
by 114/125 women with cervicitis and by 82/89 women with NSC. Reasons for not taking 
presumptive treatment included other diagnosis made at time of consultation (eg. NG, TV, 
HSV) prompting alternative treatment, declined treatment or misclassified as not having 
cervicitis at initial consultation. 
Baseline prevalence of pathogens in all women at initial enrolment was as follows: of CT 
5.8%, NG 1.1%, MG 3.8 % and TV 3.9%. Gram stain diagnosis of cervicitis was verified in 
87.2% of all women with high agreement between clinician and laboratory diagnosis (kappa 
= 0.79 (95% CI 0.74-0.84).  
There were no significant differences in the following baseline characteristics of women 
with cervicitis who followed-up/didn’t follow-up: age <25 years, presence of any symptoms, 
CSW, smoking, douching, condoms use sometimes/always and partner number >1 in the 
previous 3 months (Table 1). For all women with cervicitis who followed up who had 
presumptive treatment /didn’t have presumptive treatment, there were also no significant 
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differences for these same characteristics. However women reporting current CSW or more 
than 1 partner in the prior 3 months were more likely to have cervicitis treated with 
azithromycin than not. 
Time between initial and follow-up visit was variable with a mean of 24.9 weeks and median 
10.1 weeks.  
Presumptive treatment of women with azithromycin 1 G orally showed a non-significant 
reduction in cervicitis persistence in women with cervicitis, RR=0.74 (95% CI 0.46-1.21) 
p=0.235 and in women with NSC, RR=0.60 (95% CI 0.35-1.02) P=0.058 (Table 2). A parallel 
analysis looking at the effect of presumptive treatment on the outcome of presence of 
symptoms at follow-up found a non-significant reduction in women with cervicitis RR=0.67 
(95% CI 0.44-1.01) p=0.054 and in women with NSC, RR=0.91 (95% CI 0.46-1.79) p= 0.780 
(Table 3).  
Of 114 women with cervicitis in the follow-up analysis, 78 were able to report partner 
treatment. There was no effect of stated partner presumptive treatment on the follow-up 
outcome of persistent cervicitis, RR 1.18 (95% CI 0.70-2.00) p=0.528. For the 89 women with 
NSC, 56 could report partner treatment status. There was no additional effect of partner 
treatment on persistence of cervicitis in this NSC group, RR=1.02 (95% CI 0.54-1.90) p= 0.961 
(Table 4).  
The mean age of all women enrolled was 30.3 years and median 28.0 years with two thirds 
(69.2%) being 25 years or older and 30.8% less than 25 years of age. Neither the diagnosis of 
cervicitis nor presence of one of the main pathogens  MG, NG, CT or TV were more likely in 
women in the age group less than 25 years (p=0.115 and p=0.439 respectively). However, CT 
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alone was significantly more likely in women under 25 years (prevalence 9.3%) than in 
women older than 25 years (prevalence 4.2%) , p=0.017. 
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Table 1 
Baseline characteristics of all women with cervicitis (Cx) (30 pmnl/hpf)( n=268) who were 
followed up (n=131) or not (n=137), and of all women with cervicitis followed up who had 
azithromycin (azith) treatment (n=117) or not (n=13). 
Characteristic Women who 
followed up 
Women not 
followed up 
P 
value 
Women with Cx 
treated azith 
Women with Cx 
not treated azith 
P 
value 
Age group <25 
yrs 
47/131(35.9%) 44/137(32.1%) 0.516 42/117(35.9%) 5/13(38.5%) 0.999 
Any symptoms 92/131(70.2%) 97/136(71.3%) 0.844 81/117(69.2%) 10/13(76.9%) 0.754 
Current CSW 23/129(17.8%) 17/137(12.4%) 0.216 22/115(19.1%) 1/13(7.7%) 0.461 
Current smoker 55/128(43.0%) 52/135(38.5%) 0.463 48/115(41.7%) 7/12(58.3%) 0.361 
Current douche 15/119(12.6%) 12/118(10.2%) 0.555 13/117(12.2%) 2/11(18.2%) 0.630 
Condom use 
sometimes/alwa
ys last 3 months 
80/124(64.5%) 75/129(58.1%) 0.298 71/111(64.0%) 8/12(66.7%) 0.999 
>1 partner last 3 
months 
44/129 (34.1%) 40/132(30.3%) 0.511 40/115(34.8%) 3/13(23.1%) 0.541 
 
*Numbers vary according to data availability for baseline characteristic 
 
Table 2 
Effect of presumptive azithromycin (azith) treatment in women with cervicitis (Cx)* and 
non-specific cervicitis (NSC) (CT,MG, NG, TV excluded) on follow-up outcome of persistent 
cervicitis.  
 Followup 
number# 
Treatment 
with azith 
number 
Cx persistence 
with Rx azith 
Cx 
persistence 
not Rx azith 
RR of cervicitis 
persistence 
with Rx azith 
P value 
All women with 
Cx  n=268 
125 114 54/114 7/11 0.74(0.46-1.21) 0.235 
Women with 
NSC n=208 
89 82 35/82 5/7 0.60(0.35-1.02) 0.058 
 
*Diagnosis of cervicitis > 30 pmnl/hpf on cervical gram stain 
# Women with CT, MG, NG or TV at follow up (ie persistent or incident infections) were 
excluded 
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Table 3 
Effect of presumptive azithromycin (azith) treatment in women with cervicitis (Cx)* and 
non-specific cervicitis (NSC) (MG, CT, NG, TV excluded) on follow-up outcome of any genital 
symptoms 
 
 
*Diagnosis of cervicitis > 30 pmnl/hpf on cervical gram stain 
# Women with CT, MG, NG or TV at follow up (ie persistent or incident infections) were 
excluded. Missing data on symptoms at follow-up in 3 women 
 
 
 
 
 
 
 
 
 
 
 
 
 Follow-up 
number# 
Treatment 
with azith 
number 
Symptoms 
at follow-up 
with Rx 
azith 
Symptoms 
at follow-up 
not Rx azith 
RR Symptoms 
at follow-up 
P value 
All women with 
Cx 
122 114 54/111 8/11 0.67(0.45-1.03) 0.054 
Women with 
NSC 
86 82 41/79 4/7 0.91(0.46-1.79) 0.780 
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Table 4 
Effect of additional stated partner presumptive azithromycin (azith) treatment, in women 
presumptively treated with azithromycin for cervicitis (Cx)* and non-specific cervicitis, on 
follow-up outcome of persistent cervicitis 
 Number of 
women 
with Cx 
followed up 
and Rx 
azith 
Number of 
women 
able to 
report 
partner Rx 
status 
Cx 
persistence 
with 
women 
stated 
partner Rx 
azith 
Cx 
persistence 
in women 
stated 
partner not 
Rx azith  
RR of Cx 
persistence in 
women whose 
partners Rx azith 
P 
value 
All cervicitis 114 78 21/45 13/33 1.18(0.70-2.00) 0.528 
NSC 82 56 12/29 11/27 1.02(0.54-1.90) 0.961 
 
*Diagnosis of cervicitis > 30 pmnl/hpf on cervical gram stain 
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DISCUSSION 
Although we found presumptive azithromycin treatment was associated with a 30% to 40% 
reduction in cervicitis persistence in women with NSC and a similar reduction in symptoms 
for women with cervicitis, these effects did not reach statistical significance. The strongest 
effect of presumptive treatment was seen in reduction of cervicitis persistence in women 
with NSC. If azithromycin treatment of women with cervicitis and NSC is associated with a 
reduction of the outcomes assessed, our results suggest it is not a large effect. A larger RCT 
study may have more conclusive results.  
The benefits of presumptive treatment may be greater in younger women with their 
reproductive years ahead, particularly in populations with high CT and MG prevalence. 
There may also be benefits for symptomatic women wanting resolution of their symptoms. 
We did not find any benefit on cervicitis persistence of presumptive partner treatment with 
azithromycin for women with cervicitis or NSC. Given the lack of clear benefit of treating 
affected women, lack of added benefit of presumptive partner treatment is not surprising. 
Numbers were small and so confidence intervals wide and there was reliance on stated 
history of partner treatment.  
Cervicitis was a very common diagnosis (48.8%) but prevalence of pathogens commonly 
associated with cervicitis (CT, MG, NG or TV) was low compared to some other STD 
populations 8, 9. The age of women in this study was relatively high with two thirds of 
women being older than 25 years. We did not find cervicitis or isolation of one of the main 
pathogens (CT, MG, NG or TV) to be more likely in women younger than 25 years, however 
CT alone was more likely in women younger than 25 years.  Marrazzo 10, 14 and the CDC 
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guidelines 7 recommended presumptive treatment of cervicitis in women less than 25 years. 
These recommendations reflect generally higher chlamydia rates in younger women, but as 
cervicitis is also associated with pathogens other than chlamydia, this age cutoff for 
presumptive azithromycin treatment may be less applicable to populations where 
chlamydia rates are low. 
An anti-inflammatory role of macrolides including azithromycin has been demonstrated in 
the respiratory tract 15, 16 and a benefit of azithromycin treatment in cervicitis is plausible, 
arising from anti-inflammatory effects particularly in cases of NSC, not just from 
antimicrobial action. The post-treatment outcomes examined in this study were persistence 
of cervicitis and persistence of any symptoms. If lower genital tract inflammation (cervicitis 
or leucorrhoea) is an indicator of endometritis or subclinical pelvic infection, even in the 
absence of known pathogens 2, 17, azithromycin treatment in women with cervicitis and NSC 
could have potential benefits in the reduction of sequelae of subclinical PID. This is a more 
difficult treatment outcome to assess but may be more important than the outcomes 
assessed in this study. 
Study strengths and limitations 
The main limitations of this work are that it was not a randomized controlled trial (RCT) and 
due to loss to follow-up, sample size of women in treatment and particularly in the non-
treatment groups, was very small. Additionally mean follow-up time was long and highly 
variable. This study was part of a larger study investigating the etiology of cervicitis and so 
was not specifically powered for this treatment outcome question. In a more formalized and 
resourced study, strict follow-up of women at four to six weeks would be desirable to 
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increase sample size and more reliably link treatment effect with follow-up outcomes. 
Additionally factors including new partner exposure, condom use and interim antibiotic use, 
could not be controlled for prior to follow-up. This study was an observation of the results 
of clinical practice (a ‘real life’ observational study) and suffered the limitations of this. 
 Reliance on women’s stated history of partner treatment lessened the reliability of this 
analysis but our result provides further confidence in adopting an expectant approach with 
screening the male partner rather than presumptive antibiotic treatment.  
Strengths include the inclusion of STD testing of women at follow-up visit so that women 
with incident or persistent infections at follow-up were excluded from the analysis. Baseline 
characteristics in women who followed up/not and women who had presumptive 
treatment/not, were not significantly different. Enrolment rates for the main study were 
high; prospective design with minimal deviation from standard clinical practice facilitated 
subject participation and staff involvement. Recruitment occurred in three STD clinics within 
metropolitan Sydney, but 83% of enrolments were at a primary clinic (Short Street Centre) 
and study clinicians were a limited trained group, which has advantages from a consistency 
point but also potential biases.  
CONCLUSIONS  
Although not reaching statistical significance, our findings suggest presumptive azithromycin 
treatment of women with NSC may be associated with reduced cervicitis persistence and a 
reduction of symptoms in women with cervicitis. We did not find a benefit of partner 
presumptive treatment. A larger study, ideally a RCT, may show significant benefit of 
presumptive treatment of women, particularly in higher STD prevalence populations. 
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CHAPTER 7 
 
 Pharyngeal gonorrhoea in women: an important reservoir 
for increasing Neisseria Gonorrhoea prevalence in urban 
Australian heterosexuals?  
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FOREWORD 
This paper is included in the thesis as it is related to the main body of work and was 
commenced at the Short Street Centre towards the end of recruitment for the Cervicitis 
study.  Prevalence of N. gonorrhoea (NG) in women recruited to the Cervicitis Study was 
very low (1.1%) and we noticed subsequently that NG prevalence in women was increasing, 
particularly isolation of NG from the pharynx in women and cases of NG in heterosexual 
males with increasing reports of acquisition from oral sex. From detailed sexual histories it 
became apparent that we might be missing a proportion of NG in women because we were 
not routinely testing for infection in the pharynx (apart from routine pharyngeal screening in 
female commercial sex workers). Pharyngeal screening in men who have sex with men 
(MSM) has been routine screening practice for a number of years due to the well 
documented reservoir of pharyngeal infection in this group with reports of increasing 
Minimum Inhibitory Concentrations (MIC) to ceftriaxone in extra genital sites. We 
postulated a similar reservoir in females, especially those regularly engaging in oral sex and 
changing partners. This study was a collaboration with Monica Lahra at the Neisseria 
Reference Laboratory, SEALS Laboratory, Prince of Wales Hospital. The study aimed to 
demonstrate this change in NG epidemiology and also to determine if NG resistance was 
occurring in this population of heterosexuals alongside the rising reports of ceftriaxone 
resistance in MSM. 
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ABSTRACT  
 
 We aim to characterize sexual behavioral aspects of heterosexual Neisseria gonorrhoea 
(NG) acquisition in two Sexually Transmitted Diseases clinics in Sydney, Australia, 2008-
2012. Of 167 NG cases 102 were heterosexually acquired with a trend of increasing NG 
prevalence in heterosexuals from 1.1% (95%CI 0.6-2.1) in 2008 to 3.0% (95% CI 2.0-4.0) in 
2012 (p=0.027). Of heterosexual male cases unprotected fellatio was the likely sexual 
activity for NG acquisition in 21/69 (30.4%) and commercial sex work (CSW) contact the 
likely source in 28/69 (40.6%)  NG prevalence overall in CSW (2.2%) was not significantly 
higher than in non-CSW (1.2%) (p=0.15) but in 2012 there was a significant increase in NG 
prevalence in CSW (8.6%) compared to non-CSW (1.6%) (p<0.001). Pharyngeal NG was 
found in 9/33 (27.3%) female cases. 
Decreased susceptibility to ceftriaxone (MIC ≥0.03 mg/L) occurred in 2.5% NG isolates, none 
heterosexually acquired. All were azithromycin susceptible. 
173 
 
A significant trend of increasing prevalence of heterosexual gonorrhoea in an urban 
Australian STD clinic setting is reported. We advocate maintenance of NG screening in 
women, including pharyngeal screening in all women with partner change who report 
fellatio, as pharyngeal NG may be an important reservoir for heterosexual transmission. 
Outreach to CSW should be enhanced. 
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INTRODUCTION 
 
Latest surveillance indicates rising rates of Neisseria gonorrhoea (NG) in New South Wales, 
Australia 1. The risk of HIV transmission is significantly enhanced by co-infection with NG 2,3  
and so the control of NG particularly in light of increasing minimum inhibitory concentration 
(MIC) values to ceftriaxone, is a major public health concern 4,5 . The predominance of 
gonorrhoea amongst Australian urban men who have sex with men (MSM) is well 
documented 1,6 but heterosexual gonorrhoea in urban settings is less well characterised. NG 
is a notifiable disease in Australia but data is only collected by age, sex and region of 
diagnosis and so heterosexual trends are poorly defined. Trends of increasing prevalence of 
heterosexually acquired NG and acquisition from fellatio and commercial sex worker (CSW) 
contact were noted in our suburban STD services in 2009, prompting this investigation 
specifically aimed at examining sexual behavioral aspects of heterosexual NG acquisition. 
 
METHODS 
A case series was conducted from patient records at two STD services in South Eastern 
Sydney over a 5 year period, 1 January 2008 to 31 December 2012. Data was collected 
prospectively from late 2009 when the study started but retrospectively prior to this. These 
clinics operate in a culturally diverse suburban environment and offer free services by triage 
to high risk patients defined by ‘priority populations’ specified in the 2010-2013 NSW STI 
(Sexually Transmitted Infection) strategy 7 (ie MSM, youth, CSW, Multi-partnered 
heterosexuals, intravenous drug users, HIV positive, indigenous) and other symptomatic 
patients, contacts of STDs or those referred by General Practitioners (GPs).  
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NG cases were identified from the clinic database. All NG cases were included whether 
detected by routine screening or testing in symptomatic patients. Heterosexual acquisition 
was defined as sexual activity not involving any same sex contact in the preceding 12 
months. Heterosexual patient numbers were derived from total client numbers, minus MSM 
and women who have sex with women (WSW). Likely acquisition source and activity was 
identified from detailed sexual histories, which routinely seek information on the nature and 
timing of recent sexual contacts including number and sex of consorts, type of sexual 
contact (oral, vaginal, anal, insertive /receptive) and condom use for each activity. In 
deciding the likely transmission mode and source of NG, we took into account onset of 
symptoms and NG disease incubation time. 
Receipt of oral sex (fellatio) was considered the likely route of NG infection when this 
activity occurred in isolation without a condom or if this occurred concurrently with vaginal 
or anal sex where a condom was used for the latter activities but not for oral sex. A female 
commercial sex worker was defined as a woman who stated she was currently engaged in 
sex work. Local contact was defined as sexual contact with a person in Australia. 
Clinic policy states that all symptomatic patients are tested for NG in the relevant 
anatomical site. MSM are screened for NG in the rectum, urine and throat, CSW in the 
throat and cervix or urine, heterosexual men in the urine and heterosexual women in the 
cervix or urine. Cases diagnosed by PCR are also cultured where possible, in order to 
ascertain antimicrobial susceptibility data. NG was treated during the study with ceftriaxone 
250mg IMI and this was increased to 500 mg IMI from early 2010 in keeping with local 
recommendations. Cefixime is not available in Australia. 
176 
 
NG was cultured on selective media of lysed horse blood agar containing vancomycin, 
colistin, nystatin and trimethoprim (VCNT) inhibitors. Antimicrobial susceptibility testing was 
performed prospectively at the Neisseria Reference Laboratory, Randwick, Sydney a WHO 
Collaborating Centre for STD, using published methodology [8]. Decreased susceptibility of 
NG to ceftriaxone in extra genital sites was reported when the MIC value was ≥0.03 mg/L 
and ≥0.06 mg/L in genital sites 8. All samples positive for NG using Nucleic Acid Amplification 
Techniques (NAAT) (Roche Amplicor PCR from study commencement to June 2011 and then 
from July 2011 by Roche Cobas 4800) were confirmed by supplementary assays targeting 
porA and opa genes as required by the National Testing Guidelines 9. 
Proportions were compared using Chi-Square tests and trends identified using a Mantel-
Haenszel Chi-Square test with SAS (version 9.2; SAS Institute Inc., Cary, NC, USA)  
Ethics approval was granted by the South Eastern Illawarra Area Health Service Ethics 
Committee. 
 
RESULTS 
During the study 6164 patients were seen of which 5118 (83.0%) were classified as 
heterosexual and 1046 (17.0%) MSM or WSW, with approximately equal numbers of male 
(53.1%) and female (46.9%) heterosexual patients (table 1). There were 167 cases of NG, 
102 (61.1%) heterosexually acquired (overall prevalence 2.0%) and 65 (38.9%) MSM 
acquired (overall prevalence 6.9%). Over the 5 year period there was a significant trend of 
increasing NG prevalence in heterosexuals rising from 1.1% (95%CI 0.6-2.1) in 2008 to 3.0% 
(95% CI 2.0-4.0) in 2012 (p=0.027). 
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Of heterosexual cases, 69 were male and 33 were female (Male: Female ratio 2.1:1). 67/69 
(97.1%) of heterosexual males and 25/33 (75.8%) of females had genital symptoms.  
Receipt of unprotected fellatio was the likely source of acquisition for 21/69 (30.4%) of 
heterosexual males (11/21 CSW related and 10/21 non-CSW related). Commercial sex work 
(CSW) contact was the probable NG source for 28/69 (40.6%) of heterosexual males (18 
CSW contacts local, and 10 whilst overseas). Only 7/33 (21.2%) of female cases reported 
current CSW. Importantly, NG prevalence during the study overall in CSW (2.2%) was not 
significantly higher than in non-CSW (1.2%) (p=0.15) but in 2012 there was a significant 
increase in NG prevalence in CSW seen (8.6%) compared to non CSW (1.6%), p<0.001 
Of female cases, 31/33(93.9%) reported unprotected vaginal sex. Pharyngeal NG was found 
in 9/33 (27.3%) women, 5 of these CSW. NG was acquired locally in 24/33 (72.7%) of 
females and 47/69 (68.1%) of heterosexual males.  
137/167 (82%) of NG cases were diagnosed by positive culture and 30/167(18 %) by positive 
PCR alone. Antimicrobial susceptibility data was available in 122/137 (89%) of NG cases 
diagnosed by culture. Decreased susceptibility to ceftriaxone was reported in 3/122 (2.5%), 
(two pharyngeal and one rectal isolate) all MSM related isolates, none heterosexually 
acquired. Of the 122 isolates with antibiotic susceptibility data, 55/122(45.1%) were MSM 
related and 67/122 (54.9%) were heterosexually related. All NG isolates were azithromycin 
susceptible. 
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Table 1.Summary of heterosexual patients and NG cases 2008-2012 
 
 2008 2009 2010 2011 2012 Overall  
No. Hetero patients 
(male & female) 
875 1009 1102 1041 1091 5118 
No. hetero male 
patients 
473 529 577 539 599 2717 
No. hetero female 
patients  
402 480 525 502 492 2401 
Total NG cases 18 35 27 33 54 167 
Total hetero NG 10 26 13 20 33 102 
Hetero male NG 5 19 11 13 21 69 
Hetero female NG 5 7 2 7 12 33 
Prevalence of NG in 
heterosexuals (%)* 
1.14  2.58  1.18   1.92  3.02 
 
2.0 
No. female CSW 50 63 76 75 58 322 
Mean age(yrs) hetero 
males with NG** 
32.4 33.1 38.2 44.3 37.4 37.3 
Mean age (yrs)hetero 
female with NG*** 
32.4 39.0 44.0 25.7 32.8 33.2 
 
*A significant trend of increasing NG prevalence in heterosexuals was noted over the 5 year 
period (p=0.027). 
**No significant age trend in heterosexual male NG cases (p=0.122) 
***No significant age trend in heterosexual female cases (p=0.387) 
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DISCUSSION   
This study found an increasing prevalence of heterosexual gonorrhoea in an urban 
Australian setting from 2008-2012, a trend which may be contributing significantly to rising 
NG notifications in Australia. At our services heterosexual acquisition accounted for 61.0% 
(102/167) of NG cases. The male: female ratio in heterosexual cases of 2.1:1 is comparable 
to the overall national Australian surveillance ratio of 2:1 10. The overall study male: female 
ratio, including the MSM cases was 4.0:1, which is in marked contrast to our South East 
Sydney local health district reported ratio of 8:1 where NG detection predominates in the 
large MSM population 1,10. This reflects the lower proportion of MSM attendances at our 
clinics (25.8%) compared to inner city services. The persistence of the 2:1 male: female case 
ratio in heterosexuals is interesting. Factors contributing to this male predominance in 
heterosexual NG case detection might include increased likelihood of symptomatic disease 
and therefore detection in males (and more asymptomatic disease in females), lack of 
pharyngeal screening in  females, suboptimal screening of CSW and high risk females and 
possibly some misclassification of ‘heterosexual’ acquisition. Enhanced surveillance of NG 
might help to clarify this enigma. 
Receipt of unprotected fellatio was the likely sexual activity resulting in NG acquisition for 
30% of heterosexual men. Additionally the number of heterosexual male NG cases due to 
fellatio may be underestimated in this study if receipt of unprotected oral sex occurred in 
conjunction with unprotected vaginal or anal sex. The pharyngeal NG reservoir in MSM is 
well recognized 11,12 but this reservoir could also be important in all women with partner 
change who practise fellatio, not just CSW. This theory is supported by the high transmission 
rate in heterosexual men receiving fellatio and noting that equal numbers of fellatio-related 
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transmissions occurred in men reporting contact with CSW and non-CSW females. Oral sex 
is frequent amongst heterosexuals and is typically unprotected. This combined with lack of 
awareness of the associated STD transmission risk, common perception that oral sex is not 
sex 13 and infrequent pharyngeal screening in women, may facilitate heterosexual NG 
transmission via this route. We isolated pharyngeal NG from 27 % of female cases (by 
culture) but this is likely to be an underestimate due to clinic policy at the time of only 
undertaking pharyngeal screening in CSW and MSM. Increased uptake of more sensitive 
NAAT testing in the pharynx 14 is also likely to improve female NG detection. Our findings in 
both men and women suggest a NG pharyngeal reservoir in women may be a common 
source of NG infection for heterosexual males. A recent UK study 15 also suggested the 
pharynx may be an important NG reservoir in heterosexual women with a similar finding of 
30% of female NG cases being pharyngeal. We found NG Infections in heterosexual men 
were almost always associated with genital symptoms (97.1%) but women less commonly so 
(75.8%). Hence asymptomatic screening in women may be particularly important. 
Accordingly, our clinic guideline has changed to recommend the maintenance of NG 
screening in heterosexual women with additional pharyngeal NG screening in those women 
reporting partner change and fellatio. As female cases generally reported unprotected 
vaginal sex (93.9%), condom use is also reiterated.  
CSW in Australia have low rates of STDs reflecting good condom use 16. However a recent 
study of CSWs providing fellatio in Sydney 17 found Cantonese speaking women were 
significantly less likely to use condoms for this service than Thai-speaking and English-
speaking CSW. Additionally, women who don’t identify as being CSW (eg. working in 
massage) may be less likely to engage in safe sex, including safe oral sex 1. Our study found 
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40% of heterosexual males reported CSW contact but only 21% of female cases were CSW, 
an inconsistency which could reflect suboptimal testing rates and outreach to CSW in our 
population. Importantly NG prevalence in female CSW overall was no different from that in 
female non-CSW, except for the significant rise noted in 2012. Of concern however was the 
finding that 2/3 of the NG infections related to CSW contact occurred locally in Sydney, the 
rest acquired from overseas contacts. This would suggest a need to enhance local 
educational and testing services available to women engaged in CSW.  
Three quarters of all infections were acquired from local contact, reflecting the increasing 
local heterosexual NG prevalence noted in this study and from local surveillance 1. Numbers 
of NG cases rose in 2012 which is also in keeping with the rise in local NG prevalence. 
Antimicrobial susceptibility data was available for 89% of cultured isolates. Decreased 
susceptibility to ceftriaxone occurred in 3/122 (2.5%) isolates, all MSM related cases from 
extra genital sites. No decreased susceptibility was noted in heterosexually acquired isolates 
but numbers are too small to speculate on the significance of any difference in antibiotic 
susceptibilities between these populations at this time, but this should be the subject of 
ongoing monitoring and surveillance to inform treatment recommendations in these 
different populations. The finding of three isolates with decreased susceptibility to 
ceftriaxone is consistent with the right shift in MIC values to ceftriaxone reported locally 4 
and globally 5,18 and cause for concern for disease control in the absence of viable treatment 
alternatives if resistance to ceftriaxone develops. All isolates were sensitive to azithromycin. 
We recommend cases positive by PCR should also be cultured where possible for purposes 
of monitoring NG isolate susceptibility. The widespread supplanting of culture methods with 
PCR has the advantages of greater sensitivity and no fuss specimen transport, but at the 
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cost of antimicrobial surveillance. STD services are best placed to maintain this NG 
antimicrobial resistance surveillance role. 
This study is limited by small numbers, reliance on patient sexual histories and its partially 
retrospective nature in two triaged STD clinic populations within the same local health 
district. Inevitably some definitions, particularly relating to transactional sex can become 
blurred and sexual histories are reliant on patient recall and propensity to disclose the exact 
nature of the contact. Some cases were unwilling or unable to identify the likely source of 
the infection. Clinical judgment was applied to determine the likely source of infection 
based on disease incubation, onset of symptoms and detailed recent sexual history. Triage 
processes were unchanged over the study period and priority population groups remained 
relatively stable. Importantly antibiotic resistance testing was prospective and performed in 
a reference laboratory, a WHO Collaborating Centre for STD. 
 
CONCLUSION 
A significant trend of increasing prevalence of heterosexual gonorrhoea in an urban 
Australian STD clinic setting is reported. This study suggests the pharynx may be an 
important reservoir for heterosexual NG transmission and we advocate maintenance of NG 
screening in women, particularly inclusion of pharyngeal screening in women with partner 
change who practise fellatio. Case detection, enhanced surveillance and health promotion 
are pivotal to NG control. Health promotion efforts should include messages concerning STD 
transmission risks associated with oral sex in heterosexuals and we recommend enhanced 
CSW engagement with education and STD testing opportunities. 
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SUMMARY and CONCLUSIONS 
 
The aims of the Cervicitis Study have been addressed in these chapters and papers as well as 
exploration of side topics including the associations and eipidemiology of the mollicutes, 
diagnostic recommendations concerning Trichomonas vaginalis and changing epidemiology 
of  Neisseria gonorrhoea in STI clinic populations in Sydney. 
This body of work has contributed to the literature, both internationally and nationally, 
informing Australian clinicians on the cervicitis prevalence and associations we may expect 
to find in our urban populations. To date this is the only study of cervicitis in Australian 
women. 
Chapters 5 and 6 present the summary papers of the full Cervicitis Study findings and make 
some substantial contributions to our knowledge of the etiology, consensus definition and 
management of cervicitis. Using a large multi-site cross-sectional study we comprehensively 
examined all infectious and non-infectious exposures putatively associated with cervicitis in 
the literature and were able to demonstrate by multivariate analysis significantly increased 
risks of cervicitis for CT, MG, NG and TV and a reduction in cervicitis risk with condom use. 
Important negative findings were the lack of associations of cervicitis with BV, CMV, HIV, 
HSV and young age.  
The Study also demonstrated the superior utility of the cervicitis case definitions 
mucopurulent discharge and yellow discharge. These definitions diagnose fewer women 
with a ‘disease’ and have consistently higher PPVs and specificities for the significantly 
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associated pathogens than the traditional microscopy case definition of >30 pmnl/hpf. 
These findings provide evidence for a consensus case definition for cervicitis and concur 
with the growing opinion that cervicitis case definition by microscopy lacks practicality and 
utility in most clinical settings.  
Despite this comprehensive study of potential causative infections associated with cervicitis, 
the population attributable risks for cervicitis of the significant pathogens, namely CT, NG, 
MG and TV (assuming causative roles), might still only account for 23.4% of cervicitis in our 
STI population, using the most predictive cervicitis definition of MCP. This leaves the 
majority of cases unexplained which is a slightly disappointing result. Pathogen prevalence 
was low in this study (reflecting the relatively high socioeconomic status of our population 
with good access to health care) and the population attributable risk% (PAR%) figure would 
rise in populations with higher STI rates. It does raise the question though, of other factors 
at play (such as cytokines and mechanical factors) and the possibility that cervicitis could be 
part of a normal continuum in some women. There is also the likelihood of other organisms 
involved in the etiology of cervicitis that are yet to be found. MG is the ‘new chlamydia’ and 
there may be more pathogen discoveries as ability to detect and study our microbiome 
expands.  
The results of the observational treatment study of women and their male partners with 
azithromycin 1 G orally, are interesting and add to our current sparse knowledge of how 
best to manage this very common and often symptomatic condition.  
Although we found presumptive azithromycin treatment was associated with a 30% to 40% 
reduction in cervicitis persistence in women with NSC and a similar reduction in symptoms 
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in women with cervicitis, these effects did not reach statistical significance. A larger RCT 
study may show more conclusive results. If azithromycin treatment of women with cervicitis 
and NSC is associated with a reduction of the outcomes assessed, our results suggest it is 
not a large effect. Longer term reproductive and genital tract health outcomes in women 
may be more relevant outcomes to measure in assessing the benefit or not of presumptively 
treating women with cervicitis and NSC. 
From the literature review it seems likely there are benefits of azithromycin treatment 
stemming from its anti-inflammatory properties as well as the treatment of undiagnosed 
subclinical PID and endometritis, outcomes that have not been assessed in this study. 
Evidence suggesting that cervicitis may predict upper genital tract infection is quite 
compelling and logical and this adds to argument for treating women with cervicitis. These 
potential benefits of treating women must be weighed against with the disadvantages of 
labelling them as having an ‘STI’ and potentially overusing antibiotics. The benefits of 
presumptive treatment may be greater in younger women with their reproductive years 
ahead, particularly in populations with high CT and MG prevalence. There may also be 
benefits for symptomatic women wanting resolution of their symptoms. 
The finding of no benefit of additional male partner treatment was also useful and not 
unexpected given the non-significant benefit in women themselves. Our result provides 
further confidence in adopting an expectant approach with screening male partners rather 
than giving them presumptive antibiotic treatment. 
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Study strengths and weaknesses  
This research was not commissioned and was minimally supported by specific funding, 
borne out of a genuine curiosity and desire to provide clarity and practical solutions for a 
commonly encountered problem in clinical practice. Accordingly it had to be designed to 
take place opportunistically as part of routine practice, in publically-funded STI services in 
Sydney and by necessity involved considerable collaboration with SEALS Laboratory. 
Recruitment of women to the study involved a convenience sample of 558 of consecutively 
presenting women >18 years of age who required vaginal examination based on presenting 
complaint or who requested examination. Hence the sample was biased towards the 
recruitment of symptomatic women and in fact 60 % of women recruited had genital 
symptoms. This biased could contribute to the high rates of Trichomans vaginalis and also to 
the high rates of cervicitis prevalence, particularly by the microscopy definition of (> 30 
pmnl/hpf).This high prevalence of cervicitis is fully discussed in Chapter 5 of the thesis, 
where findings are compared using different cervicitis definitions; in particular cervicitis by 
the definition MCP was found to be much less prevalent and more predictive of significant 
pathogens. 
The main study was cross-sectional and so had limited inference on causality, but sample 
size was large and appropriately powered. Recruitment occurred at three related STI clinics 
but 83% at the primary clinic (Short Street Centre) using a small group of trained recruiting 
clinicians with advantages for consistency but also potential biases. 
The findings of the treatment study do have significant limitations and need to be 
interpreted in the context of the main Cervicitis Study paper (chapter 5). Main limitations 
191 
 
were that it was not a RCT, follow-up numbers were small and there was a long and variable 
time to follow-up for many women (reflecting clinical medicine as it really happens). 
However, women with incident or persistent infections at follow up were excluded from the 
analysis. In a more formalized and resourced study, strict follow-up of women at 4 to 6 
weeks would be desirable to more reliably link treatment with effect on follow-up 
outcomes. For the analysis of effect of additional partner treatment we were reliant on 
patient report. This study was an observation of the results of clinical practice and suffered 
the limitations of this.  
The completion of the study was a result of the dedication and hard work of all the 
investigators and collaborators and represents quite a unique effort. There were no conflicts 
of interest. 
 
Areas of future research  
A vast amount of clinical and laboratory data was collected for this study and accordingly 
there are several areas of potential future study from the existing data and other research 
questions generated. 
There is a subset of women who had multiplex PCR testing in cervical as well as urine 
samples, and a comparison of the yields from these specimens would be a useful study of 
test performance and help to guide testing practice. It would be good to see SEALS 
Laboratory develop a multiplex PCR for CT/NG/MG and TV as a flow-on from this study. It 
would be a big seller! 
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There were a large number of women in the Cervicitis Study who had persistent cervicitis 
and persistent symptoms who were followed up over several visits. Most clinicians will be 
familiar with these cases who present a diagnostic and management dilemma and often end 
up being referred to gynecologists for investigations and surgical interventions. A hypothesis 
I have concerning these women is that a number of them have gynecological pathology, in 
particular conditions such as chronic PID, endometriosis, adenomyosis and polycystic 
ovarian syndrome which may be associated with chronic discharge. A case-control study of 
these potential associations could be considered but such a plan might be hampered 
somewhat by the disconnect between gynaecology and STI research and would require 
collaboration with a gynaecology service. 
In the study of women with MG (Chapter 4) two women with MG were found to have 
ectopic pregnancies, one at the time of diagnosis and one just after diagnosis of MG. There 
is only one previous study examining the relationship between MG and ectopic pregnancy 
and this was inconclusive. Given that MG seems to behave very similarly to CT, it is possible 
that untreated MG may be associated with ectopic pregnancy, a disastrous health and 
reproductive outcome. A case-control study of this association would be relatively straight 
forward and something I am considering in the future dependent upon funding 
opportunities. 
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CERVICITIS MANAGEMENT GUIDELINE 
 
The following is a guideline for the diagnosis, testing and management of women with 
cervicitis, based on the findings of this Cervicitis Study in the context of my extensive 
literature review chapters.  
Background 
Cervicitis is a common, often symptomatic condition that can be associated with the 
infections CT, MG, NG and TV. However many cases are present in the absence of these 
pathogens (non-specific cervicitis) and so cervicitis should not be considered synonymous 
with STI infection. In STI populations prevalence can range from 20 to 40 % of women. 
Cervicitis can be an indicator of upper genital tract infection in some women. 
Testing & Diagnosis 
Diagnostic criteria differ but the presence of a mucopurulent discharge or yellow discharge 
(observed by clinician or noted by the patient) are case definitions for cervicitis with better 
prediction and higher specificity for the pathogens CT, MG, NG and TV than the microscopy 
Gram stain diagnosis of >30 pmnl/hpf.  
Microscopy is still an extremely useful tool at the point of consultation for diagnosing many 
causes of vaginal discharge and should be encouraged where available to confirm the 
presence of cervicitis, bacterial vaginosis and candida by Gram Stain and TV by wet 
preparation. PH measurement is also very useful and will be elevated in BV, TV and 
frequently secondary to douching and presence of semen or leucorrhoea.  
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All women presenting for screening or symptomatic assessment should be tested for CT and 
NG. If cervicitis is present, laboratory testing should also be performed for MG and TV by 
PCR, if available. Selective testing for MG and TV is particularly suggested for women with 
sexual contact or reporting consort contacts in higher prevalence areas such as Asia, Africa, 
USA and South America. TV may be more likely after rural Australian or Pacific sexual 
contacts.  
PCR testing from a vaginal swab is more sensitive than testing a first void urine sample. 
Treatment/management 
The benefit of presumptive azithromycin treatment of women with cervicitis is unclear, but 
there may be benefit of treating women for resolution of cervicitis and/or vaginal 
symptoms. Presumptive treatment should only be offered to women who are unlikely to 
return for follow-up, women of reproductive age reporting recent partner change and 
unprotected vaginal sex or women with HIV or at high risk of HIV acquisition. 
If a woman is low-risk sexually and /or has asymptomatic cervicitis, presumptive treatment 
should be deferred pending laboratory testing results and treatment given if informed by 
test results.  
Condom use reduces the risk of cervicitis. 
Follow-up of women with asymptomatic cervicitis, in the absence of isolation of a pathogen, 
is not necessary. If a woman has persistent symptoms, follow-up is recommended in 4 to 6 
weeks. 
The recommended treatment for cervicitis is azithromycin 1 G orally. 
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If a woman has additional genital symptoms such as dyspareunia, pelvic pain, changed 
menstrual pattern (heavy/painful/spotting) or urinary symptoms in the presence of 
cervicitis, the clinician should have a low threshold for treating for subclinical PID 
particularly in women of reproductive age. 
Treatment if PID is suspected: 
Azithromycin 1 G orally  
Repeat dose in 1 week (or add doxycycline 100mg BD for 10 days) 
PLUS metronidazole for 10 days orally 
PLUS ceftriaxone 500mg IMI 
 
The presumptive treatment of male sexual partners is not recommended, however if a 
pathogen is isolated on testing or a woman has persistent cervicitis, partners should be 
tested and their treatment informed by pathogen isolation. 
Persistent Cervicitis 
If cervicitis is persistent after treatment with azithromycin 1 G orally, testing for MG and TV 
should be done and tests for CT and NG repeated if reinfection is possible or a new partner 
reported. Make sure she has had a recent pap smear and pelvic examination. 
If a woman has persistent asymptomatic cervicitis and tests for CT, NG, MG and TV are 
negative it is reasonable to give no further treatment and review as required. 
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If a woman has persistent cervicitis accompanied by other symptoms such as pelvic pain, 
menstrual irregularity, urinary symptoms or dyspareunia, broader spectrum antibiotic 
treatment should be used to cover the possibility of MG-associated PID (in the absence of 
access to MG testing). 
 
Treatment for MG-associated PID 
Azithromycin 500mg on day 1 then 250 mg for a further 5 days 
PLUS Metronidazole 400mg BD for 10 days        
PLUS ceftriaxone 500mg IMI  
If MG is isolated a test of cure should be performed in 4 to 6 weeks from a vaginal/cervical 
swab and check that partner(s) have also been treated for MG. If MG is not responsive to 
azithromycin treat with moxifloxacin 400mg once daily for 7 days and again perform a test 
of cure at 4 to 6 weeks post treatment. 
If treatment is unsuccessful in resolving symptoms, high resolution pelvic ultrasound is 
recommended and consideration of gynaecological investigation. 
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Conference and meeting abstracts   
 
FOREWORD 
 
In 2009 I was invited to give two oral presentations at the Australasian Sexual Health 
Conference in Brisbane. These were interim findings from the Cervicitis Study and were also 
oral platform presentations that same year at the St George Hospital Research Symposium. 
In 2010 the abstract ‘Mycoplasma genitalium: association with cervicitis, response to 
azithromycin treatment and partner carriage’ was accepted for poster presentation at the 
Australasian Sexual Health Conference. 
On 19 June 2015 I presented the findings of the NG Epidemiology study (Chapter 7) to the 
National Neisseria Network meeting in Sydney, Australia.  
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Mycoplasma genitalium is associated with cervicitis in a 
metropolitan Sydney Sexual Health Clinic Population.  
2009 Oral presentations Australasian Sexual Health Conference and St George Hospital 
Research Symposium 
 
Mycoplasma genitalium (MG) is a recognised causative agent of sexually transmissible 
infection (STI). Its role in male non-specific urethritis has been recently established, but the 
epidemiology of MG in women and its role in cervicitis is less well characterised. The 
development of molecular diagnostic testing has facilitated identification of a wider range of 
organisms potentially implicated in urogenital disease. 
 A prospective cross-sectional study investigating the prevalence and aetiology of cervicitis 
in two Sydney STI clinics enrolled 423 women from 2006-2009. A multiplex polymerase 
chain reaction (mPCR) assay designated VDL06 was configured and validated for the 
detection of MG, Ureaplasma parvum, Ureaplasma urealyticum and Mycoplasma hominis. 
Cervical samples were analysed using VDLO6. Cervicitis was defined as >30  
polymorphonuclear leucocytes per high-powered field (>30 pmnl/hpf) on three non- 
adjacent fields in a Gram stain of cervical mucous.  
Cervicitis prevalence in this cohort was 39%. MG was detected in 14/423 women, a 
prevalence of 3.31% (95 % CI 1.82%, 5.49%). The unadjusted prevalence ratio of cervicitis in 
women with MG was 2.09 (95 % CI 1.55, 2.82 P=0.002). The frequency of MG in the women 
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with cervicitis was 11/165 (6.7%). The clinical and demographic data for the women with 
MG will be presented. Data will also be presented on the prevalence and cervicitis 
association of the other mollicutes studied in this cohort. 
This is the first Australian study to demonstrate a significant association of MG with 
cervicitis and to determine prevalence of MG in urban Australian women. The application of 
a mPCR increased our ability to investigate a range of organisms potentially associated with 
cervicitis. The capacity to detect MG in women with cervicitis will facilitate better targeted 
therapy for this common condition. Molecular testing for MG should be available routinely 
for clinical services to improve STI management, particularly tor cervicitis and urethritis. 
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Trichomonas vaginalis: under-diagnosis in urban Australia could 
facilitate re-emergence 
2009 Oral presentations Sexual Health conference and St George Hospital Research 
Symposium. 
 
Trichomonas vaginalis (TV) has a low profile in urban sexually transmitted disease (STD) 
clinics in Australia and in many developed countries.  TV prevalence in urban Australia is 
reportedly low based largely upon routine wet preparation direct microscopy in highly 
screened CSW populations. 
A prospective study in a metropolitan Sydney STD clinic, TV was detected by a polymerase 
chain reaction (PCR) assay in 16/356 women (4.5%, 95% Confidence Interval (CI) 2.6% -
7.2%), whereas discretionary wet preparation microscopy in women with clinically 
suspicious vaginal discharge found only four cases (1.1%, 95% CI  0.3%-2.8%). This PCR result 
exceeds recently reported urban Australian rates of <1%. The clinical and demographic 
features of the TV positive women will be presented. 
In this cohort a high proportion of women with TV were not from a recognized geographic 
risk group but their consorts were. Local acquisition of TV was common. Urban society in 
Australia, as in other developed countries, is very culturally diverse. Accordingly, sexual 
networks particularly of migrant and first generation Australians may include contacts from 
populations with higher TV prevalence.   
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This data suggests that the current low profile of TV in urban Australian STD clinics and the 
variable application of insensitive tests for case detection may be leading to under-diagnosis 
of TV.  This could facilitate a re–emergence of TV in diverse urban populations.  An increase 
in trichomoniasis-associated adverse reproductive outcomes and enhanced HIV 
transmission could pose a salient public health threat. Accordingly we propose that 
standardized molecular detection tests for trichomoniasis be part of routine testing in urban 
Australian STD settings. 
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Mycoplasma genitalium: association with cervicitis, response to 
azithromycin treatment and partner carriage’ 
2010 poster presentation Australasian Sexual Health Conference 
 
AIM  
To assess Mycoplasma genitalium (MG) prevalence, association with cervicitis, response to 
Azithromycin treatment and partner carriage in women enrolled in the Cervicitis Study in an 
STI clinic setting in Sydney. 
METHODS 
Twenty one women from a cross-sectional study of 541 women at two STI clinics in Sydney 
tested positive on cervical swabs for MG. Prevalence of MG, association with cervicitis, 
response to Azithromycin treatment, and partner carriage rates were analyzed. 
RESULTS  
The prevalence of MG was 21/541(3.9%). MG was significantly associated with cervicitis 
(18/21) (RR 1.85 (1.53-2.28) p<0.0001). Of the 21 women with MG, 16 were treated with 
Azithromycin (1G stat) for cervicitis at the time of consultation. Follow-up MG testing with 
clinical assessment was possible in 13 women (of whom 11 had received Azithromycin 
treatment and two had received doxycycline and metronidazole as cover for PID). All 13 
women were negative for MG although nine had persistent cervicitis. Of the five male 
partners of women with MG, asymptomatic MG carriage was found in 2/5 (40%). 
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CONCLUSION  
Azithromycin appears to be an effective treatment for Mycoplasma genitalium infection. 
MG is common in an STI clinic population and is associated with cervicitis. Carriage in 40% of 
male partners supports sexual transmission. The significance of persistent cervicitis after 
microbiological cure in these women warrants further investigation and will be discussed. 
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CLINIC LOGO 
 
 
 
 
 
 
Infectious organisms associated with Cervicitis in 
Sexual Health populations in Sydney. 
 
 
 
 
 
To women attending the service, we are now 
running an approved research study to try to 
improve the health of Women. 
 
We need your help. 
 
Please read on …. 
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Infectious organisms associated with Cervicitis in 
Sexual Health populations in Sydney. 
 
 
 
 
 
 
 
 
 
 
Cervicitis Study Eligibility 
 
Eligible for study (tick any that apply to you) 
 
□ > 18 yrs 
□ Sexually active in last 3 months 
□ Require/requesting vaginal examination today 
 
Not Eligible for study (tick any that apply to you) 
 
 □ < 18 yrs 
 □ Not sexually active in last 3 months 
 □ Not requiring/requesting vaginal examination today 
 □ Have period currently 
 □ Pregnant 
 □ Have IUD contraceptive device 
 □ Cervical surgery in last month 
 □ Termination of Pregnancy (TOP) in last month 
 □ Clinical pelvic infection (PID) 
 □ Antibiotics in previous month 
 □ Hysterectomy 
 □ Previously enrolled 
 
 
Patient Enrolment 
 □ Consenting to take part in study 
 
 □ Not consenting to take part in study 
 
 □ Defer  
 
 
 
 
Patient Sticker 
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Short Street Centre 
Sexual Health Service 
St George Hospital 
Ground Floor, Prichard Wing, Short Street 
Kogarah  NSW  2217 
Enquiries:  9350 2742 
Fax No:      9588 7521 
Clinic Hours:  Mon 1-5 pm, Tues 3.30-7 pm, Wed 1-5 pm, Thurs 1-5 pm & Fri 9.30 am–1 pm 
 
 
Infectious organisms associated with Cervicitis in a metropolitan Sydney 
Sexual Health Clinic population. 
 
Participant Information statement  
 
As a female patient attending the Short Street Centre, you are invited to participate 
in a Cervicitis Study we are conducting at this clinic. 
 
We hope to learn more about the condition of CERVICITIS (inflammation of the 
cervix). This is a poorly understood, relatively common condition affecting the cervix 
(neck of the womb), which can be caused by the sexually transmitted infections 
chlamydia and gonorrhoea. However in over half of the cases of cervicitis other 
infective agents may be involved, which are often not identified in routine testing and 
their role is not well defined in this condition, termed ‘non-specific cervicitis’. Some of 
these less well known infections can also lead to pelvic infection and have an effect 
on subsequent pregnancies if not treated. Due to recent advances in modern 
laboratory technology we now have the capacity to more easily identify these 
organisms. 
 
Presently when cervicitis is diagnosed, we offer routine antibiotic treatment 
(azithromycin tablets). By finding out more about the possible causes of cervicitis, we 
hope to contribute information to improve understanding, definition and current 
treatment and so reduce potential complications of this condition. 
 
Cervicitis is diagnosed on an internal vaginal examination with a speculum (like 
having a Pap test). Depending on your reasons for attending today, an internal 
examination may be appropriate and only if so, will we invite you to participate in this 
study (provided you fulfil eligibility criteria). 
 
Your participation in the study is completely voluntary and optional and will in no way 
affect the quality of the care you receive at this Clinic. We cannot guarantee that you 
will gain any direct benefit from participation. There is no financial incentive provided 
for participation. 
 
If you decide to participate, you will be offered our routine clinic tests and in addition 
two extra swabs will be taken from the cervix for the ‘additional tests’. These 
‘additional tests’ are looking for other infectious agents believed to be associated 
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Infectious organisms associated with Cervicitis in a metropolitan Sydney 
Sexual Health Clinic population. 
 
 
 
with cervicitis. We plan to look at how common cervicitis is in women with and 
without these infections. By participating you will only have two additional cervical 
swabs. There are no other interventions involved or changes from routine clinical 
practice, hence we believe there to be minimal additional risk of harm to you by 
participation. Sometimes after swabs are taken from the cervix, there may be some 
slight spotting or discomfort 
 
If cervicitis is diagnosed you will be offered the standard treatment for cervicitis 
(azithromycin tablets), regardless of participation in the study. Additional treatment 
will be provided to you if the additional test results identify any infectious agent 
where there is treatment of known benefit. 
 
We advise that current sexual partners be offered treatment also. We will provide 
you with a contact/information slip for your partner, who can receive testing and 
treatment at this clinic or elsewhere. We are hoping to test partners as part of this 
Cervicitis study and so would encourage partners return to this clinic. 
 
We will request that women diagnosed as having cervicitis return for follow-up 
testing and review at 4 to 6 weeks which is routine clinical practice. 
 
During your consultation today we will ask you if you wish to participate in this study 
and if so, after full discussion, will ask you to sign a participant consent form 
(attached). 
 
 
 
Dr Josephine Lusk   
  
       
Senior Sexual Health Registrar   
Cervicitis Study Chief Investigator             
BSc FRNZCGP DRCOG 
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Short Street Centre 
Sexual Health Service 
St George Hospital 
Ground Floor, Prichard Wing, Short Street 
Kogarah  NSW  2217 
Enquiries:  9350 2742 
Fax No:      9588 7521 
Clinic Hours:  Mon 1-5 pm, Tues 3.30-7 pm, Wed 1-5 pm, Thurs 1-5 pm & Fri 9.30 am–1 pm 
 
 
 
Infectious organisms associated with Cervicitis in a metropolitan Sydney 
Sexual Health Clinic population. 
 
Participant Consent form 
 
1. I,……………………………………………of………………………………….. 
…………………………………………………. …………aged ……….years, 
agree to participate as a subject in the study described in the subject information 
statement ,attached to this form. 
 
2. I acknowledge that I have read the Subject Information Statement, which explains 
why I have been selected, the aims of the experiment and the nature and 
possible risk of the investigation, and I understand the statement to my 
satisfaction. 
 
3. Before signing this consent form, I have been given the opportunity to ask 
questions relating to any harm I might suffer as a result of my participation and I 
have received satisfactory answers. 
 
4. I understand that I can withdraw from the study at any time without prejudice to 
my relationship to the Short Street Clinic and St George hospital. 
 
5. I agree that research data gathered from the results of the study may be 
published, provided that I cannot be identified. 
 
6. I understand that if I have any questions relating to my participation in this 
research, I may contact Dr. Josephine Lusk or Dr. Pam Konecny on ph 9350 
2742, who will assist with my queries. 
 
7. I acknowledge receipt of a copy of this consent form and the Subject information 
sheet. 
 
Complaints may be directed to the South Eastern and Illawarra Area Health Service 
Human Ethics Committee, Southern Section, St George Hospital, Gray Street, 
Kogarah, 2217. Ph 9350 2481 fax 9350 3968 
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Infectious organisms associated with Cervicitis in a metropolitan Sydney 
Sexual Health Clinic population. 
 
 
 
 
 
---------------------------------------   ----------------------------------------- 
Signature of subject     Signature of witness 
 
---------------------------------------   ------------------------------------------ 
Print name      Print name 
 
---------------------------------------   ------------------------------------------- 
Date       Nature of witness 
 
 
 
 
Revocation of consent 
 
 
I hereby wish to WITHDRAW my consent to participate in the research project (titled 
above) and described in the patient information statement, and understand that 
Short Street Clinic and St George Hospital have previously agreed that such 
withdrawal WILL NOT jeopardize any treatment or my relationship with Short Street 
clinic or St George Hospital, or my medical attendants. 
 
 
 
---------------------------------------------------  --------------------------------------------- 
Signature      Date 
 
 
----------------------------------------------- 
Print name 
 
 
The section for Revocation of consent should be forwarded to Dr Josephine Lusk 
(Chief Investigator), Short Street Clinic, Ground Floor Prichard Wing, St George 
Hospital, Kogarah, 2217 
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Short Street Centre 
Sexual Health Service 
St George Hospital 
Ground Floor, Prichard Wing, Short Street 
Kogarah  NSW  2217 
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Fax No:      9588 7521 
Clinic Hours:  Mon 1-5 pm, Tues 3.30-7 pm, Wed 1-5 pm, Thurs 9.30 am-1 pm & Fri 9.30 am–1 pm 
 
Infectious organisms associated with Cervicitis in a metropolitan Sydney 
Sexual Health Clinic population. 
 
Partner Information Statement  
 
As a sexual partner of a female patient diagnosed as having cervicitis, who attended 
the Short Street Centre, you are invited to participate in a Cervicitis Study we are 
conducting at this clinic. 
 
We hope to learn more about the condition of CERVICITIS. This is a poorly 
understood, relatively common condition affecting the cervix (neck of the womb), 
which can be caused by the sexually transmitted infections Chlamydia or gonorrhoea 
(about 50 % of the time). However in over half of the cases of cervicitis other 
infective agents may be involved, which are often not identified in routine testing and 
their role is not well defined in this condition, termed ‘non-specific cervicitis’. 
 
Presently when cervicitis is diagnosed, we offer routine antibiotic treatment to the 
affected women and to her sexual partner. By finding out more about the possible 
causes of cervicitis, we hope to contribute information to improve understanding, 
definition and treatment and so reduce potential complications of cervicitis. 
 
If you decide to participate, you will be offered the standard tests for Chlamydia and 
gonorrhoea, performed on a urine sample. No other examination is necessary unless 
you have symptoms yourself. We will also test the urine sample for other infectious 
agents believed to be associated with cervicitis.  
 
You will receive the standard treatment for contacts of cervicitis (azithromycin tablets 
only), regardless of participation in the study. Additional treatment will be provided to 
you if the additional test results identify an infective agent where there is treatment of 
known benefit. 
 
Your participation in the study is completely voluntary and optional and will in no way 
affect the quality of the care you receive at this Clinic. We cannot guarantee that you 
will gain any direct benefit from participation. 
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RPA and Liverpool Sexual health versions 
 
PARTICIPANT INFORMATION SHEET 
1 of 3 
 
Infectious organisms associated with Cervicitis in metropolitan Sexual 
Health patients in Sydney. 
 
You are invited to participate in a Study. 
 
We hope to learn more about the condition of CERVICITIS (inflammation of the 
cervix or neck of the womb). This is a poorly understood, common condition which 
can be caused by the sexually transmitted infections Chlamydia and Gonorrhoea, 
however in the majority of cases other unidentified infectious organisms, which can 
be passed between sexual partners, are thought to be involved, hence the term ‘non 
specific cervicitis’. Presently we cannot test for many of these organisms, but recent 
advances in lab technology have made this easier. 
 
We plan to look at how common cervicitis is in women with and without these 
infections. Cervicitis is thought be associated with pelvic infection and so affects the 
reproductive health of women. By finding out more about the possible causes of 
cervicitis we hope to improve upon present management. 
 
The study is being conducted within this institution by Dr. Josephine Lusk, Staff 
Specialist in Sexual Health. It is part of a larger study involving one other Sexual 
Health Services and SEALS Virology Research Laboratory, Prince of Wales 
Hospital, Randwick. 
 
Cervicitis is diagnosed on an internal vaginal examination with a speculum (like 
having a Pap test). Depending on your reasons for attending today, an internal 
examination may be appropriate and only if so, will we invite you to participate in this 
study (provided you fulfil eligibility criteria).  
 
If you agree to participate in this study, you will be asked to sign a Participant 
Consent Form. Two extra sterile swabs will then be taken from the cervix during 
your vaginal examination. These extra study swabs will be used to look for other 
infectious agents believed to be associated with cervicitis. There are no other 
interventions involved or changes from routine clinical practice. If cervicitis is 
diagnosed you will receive the standard treatment of a single dose of an antibiotic, 
regardless of participation in the study. Results of any routine tests done today will 
be available to you as per usual. The additional ‘study swabs’ will be tested in 
batches at a later time, and results only available to you if these additional tests 
identify organisms where there is further treatment of known benefit.  
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Infectious organisms associated with Cervicitis in metropolitan Sexual 
Health and Gynaecology clinic patients in Sydney. 
 
If you are diagnosed with cervicitis, you will be asked to return for follow-up 
testing and review 4 to 6 weeks later, which is routine clinical practice. We 
would advise that your current sexual partner(s) be offered treatment also. We 
will provide you with a contact/information slip for your partner(s), who can 
receive testing and treatment at this clinic or elsewhere. We are also hoping to 
test partners as part of this Cervicitis study and so would encourage partners 
to return to this clinic, however their participation in this study is completely 
optional and will not affect their quality of care. 
In addition the researchers would like to have access to your medical record to 
obtain information relevant to this study only. 
 
RISKS 
 
The risks of participating in this study are: 
- Sometimes after swabs are taken from the cervix, there may be some slight 
spotting or discomfort, which usually settles quickly. 
- You may receive special study results in addition to routine results at a time 
later than the initial consultation. These will only be made available to you if 
they are validated and there is a recognised intervention available of known 
benefit  
 
BENEFITS 
 
While we intend that this research study furthers medical knowledge and may 
improve management of cervicitis in the future, it may not be of direct benefit to you. 
 
COSTS 
 
Participation in this study will not cost you anything, nor will you be paid.  
 
VOLUNTARY PARTICIPATION 
 
Participation in this study is entirely voluntary. You do not have to take part in it. 
If you do take part, you can withdraw at any time without having to give a reason. 
Whatever your decision, please be assured that it will not affect your medical 
treatment or your relationship with the staff who are caring for you. 
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Infectious organisms associated with Cervicitis in metropolitan Sexual 
Health and Gynaecology clinic patients in Sydney. 
 
CONFIDENTIALITY 
 
All the information collected from you for the study will be treated confidentially, and 
only the researchers named above and the clinician who you see will have access to 
it. The study results may be presented at a conference or in a scientific publication, 
but individual participants will not be identifiable in such a presentation.  
 
FURTHER INFORMATION 
 
When you have read this information, Dr Josephine Lusk will discuss it with you 
further and answer any questions you may have. If you would like to know more at 
any stage, please feel free to contact her 95153131. 
This information sheet is for you to keep.  
 
ETHICS APPROVAL 
 
This study has been approved of the Ethics Review Committee (RPAH Zone) of the 
Sydney South West Area Health Service. If you wish to discuss your rights as a 
study participant or if you have concerns or complaints about the conduct of this 
study, you should contact the Secretary on 02 9515 6766 and quote the protocol 
number X07-0277/07/RPAH/170. 
 
 
Dr. Josephine Lusk  
 
 
 
Cervicitis Study Chief Investigator  
Staff specialist in Sexual Health           
BSc MBChB FRNZCGP DRCOG MPH FAChSHM 
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Infectious organisms associated with Cervicitis in a metropolitan Sydney 
Sexual Health Clinic population. 
 
Partner Information Statement  
 
As a sexual partner of a female patient diagnosed as having cervicitis, who attended 
the Short Street Centre, you are invited to participate in a Cervicitis Study we are 
conducting at this clinic. 
 
We hope to learn more about the condition of CERVICITIS. This is a poorly 
understood, relatively common condition affecting the cervix (neck of the womb), 
which can be caused by the sexually transmitted infections Chlamydia or gonorrhoea 
(about 50 % of the time). However in over half of the cases of cervicitis other 
infective agents may be involved, which are often not identified in routine testing and 
their role is not well defined in this condition, termed ‘non-specific cervicitis’. 
 
Presently when cervicitis is diagnosed, we offer routine antibiotic treatment to the 
affected women and to her sexual partner. By finding out more about the possible 
causes of cervicitis, we hope to contribute information to improve understanding, 
definition and treatment and so reduce potential complications of cervicitis. 
 
If you decide to participate, you will be offered the standard tests for Chlamydia and 
gonorrhoea, performed on a urine sample. No other examination is necessary unless 
you have symptoms yourself. We will also test the urine sample for other infectious 
agents believed to be associated with cervicitis.  
 
You will receive the standard treatment for contacts of cervicitis (azithromycin  
tablets only), regardless of participation in the study. Additional treatment will be 
provided to you if the additional test results identify an infective agent where there is 
treatment of known benefit. 
 
Your participation in the study is completely voluntary and optional and will in no way 
affect the quality of the care you receive at this Clinic. We cannot guarantee that you 
will gain any direct benefit from participation. 
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PARTICIPANT CONSENT FORM 
Page 1 of 2 
 
 
Infectious organisms associated with Cervicitis in metropolitan Sexual 
Health and Gynaecology clinic patients in Sydney. 
 
 
 
1. I ........................................................... of  ......................................................  
agree to be a participant in the study described in the participant information 
statement for the research project set out above. 
 
2. I acknowledge that I have read the participant information statement, which 
explains why I have been selected, the aims of the study and the nature and 
the possible risks of the investigation, and the statement has been explained 
to me to my satisfaction. 
 
3. Before signing this consent form, I have been given the opportunity of asking 
any questions relating to any possible physical and mental harm I might suffer 
as a result of my participation and I have received satisfactory answers. 
 
4. I understand that I can withdraw from the study at any time without prejudice 
to my relationship to RPA Sexual Health or any other facility required for my 
care. 
 
5. I agree that research data gathered from the results of the study may be 
published or presented provided that I cannot be identified. 
 
6. I understand that if I have any questions relating to my participation in this 
research, I may contact Dr. Josephine Lusk, who will be pleased to answer 
them. 
 
7. I acknowledge receipt of a copy of this Consent Form and the Participant 
Information Statement. 
 
 _______________________________   _______________________________  
Signature of participant     Signature of witness 
 
 _______________________________   _______________________________  
Please PRINT name     Please PRINT name 
 
 _______________________________   _______________________________  
Date        Nature of Witness 
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PARTICIPANT REVOCATION OF CONSENT FORM 
 
 
Page 2 of 2 
 
 
 
Infectious organisms associated with Cervicitis in metropolitan Sexual 
Health and Gynaecology clinic patients in Sydney 
 
 
I hereby wish to WITHDRAW my consent to participate in the research project 
described above and understand that such withdrawal WILL NOT jeopardize any 
treatment or my relationship with RPA Sexual Health or my medical or nursing 
attendants. 
 
 
 
 _____________________________   ___________________________ 
Signature Date 
 
 _____________________________  
Please PRINT Name 
 
 
 
The section for Revocation of Consent should be forwarded to Dr. Josephine Lusk, 
Chief Investigator of Cervicitis Study, RPA Sexual Health, Page Building, RPA 
Hospital, Camperdown, NSW 2050       
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Multiplex PCR Testing Detection of Higher-than-Expected Rates of Cervical
Mycoplasma, Ureaplasma, and Trichomonas and Viral Agent Infections in
Sexually Active Australian Women
Christopher J. McIver,1,2,3 Nikolas Rismanto,1 Catherine Smith,1 Zin Wai Naing,1 Ben Rayner,1
M. Josephine Lusk,4 Pamela Konecny,2,4 Peter A. White,3 and William D. Rawlinson1,2,3*
Virology Division, Microbiology Department (SEALS), Prince of Wales Hospital,1 School of Medical Sciences,2 School of
Biotechnology and Biomolecular Sciences, University of New South Wales,3 and Department of Immunology and
Infectious Diseases, St George Hospital,4 Sydney, Australia
Received 28 September 2008/Returned for modification 12 November 2008/Accepted 13 February 2009
Knowing the prevalence of potential etiologic agents of nongonococcal and nonchlamydial cervicitis is
important for improving the efficacy of empirical treatments for this commonly encountered condition. We
describe four multiplex PCRs (mPCRs), designated VDL05, VDL06, VDL07, and VDL09, which facilitate the
detection of a wide range of agents either known to be or putatively associated with cervicitis, including
cytomegalovirus (CMV), enterovirus (EV), Epstein-Barr virus (EBV), varicella-zoster virus (VZV), herpes
simplex virus type 1 (HSV-1), and herpes simplex virus type 2 (HSV-2) (VDL05); Ureaplasma parvum, Urea-
plasma urealyticum, Mycoplasma genitalium, and Mycoplasma hominis (VDL06); Chlamydia trachomatis,
Trichomonas vaginalis, Treponema pallidum, and group B streptococci (VDL07); and adenovirus species A to E
(VDL09). The mPCRs were used to test 233 cervical swabs from 175 women attending a sexual-health clinic in
Sydney, Australia, during 2006 and 2007. The agents detected alone or in combination in all cervical swabs
(percentage of total swabs) included CMV (6.0), EV (2.1), EBV (2.6), VZV (4.7), HSV-1 (2.6), HSV-2 (0.8),
HSV-2 and VZV (0.4), U. parvum (57.0), U. urealyticum (6.1), M. genitalium (1.3), M. hominis (13.7), C.
trachomatis (0.4), T. vaginalis (3.4), and group B streptococci (0.4). Adenovirus species A to E and T. pallidum
were not detected. These assays are adaptable for routine diagnostic laboratories and provide an opportunity
to measure the true prevalence of microorganisms potentially associated with cervicitis and other genital
infections.
Cervicitis, an acute or chronic inflammation of the uterine
cervix, is generally viewed as a consequence of infection with
sexually transmissible agents. Neisseria gonorrhoeae and Chla-
mydia trachomatis are the most commonly reported pathogens,
possibly because they are most frequently screened for. How-
ever, the etiology of most cases is undetermined and could be
multifactorial in nature (11, 34, 35, 40). Studies undertaken in
other epidemiologic settings indicate significant differences in
the prevalences of other cervical infectious agents (1, 41, 44,
45, 58). An underappreciation of the prevalences of and roles
played by these nongonococcal and nonchlamydial agents po-
tentially jeopardizes the effectiveness of empirical treatments
for cervicitis. Unresolved cervicitis can result in ascending in-
fection, endometritis, pelvic inflammatory disease, and salpin-
gitis (11, 23, 46). Furthermore, cervicitis may enhance human
immunodeficiency virus susceptibility by the disruption of mu-
cosa, allowing increased viral replication within recruited in-
flammatory cells (30). The development of molecular methods,
such as PCR and DNA hybridization, has allowed the detec-
tion of a range of agents whose etiologic roles in genital infec-
tions need to be further investigated, including the viruses
cytomegalovirus (CMV), herpes simplex virus type 1 (HSV-1)
and HSV-2 (4, 43), adenovirus (6, 10, 50), and the Mollicutes
Ureaplasma parvum, Ureaplasma urealyticum, Mycoplasma
hominis, and Mycoplasma genitalium (1, 28, 59). There have
also been reports of genital infections caused by Epstein-Barr
virus (EBV) (4, 55), varicella-zoster virus (VZV) (27), and
enterovirus (EV) (24). We report here the use of four multi-
plex PCR (mPCR) assays, designated VDL05, VDL06,
VDL07, and VDL09, based on a conventional platform, for the
detection of 19 microorganisms in cervical swabs, including
Treponema pallidum and C. trachomatis, Trichomonas vagina-
lis, group B streptococci, and five adenovirus species, in addi-
tion to those mentioned above. The assays were developed
using cervical swabs from different women taken on one or
more occasions during different visits to a sexual-health clinic.
MATERIALS AND METHODS
Patients. Cervical swabs (n  233) were taken from 175 women consecutively
attending a sexual-health clinic in Sydney, Australia (between one and three
visits), during 2006 and 2007 who were all eligible for recruitment to an as-yet-
unpublished case-control study investigating cervicitis. They included women
with and without cervicitis. All of the women were aged 18 years, had been
sexually active in the preceding 3 months, required an internal examination
regardless of symptoms, had not been treated with antibiotics or received gyne-
cologic intervention in the preceding month, did not have an intrauterine con-
traceptive device in situ, and were not currently menstruating or pregnant.
Women with pelvic inflammatory disease were excluded. Written informed con-
sent was obtained from all of the women. The study protocol and data manage-
ment were approved by the South Eastern Sydney and Illawarra Area Health
Service Human Research Ethics Committee.
* Corresponding author. Mailing address: Virology Division, Micro-
biology Department (SEALS), Prince of Wales Hospital, Barker
Street, Randwick, NSW 2031, Australia. Phone: 61-2-93829113. Fax:
61-2-93984275. E-mail: w.rawlinson@unsw.edu.au.
 Published ahead of print on 4 March 2009.
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Sampling procedure. The cervix was accessed using a sterile metal speculum
and was prepared for swabbing by removing exudate with a large nonsterile swab
(Multigate Medical Products, China). An initial swab of the endocervix was
taken with a sterile cotton swab (Copan, California) and was used to screen
bacterial agents before being placed in viral transport medium 199 (Gibco In-
vitrogen, New York) and stored at 70°C. Two consecutive specimens from the
same region were taken using viral transport swabs (Copan Diagnostics), sus-
pended in viral transport medium, and stored at 70°C. These two specimens
were tested by the assays described below.
Nucleic acid extraction and PCR amplification. The swabs were suspended in
500 l of universal viral transport medium before extraction of the total nucleic
acid using a robotic extraction machine (MagNaPure LC; Roche, Germany)
applying the Total NA protocol according to the manufacturer’s instructions
(Roche, Germany). Extracts were stored at 4°C before being tested within 48 h
of collection.
Detection of Mollicutes species (VDL06). A single-round mPCR using Qiagen
OneStep reverse transcription (RT)-PCR (Qiagen, Gemany) master mix was
designed to detect U. parvum, U. urealyticum, M. genitalium, and M. hominis. This
commercial master mix was used to conform to other molecular procedures
currently used in diagnostic laboratories, allowing simplified quality assurance
and workflow. The reaction mixtures were prepared in accordance with the
manufacturer’s instructions for a 50-l reaction and consisted of 5.8 l of RNase-
free water, 10.0 l of buffer, 2.0 l of deoxynucleoside triphosphate mix, 2.5 l
of each primer (including primers for internal control at a final concentration of
0.5 M) (Table 1), 2.0 l Qiagen OneStep RT-PCR enzyme mix at a final activity
of 0.5 U, 0.2 l digoxigenin-11-dUTP (Roche, Germany), and 10 l of template.
The cycling procedures included an RT step at 50°C for 30 min, denaturation at
95°C for 15 min, and then 50 cycles of 94°C for 30 s, 57°C for 30 s, and 72°C for
1 min, a final extension of 7 min at 72°C, and a 4°C hold. The products were
visualized by gel electrophoresis, and the amplicons were identified by probe
hybridization, followed by PCR enzyme-linked immunosorbent assay (digoxige-
nin detection) (Roche, Germany). Known-positive clinical samples were used as
reaction controls for the PCR.
Virus detection (VDL05). A nested mPCR of the same designation previously
described (38) was used without modification for the detection of CMV, HSV-1,
HSV-2, EBV, EV, and VZV. Briefly, a first-round reaction comprising 20 l of
template, 0.5 l of AmpErase (uracil N-glycosylase) (Applied Biosystems), and
0.10 M of each primer (38) was included in a 50-l reaction mixture of the
Qiagen OneStep RT-PCR kit (Qiagen, Germany). A second-round reaction was
undertaken using 2 l of first-round product, 0.2 l digoxigenin-11-dUTP
(Roche, Germany), and 0.10 M of each primer in a 50-l reaction mixture of
AmpliTaq Gold PCR Master Mix (Applied Biosystems). The thermocycling
conditions used for each round were as previously described (38). The products
were visualized by gel electrophoresis, and the amplicons were identified by
probe hybridization (as described above).
Detection of adenovirus species A to E (VDL09). The adenovirus detection
method is based on that previously described by Xu et al. (56) and was modified
to conform to the above-mentioned protocols. A single-round reaction was
performed comprising 5 l of template and 0.20 M of each primer (Table 1) in
a 50-l reaction mixture of AmpliTaq Gold PCR Master Mix (Applied Biosys-
TABLE 1. Oligonucleotides used in molecular detection methods
mPCR Agent Oligonucleotidea Code Oligonucleotide sequence (5–3) Target (bp)b LDc Reference
For Mollicutes Urea- and A My-ins GTA ATA CAT AGG TCG CAA GCG TTA TC 16S tRNA gene
(520)
59
(VDL06) mycoplasma B MGSO-2-Bi CAC CAT CTG TCA CTC TGT TAA CCT C
M. hominis P Mhom-P10-Am GAC ACT AGC AAA CTA GAG TTA G 103
M. genitalium P Mgen-P3-Am TCG GAG CGA TCC CTT CGG T 103
U. parvum A UMS-57 (T/C)AA ATC TTA GTG TTC ATA TTT TTT AC Multiple banded 28
B UMA222 GTA AGT GCA GCA TTA AAT TCA ATG antigen gene
P UP-PROBE1 CTG AGC TAT GAC ATT AGG AGT TAC C (326–327)d 103
U. urealyticum A UMS-170 GTA TTT GCA ATC TTT ATA TGT TTT CG Multiple banded 54
B UMA263 TTT GTT GTT GCG TTT TCT G antigen gene (476)
P UU-PROBE1 CTG AAT TCA ATG TTG CAA TTA CAT CAG
CTG A
103
For nonviral C. trachomatis A CT-OF TTG CAA GCT CTG CCT GTG GGG AATe Omp1
agents B CT-OR TCA CAT CGC CAG CTC CAG CAA TAGe (931/378)
(VDL07) C CT-IF ACA TTA GGA GCC ACC AGT GGA TAT Ce
D CT-IR ATC CTT AGT TCC TGT CGC AGC ATC Te
P CT-PROBE TGC GTG GAG CGT CGG CGC TCG CGC Ae 102
T. vaginalis A TricV-OF CTA TTG TCG AAC ATT GGT CTT ACC CTCf G3 (264/206) 31
B TricV-OR TCT GTG CCG TCT TCA AGT ATG CCC
C TricV-IF CTC AGT TCG CAA AGG CAG TCC TTG Ae
D TricV-IR GCT TGG AGA GGA CAT GAA CTT CGG Ae
P TricV-PROBE CTA CAA CAA ATT CTT CTC Ce 101
T. pallidum A TP7-OF CTC AGC ACT GCT GAG CGT AG bmp gene (616/506) 39
B TP8-OR AAC GCC TCC ATC GTC AGA CC
C TP3-IF CAG GTA ACG GAT GCT GAA GT
D TP4-IR CGT GGC AGT AAC CGC AGT CT
P TP5-PROBE GAC CTG AGG ACT CTC AAA TC 105
Group B A STB-OF AAC CAG CCA ACC GGT TTA CCG TGAe scpB (418/260) 12
streptococci B STB-OR GGT CAA CCT TCT CGT ACT CTA GAG AAAe
C STB-IF ACA ACG GAA GGC GCT ACT GTT CC
D STB-IR GTT TTA CCT GGT GTT TGA CCT GAA CTA TC
P STB-PROBE ACA ACG GAA GGC GCT ACT GTT CCe 102
Adenovirus Adenovirus sp. A A AdA1 GCT GAA GAA MCW GAA GAA AAT GA Fiber (1,444–1,537) 57
species B AdA2 CRT TTG GTC TAG GGT AAG CAC 103
specific Adenovirus sp. B A AdB1 TST ACC CYT ATG AAG ATG AAA GC Fiber (670–772)
(VDL09) B AdB2 GGA TAA GCT GTA GTR CTK GGC AT 103
Adenovirus sp. C A AdC1 TAT TCA GCA TCA CCT CCT TTC C Fiber (1,988–2,000)
B AdC2 AAG CTA TGT GGT GGT GGG GC 104
Adenovirus sp. D A AdD1 GAT GTC AAA TTC CTG GTC CAC Fiber (1,205–1,221)
B AdD2 TAC CCG TGC TGG TGT AAA AAT C 104
Adenovirus sp. E A AdE1 TCC CTA CGA TGC AGA CAA CG Fiber (967)
B AdE2 AGT GCC ATC TAT GCT ATC TCC 103
a A, outer sense primer; B, outer antisense primer; C, inner sense primer; D, inner antisense primer; P, probe.
b First-round product/second-round product.
c LD, limit of detection (number of copies per reaction).
d 326 bp for U. parvum serovars 1 and 3/14 and 327 bp for serovar 6 (28).
e Oligonucleotide designed by Nikolas Rismanto.
f Underlined sequences are modifications of the published primers cited.
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tems). The thermocycling conditions included a preliminary denaturation step at
94°C for 5 min, 30 cycles of amplification (denaturation at 94°C for 1 min,
annealing at 54°C for 45 s, and extension at 72°C for 2 min), and a final extension
at 72°C for 5 min. The products were visualized using gel electrophoresis.
Detection of other agents (VDL07). Using the primers listed in Table 1, an
mPCR was developed using the same protocol as for VDL05 for the detection of
C. trachomatis, T. vaginalis, T. pallidum, and group B streptococci.
Measurement of sensitivity and specificity. As an adequate number of positive
controls (cultures or proven positives) were not available for most agents, the
sensitivities of the assays were assessed by measuring the limit of detection of
plasmid constructs of the target sites for each agent. Briefly, amplification prod-
ucts from first-round (or single-round) reactions were cloned using the pGEM-T
Easy Vector System II (Promega), and constructs were extracted using the
Wizard PCR Preps DNA purification system (Promega). The genomic concen-
tration was measured using the NanoDrop Spectrophotometer (NanoDrop
Technologies). The limit of detection for each target site was defined as the
lowest dilution of a series of serially diluted (1:10) plasmid constructs that was
amplified by each assay. The specificity was determined by testing proven-neg-
ative samples.
Controls. Positive controls for the above-mentioned assays were derived from
either culture-proven or molecularly proven sources. Amplification of the glyc-
eraldehyde-3-phosphate dehydrogenase gene from all samples using previously
described primers (38) was performed to validate extraction and PCRs.
RESULTS
The limit of detection (Table 1) for each agent ranged from
10 (for T. vaginalis) to 105 (for T. pallidum) copies per reaction.
False positives were not detected when between 17 and 96
proven-negative control samples of each agent were tested.
The results of the screening of 233 cervical swabs from 175
women by the four mPCRs are shown in Table 2. The total
agents detected among the 175 participating women at the
initial and subsequent visits are also shown. The Mollicutes
were the most common group of organisms detected, and were
recovered from 159 (68.2%) of the 233 cervical swabs tested.
Either alone or in combination with another member of the
Mollicutes, U. parvum was the species most commonly detected
(57.0%), followed by M. hominis (13.7%), U. urealyticum
(6.1%), and M. genitalium (1.3%). CMV was the predominant
virus detected (6.0%), followed by VZV (4.3%). The remain-
ing viruses (EV, EBV, HSV-1, and HSV-2) were each detected
in 3% of the samples, and adenoviruses (A to E) were not
detected. T. vaginalis (4.0%) was the commonest agent de-
tected by VDL07 (for other agents). C. trachomatis and group
B streptococci were detected in 1% of these samples, while
T. pallidum was not detected.
Multiple infections were detected in 42 (24.0%) of the 175
women tested. Two of these patients had multiple infections on
two separate occasions. All 44 coinfections included a Molli-
cutes sp., most commonly U. parvum (88.6%). Of the eight
patients diagnosed with trichomoniasis, six (75.0%) had coin-
fections with U. parvum. Two of these patients were also coin-
fected with either VZV or CMV.
DISCUSSION
mPCR assays allow simultaneous detection of multiple
agents in a single reaction and were applied here to detect a
broad range of microorganisms. The mPCRs developed in this
study are based on those we previously described for the de-
tection of viruses in a routine diagnostic laboratory (38) utiliz-
ing identical reagent and cycling conditions. This simplifies the
workflow, allowing performance of these assays in a routine
diagnostic laboratory with basic molecular facilities. The
choice of a commercial master mix including a reverse trans-
criptase reaction benefits a busy laboratory environment where
both RNA and DNA agents are being detected.
The mPCRs VDL05 and VDL07 are nested PCRs to in-
crease sensitivity, while specificity is enhanced with a post-PCR
probe hybridization assay. The adenovirus mPCR (VDL09)
was limited to a single-round reaction without post-PCR probe
hybridization because of variation in regions targeted by the
species-specific primers (57). A single-round PCR was used to
detect M. hominis, M. genitalium, U. parvum, and U. urealyti-
cum (VDL06). The method developed by Yoshida et al. (59)
was first considered for the detection of these agents. However,
our evaluation of this method showed cross-reactions with the
hybridization reactions for U. parvum (serotypes 6 and 149)
and U. urealyticum and weak reactions for U. parvum with wild
strains of M. hominis (data not shown). The mPCR employed
in this study utilizes the method of Yoshida et al. for the
detection of Mycoplasma spp. and includes specific primers for
U. parvum (28) and U. urealyticum (54). These primer sets
allow differentiation of the ureaplasmas by characteristic elec-
trophoretic-band sizes, which are confirmed by probe hybrid-
ization.
CMV was the most frequent virus detected using the VDL05
mPCR. CMV is not a common cause of cervicitis in immuno-
competent women (37). However, studies in China have shown
detection rates of 5.1% in a prospective study of women with
cervical human papillomavirus (58) and 14.0% in erosive cer-
vicitis (44), possibly as a result of cervical carriage and reacti-
vation by localized inflammation (36). Infection in pregnancy
TABLE 2. Use of mPCRs for screening nongonococcal agents in
cervical swabs
Microorganism(s) mPCR
No. (%) detected
Total cervical
swabs
(n  233)
Total
women
(n  175)
Mollicutes VDL06
U. parvum 112 (48.0) 93 (53.1)
U. urealyticum 6 (2.6) 6 (3.4)
M. hominis 15 (6.4) 13 (7.4)
M. genitalium 3 (1.3) 3 (1.7)
U. parvum  M. hominis 15 (6.4) 13 (7.4)
U. urealyticum  M. hominis 2 (0.9) 2 (1.1)
U. parvum  U. urealyticum 6 (2.6) 5 (2.9)
Viruses VDL05
CMV 14 (6.0) 11 (6.3)
EV 5 (2.1) 5 (2.8)
EBV 6 (2.6) 6 (3.4)
HSV-1 6 (2.6) 6 (3.4)
HSV-2 2 (0.8) 2 (1.1)
VZV 10 (4.3) 9 (5.1)
VZV  HSV-2 1 (0.4%) 1 (0.6)
Adenovirus species VDL09
A, B, C, D, E 0
Other agents VDL07
C. trachomatis 1 (0.4) 1 (0.6)
T. vaginalis 8 (3.4) 7 (4)
T. pallidum 0 0
Group B streptococci 1 (0.4) 1 (0.6)
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may cause spontaneous abortion, and there is a significant risk
of fetal infection with congenital abnormalities (3, 8, 37). In
this study, CMV was detected in 6.3% of female patients
tested, which is a prevalence not previously reported in Aus-
tralian clinics, suggesting the need to consider routine testing
in pregnant high-risk patients.
Previous studies have suggested that most genital HSV in-
fections are caused by HSV-2 (13, 42, 43, 52). Consistent with
more recent findings (6, 13, 17, 29, 56) increasingly implicating
HSV-1 in genital infection, we detected HSV-1 (3.4%) more
commonly than HSV-2 (1.7%) in the female patients tested.
An early study in China showed detection rates in erosive
cervicitis to be as high as 26.5% (44), with asymptomatic shed-
ding potentially an important means of transmission (13).
None of the 175 women in our study had genital erosions or
clinical signs of acute HSV infection at the time of testing.
There have been reports of EBV-associated genital ulcers in
women (2, 7, 14, 21, 25, 32, 53, 55). This condition is under-
recognized and may be incorrectly attributed to HSV infection
(7, 32, 53). However, the clinical relevance of our detection of
EBV in 3.4% of female patients in this study has yet to be
established. A recent study showed strong evidence for sexual
transmission of the virus from a partner infected with infec-
tious mononucleosis (55). In a study in Thailand of women
with HSV-associated genital herpes, 17/30 (56.7%) cases were
found to have EBV DNA present, although the clinical signif-
icance was not determined (25).
The presence of EV in the female genital tract may also be
a predisposition to antenatal and perinatal infection (3). An
early study in Russia detected antigens of coxsackie A and B
virus in the vaginal secretions of 16.3% of young girls with
protracted forms of vulvovaginitis (33). More recently, a study
in Central Africa detected EV RNA in nearly 10% of women
of childbearing age, which may be the basis for possible ante-
natal or perinatal transmission from mother-to-child (24). De-
tection of EV in 2.8% of the women in our study indicates the
proportion of patients at risk, but again, the clinical relevance
has yet to be determined.
The Mollicutes detected in this study are associated with
infections of the genitourinary tract, reproductive failure, and
neonatal morbidity and mortality. Our detection rates of the
four species of the Mollicutes putatively associated with genital
infection are consistent with previous studies, with U. parvum
being the commonest (26, 45, 49). Detection of M. genitalium
is becoming increasingly important because of recent reports
of a high prevalence of the organism in women with cervicitis
(15, 41, 45). Furthermore, the high prevalence of infected
sexual partners supports its role as a sexually transmitted in-
fection (15).
The VDLO7 mPCR screens organisms with larger genomes
and was reduced to four detectable agents to minimize tem-
plate competition. In this assay, T. vaginalis was the most com-
monly detected agent in women at 4.0% and was included, as
there has been a proven advantage of molecular techniques
over the insensitive traditional methods of direct visualization
and wet-mount microscopy (47, 51) and Pap smear. Inclusion
in this assay enabled detection of trichomoniasis, which is
sexually transmissible and often asymptomatic. T. vaginalis is
associated with pelvic inflammatory diseases and adverse birth
outcomes (51) and is also linked to an increased risk of human
immunodeficiency virus transmission (48). Vaginal coloniza-
tion with group B streptococci is not normally symptomatic or
associated with sexual transmission. However, cervical coloni-
zation is relevant to pathology of the fetus and newborn, and
significant morbidity may arise if group B streptococcus is not
detected and eradicated (23). C. trachomatis is commonly as-
sociated with cervicitis and is the most frequent cause of bac-
terial sexually transmitted infection worldwide (9, 15, 18, 22).
The detection rate of chlamydial infections (1%) in this study
is lower than expected for this population and could be ex-
plained in part by the exclusion of women with pelvic inflam-
matory disease and recent antibiotic treatment from the study
population. As was evident again here, syphilitic cervicitis is
uncommon but is important to diagnose because infection may
clinically and colposcopically simulate a primary advanced cer-
vical cancer (19, 20). Ideally, the assay for this agent should be
more sensitive and should be performed as a monoplex to
increase sensitivity for high-risk patients.
Although uncommon, adenovirus has been associated with
genital infections (5, 6, 50). We did not detect adenovirus in
the women examined here. Recent Australian studies of men
with urethritis showed that the infection is uncommon and
seasonal (6).
A test for N. gonorrhoeae was not considered in this devel-
opment because of reports of cross-reactivity in commercial
and published methods with closely related strains, such as
Neisseria subflava and Neisseria cinerea (16). Furthermore, the
diagnosis of this pathogen is a simple and expedient process
using conventional microcopy and culture techniques.
As shown here, improved screening has demonstrated higher-
than-expected rates of occurrence of organisms, particularly
the Mollicutes, in the cervices of women attending sexual-
health clinics. These mPCR assays will facilitate further clari-
fication of the significance of these organisms in genital infec-
tions, distinguishing pathogens from commensals. Ultimately,
the improvement of the diagnosis of cervicitis and other genital
infections will guide the use of appropriate interventions tar-
geted against specific pathogens. Efficacious treatment of cer-
vicitis has important implications for the reduction of gyneco-
logic infections and risk to fetal development, for the control of
sexually transmitted diseases, and for improved reproductive
health at the public health level.
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Cervicitis: a review
M. Josephine Luska and Pam Konecnyb
Introduction
Cervicitis was first recognized as an important clinical
entity in 1984 by Brunham et al. [1]. Since then much
controversy has existed. Interpretation and comparison of
published studies is hampered by the lack of consensus in
the case definition, and variability in the populations
sampled and methods used for pathogen detection
[2]. Advances in molecular diagnostics have created
an opportunity to further clarify cervicitis. However,
given an understandable desire for rapid, sensitive,
potentially clinician-independent testing for Chlamydia
and gonorrhoea, supplanting speculum-guided cervical
specimens with urinary nucleic acid amplification tech-
nique (NAAT) testing in asymptomatic women attending
sexually transmitted infection (STI) clinics [3] may
result in a lost opportunity for detecting cervicitis before
its implications are fully realized. It is thus timely to
review cervicitis. An extensive literature search was
conducted using MEDLINE, Embase and the Cochrane
Library on the topics of cervicitis, reproductive health
and STIs.
Background
Cervicitis is a frequently asymptomatic, inflammatory
condition of the cervix [4]. It is common with rates as
high as 30–45% in some STI clinic populations [1,2,5]
and is generally considered to be associated with sexually
transmissible pathogens [1,2,4,6,7]. However, Chlamy-
dia and Neisseria gonorrhoea account for less than half of
cervicitis cases, with a largely undefined aetiology in
the remainder [1,2,8,9], referred to as nonchlamydial,
nongonococcal cervicitis or nonspecific cervicitis (NSC).
The clinical significance of the finding of NSC, especially
in asymptomatic, ‘low-risk’ women, has been debated
[8–10]. Other organisms variably implicated in the
pathogenesis of NSC include Mycoplasma genitalium,
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Purpose of review
Sexually transmitted infections impact significantly on global health. Whereas
Chlamydia, Neisseria gonorrhoea and syphilis have been extensively examined, there
remains a paucity of knowledge of nonchlamydial and nongonococcal cervicitis, an
arguably more prevalent but poorly characterized condition with uncertain clinical
implications. With increasing application of molecular diagnostic methods for the
detection of sexually transmitted infections and a growing body of literature on cervicitis,
a review is timely.
Recent findings
The number of putative aetiological agents implicated in cervicitis is growing and
includes Mycoplasma genitalium, herpes simplex virus, cytomegalovirus, bacterial
vaginosis and Trichomonas. The potential role of cervicitis in HIV transmission has been
highlighted. Increasing broad-spectrum antibiotic usage with associated emergence of
antimicrobial resistance reinforces the need for targeted antibiotic therapies, including
the management of cervicitis.
Summary
As our understanding of the aetiology and significance of cervicitis, particularly
nonspecific cervicitis, improves, management will be refined. Advances in molecular
diagnostic testing will facilitate this process, but urinary nucleic acid amplification
testing should not replace clinical examination while cervicitis prevalence and
significance are not yet established. A standardized approach to cervicitis research,
particularly with consensus of case definition, may facilitate outcomes that can be more
generally applied in clinical practice.
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Mycoplasma hominis, Ureaplasma urealyticum, bacterial
vaginosis, herpes simplex virus (HSV), cytomegalovirus
(CMV), Trichomonas vaginalis and adenovirus. This raises
concerns about the appropriateness of empirical treat-
ments currently used to treat women with cervicitis
and their sexual partner(s). Importantly, Bradshaw and
colleagues [11], in a recent Australian study of non-
specific urethritis, the analogous clinical condition in
men, highlighted the role of adenovirus, HSV-1, macro-
lide-resistant Mycoplasma species and oral sex in nonspe-
cific urethritis, factors yet to be fully characterized in
NSC. A lack of consensus on definitive treatments for
cervicitis in STI treatment guidelines [12,13] reflects
these uncertainties, with the potential for over-use of
antibiotics. Furthermore, the psychological impact of
empirically treating cervicitis as an STI has recently been
examined [14].
Significance of cervicitis
Complications of cervicitis include endometritis, pelvic
inflammatory disease (PID) and adverse outcomes of
pregnancy and the newborn. The synergy between gen-
ital infection and enhancement of HIV transmission is
well recognized. There is also literature implicating
cervical inflammation in the pathogenesis of cervical
cancer.
Pelvic inflammatory disease
Cervicitis may serve as an important marker of subclinical
PID. Mucopurulent cervicitis and endometritis may be
the only signs of PID in some women [4,9,10,15]. Many
women with tubal-factor infertility, ectopic pregnancy or
chronic pelvic pain do not give a history of PID, but
subclinical PID is likely to be an important contributing
factor [16,17]. The reported risk of women with lower-
genital-tract infection developing PID ranges from 20 to
80% depending on method used for detection, delay in
diagnosis, treatment, co-infection and other host factors
(reviewed in [17]). Peipert and colleagues’ [18] analysis
of women with pelvic pain in the PID Evaluation and
Clinical Health (PEACH) study found lower-
genital-tract leucorrhoea [>10 leucocytes per high-
powered field (hpf) on microscopic examination of
vaginal fluid] had a high sensitivity (89%) but low speci-
ficity (19%) for predicting histologically proven endome-
tritis. Other researchers have confirmed the high positive
predictive value (PPV) of leucorrhoea for PID in the
high-risk STI settings [19], particularly in the setting of
bacterial vaginosis [20]. Thus, vaginal leucorrhoea may
also be a useful adjunctive tool in the diagnosis of upper-
genital-tract infection.
Although there is disparate literature concerning
chlamydial and gonococcal contribution to PID, even
less is known about the relationship of NSC to upper-
genital-tract infection. This is an important consideration
when 20–30% cases of NSC are refractory to empirical
‘cervicitis’ treatment [9]. Furthermore, a recent novel
study modelling different management algorithms for
cervicitis in a hypothetical teen clinic population has
emphasized the important psychological ramifications
associated with diagnosis and empirical treatment of
cervicitis for women and their partners, versus the PID-
prevention benefits where there is a low prevalence of
Chlamydia [14].
Pregnancy
Chlamydia infection has been associated with a doubling
of ectopic pregnancy rates in a Norwegian study [21] and
while an association of chlamydial infection with preterm
delivery is suggested, its role is not yet fully elucidated
[17]. Nugent and Hillier’s [10] analysis of a large cohort
of high-risk pregnant women found that cervicitis was
significantly associated with the delivery of low-birth-
weight babies [adjusted relative risk 2.11, 95% confi-
dence interval (CI) 1.10–4.04]. This was despite a low
sensitivity (25%) and low PPV (24%) for Chlamydia infec-
tion, implicating NSC. A recent Chilean study [22]
examining the benefit of antibiotic administration to
women with preterm labour found that whereas there
was no overall benefit on composite neonatal morbidity/
mortality outcome, a subgroup of women with NSC
without amniotic fluid infection and intact membranes
derived benefit from antibiotic administration with sig-
nificantly lower frequency of neonatal morbidity and
mortality. This finding suggests that cervicitis may be
a useful clinical marker for women at risk who might
benefit from antibiotic intervention.
HIV transmission
Cervicitis is thought to play an important role in the
transmission of HIV infection, by increasing suscepti-
bility to HIV infection and increased HIV viral shedding.
The association of genital ulceration, particularly HSV-
related, with increased risk of HIV transmission risk is
well recognized [23]. A significant correlation between
cervical HIV DNA and microscopic evidence of cervical
inflammation [adjusted odds ratio (OR) 8.7] has been
demonstrated [24]. Mechanisms by which cervicitis
may increase HIV-1 shedding include increased viral
replication in the context of infection or inflammation
particularly in the presence of elevated pro-inflammatory
cytokines, disruption of normal mucosa and increased
numbers of HIV-infected cells in cervical secretions.
Effective treatment of chlamydial or gonococcal cervicitis
correlated with a greater than 6-fold decrease in cervical
HIV-1 RNA and with normalization of cervical polymor-
phonuclear counts, but no reduction in HIV-1-infected
cells as measured by presence or absence of HIV-1
proviral DNA in one study [25]. Intriguingly, treatment
of the subgroup of women with NSC in the same study
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did significantly reduce the number of HIV-1-infected
cells but this was not reflected in a reduction in cervical
HIV RNA. These data suggest that differing cervicitis
aetiology may variously impact on HIV-1 expression in
the genital tract. The role of NSC, in particular, requires
further elucidation.
Endometritis in HIV-1-positive Kenyan women was
associated with a 15-fold increase in HIV viral shedding
(95% CI 2–120), which is concerning as asymptomatic
endometritis may be more common in HIV-positive
women [26]. Thus implementation of effective STI
screening, management and prevention strategies could
significantly impact on HIV transmission, particularly in
resource-poor settings.
Human papillomavirus and cervical cancer
Chronic inflammation has been linked to many epithelial
cancers, and thus the role of chronic cervicitis as a cofactor
in cervical cancer seems plausible [27]. Human papillo-
mavirus (HPV), predominantly types 16 and18, is required
for the development of themajority of cervical carcinomas
[28]. The role of HPV in cervicitis is less clear. Studies
have noted a positive association between measures of
cervical inflammation and squamous intraepithelial lesions
[28,29]. A case–control study ofCosta Ricanwomen found
that in women infected with oncogenic HPV types,
the likelihood of developing high-grade squamous intra-
epithelial lesions increased with the degree of cervical
inflammation [29]. Chlamydia, HSV, Trichomonas, bacterial
vaginosis and CMV-associated cervical inflammation
have been reported as potential cofactors in development
of cervical carcinoma in past predominantly sero-
epidemiological-based studies. Recent, more convincing
evidence for a causal link of any of these pathogens is
lacking. U. urealyticum has been suggested as a possible
cofactor in the development of abnormal cervical cytology
in the presence of HPV [30].
Case definition of cervicitis
The case definition of cervicitis varies widely and is
considered by many a clinical diagnosis to be evidenced
by cervical ectopy (extension of the columnar epithelium
of the endocervix onto the visible ectocervix), a ‘friable
cervix’, presence of ‘mucopurulent’ or yellow discharge or
a combination of these signs. However, overt signs of
cervicitis may be overlooked given the variance in signs
considered indicative of cervicitis. The presence of a
yellowdischarge, indicatingneutrophil productionofmye-
loperoxidase, has been suggested as a good predictor of
Chlamydia or N. gonorrhoea infection [1,4,15]. However, a
recent evaluation of syndromic management using signs
and symptoms of vaginal discharge in women in an ante-
natal setting in Botswana failed to satisfactorily identify
women with Chlamydia or gonorrhoea infection [31].
Another approach adopted by clinicians is microscopic
analysis of mucus taken from the endocervical canal.
Leucocytes are normally present throughout the repro-
ductive tract including cervical tissue [32] but are con-
sidered pathological when present in high numbers
(usually >30/hpf) [1,4]. Cervical mucus polymorph
assessment is not affected by the phase of the menstrual
cycle except for during menstruation when it becomes
less reliable [1]. The microscopic diagnosis of cervicitis is
determined by Gram stain of the number of polymorpho-
nuclear leucocytes per hpf (PMNL/hpf; 1000, oil
immersion) in cervical mucus using different cut-off
thresholds, usually >30PMNL/hpf [4,5,8,10,25] but
often >10PMNL/hpf [1,4,32]. The validity of each
cut-off value has been reviewed [2,9]. Consensus in
the literature appears to favour the former, which has
greater specificity at the expense of reduced sensitivity.
The availability of microscopy to facilitate cervicitis
diagnosis will be impacted in resource-poor clinical set-
tings. Microscopy may be open to intra-observer varia-
bility and error with vaginal epithelial cell contamination
of cervical samples and counting polymorphs outside of
cervical mucous. Studies reporting low PPV of micro-
scopic cervicitis in detection of Chlamydia and N. gonor-
rhoea in settings of low STI prevalence [8,10] are based on
the ability to predict Chlamydia infection detected by
culture laboratory methods. The PPV of cervical findings
could be considerably improved with the use of NAAT
methods of Chlamydia detection. Additionally, PPVs are
often given in terms of Chlamydia and N. gonorrhoea
detection only and do not consider the increasing array
of recently described pathogens, such asMycoplasma spp.
Therefore, it would seem prudent to diagnose cervicitis
using a combination of microscopy (>30PMNL/hpf) and
at least one of the abovementioned clinical signs. Using
these diagnostic criteria for cervicitis may improve the
PPV for detecting disease.
Noninfectious aetiology
It has been suggested that mucopurulent discharge could
be causedby exposure of the cervical columnar epithelium
to noninfectious factors in the vagina, such as smoking,
douching and combined oral contraception. Earlier large
prospective studies found a significant associationwith use
of combined oral contraception: Paavonen et al. [33]
showed an adjusted OR of 2.5 (P¼ 0.02) and Castle
et al. [29] showed an OR of 2.9 (95% CI 1.4–5.9). Inter-
estingly, however, authors of a subsequent large cross-
sectional study found no such association after adjusting
for the presence of cervical ectopy [34].
There is conflicting literature concerning the association
between vaginal douching and cervicitis, endometritis
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and PID. PID was found to be significantly associated
with current, frequent douching in a formative Seattle
study [35]. A similar association with cervical Chlamydia
infection and douching was observed in a separate large
cross-sectional study [36]. However, in contradiction,
no association between douching and gonococcal or
Chlamydia cervicitis or PID was found recently in a
large prospective observational study of predominantly
African-American women who commonly douche [37].
Although smoking had been previously linked to an
increased risk of PID, no link between smoking and
cervicitis, dysplasia or Chlamydia infection was found,
after adjustment for confounders, in a UK cross-sectional
study [38].
Infectious aetiology
Of the known infectious agents of cervicitis, Chlamydia
and N. gonorrhoea have been the most widely studied.
Chlamydia trachomatis and Neisseria gonorrhoea
Chlamydia is the most frequently identified cause of
cervicitis with rates of Chlamydia in women with cervicitis
varying widely in the literature from 11 to 50% [1,6,
17,33] depending on population sampled, cervicitis
definition and detection methods. However only 10–
20% of Chlamydia infections may be associated with
obvious clinical signs of cervicitis [6]. This may be
explained in part by infections with a lower quantity of
infectious organisms and strain variability, including ‘non-
fusing variants’ of Chlamydia (about 1.5% of isolates) [39].
Increasing application of NAAT testing for Chlamydia has
resulted in enhanced ability to detect this pathogen, but
this does not completely account for the concerning
continued increase in Chlamydia infection [17].
Whereas N. gonorrhoea is known to cause cervicitis, the
proportion of cervicitis attributable to N. gonorrhoea is
highly variable, in keeping with the markedly different
prevalence of N. gonorrhoea in different populations.
Mycoplasma genitalium
There is strong support for the role ofM. genitalium in the
aetiology of cervicitis [5,40,41,42,43], endometritis
[43,44], PID [42,45], genital-tract disease in men
[11,42] and more recently in tubal-factor infertility
[46]. A recent serological study found a trend but not a
significant association of M. genitalium with PID and
ectopic pregnancy [47]. The organism fulfils Koch’s
postulates for pathogenicity and the balance of current
evidence supports the use of antibiotics ifM. genitalium is
detected [11,12,42,48]. A recent Danish prevalence
study found the likelihood of M. genitalium infection in
women was associated with increasing numbers of recent
sexual partners and partners with symptoms [48].
However, the lowM. genitalium prevalence of 2.3% could
not justify routine screening. Low prevalence rates of
M. genitalium in asymptomatic women are reported, 6% in
a Swedish study [40] and 7% inUS STD clinic population
study [5]; in the latter,M. genitalium infection conferred a
3-fold greater risk of cervicitis. A recent large British
study of antenatal women found a prevalence of only
0.7% and suggested that M. genitalium is not a risk factor
for adverse pregnancy outcome in healthy women [49]. A
higher prevalence of 6.2% in pregnant women in Guinea-
Bissau was significantly associated with HIV-1 infection
but not with adverse pregnancy outcomes [50]. Impor-
tantly, prevalence rates of M. genitalium in symptomatic
and high-risk populations appear considerably higher,
13–25% [41,44,51,52].
Mycoplasma hominis
M. hominis is commonly found in the genital tract of
sexually experienced females and a role in PID and
postabortal fever [45] has been suggested. Reports of
the prevalence of M. hominis in women with cervicitis
vary widely between 2.3% in a Turkish study and 26% in
a small Wisconsin college population [41]. Nugent and
Hillier [10] foundM. hominis to be significantly associated
with cervicitis (relative risk 2.96, 95% CI 1.76–4.99) in a
study of high-risk pregnant women. It is suggested that
M. hominis may exist symbiotically with the mixed bac-
teria of bacterial vaginosis [45,53]. M. hominis serum
antibody titres and vaginal leucorrhoea have been found
to be higher in women with bacterial vaginosis, than
women without bacterial vaginosis [53]. It is difficult
to determine the pathogenic role of M. hominis given
its frequent association with bacterial vaginosis [45].
Bacterial vaginosis
Bacterial vaginosis is found in up to 50% of women with
cervicitis [33], and may play a role in the aetiology
[7,33,54]. The association of bacterial vaginosis with
endometritis, PID and adverse pregnancy outcome is
increasingly accepted [16,45,55]. Even though a signifi-
cant association between PID and bacterial vaginosis was
not found in a large observational cohort of African-
American women, bacterial vaginosis was suggested as
a marker for women at higher risk of PID [56]. The
authors found that in women with bacterial vaginosis, the
presence of Chlamydia or N. gonorrhoea was associated
with a 3.1-fold risk of PID compared to a 1.91-fold risk
in the presence of normal vaginal flora. The strongest
risk for PID in the presence of bacterial vaginosis was
carriage of pigmented, anaerobic Gram-negative rods
(Porphyromonas, Prevotella, Bacteroides). The study of
Schwebke and Weiss [54] found an association between
bacterial vaginosis and cervicitis and between use
of metronidazole gel and resolution of cervicitis. A
reduction in pro-inflammatory vaginal cytokines with
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treatment of bacterial vaginosis has been noted in one
recent randomized controlled trial involving pregnant
women, suggesting that bacterial vaginosis is associated
with inflammatory changes at the cervix [57]. Marrazzo’s
group [7], investigating risk factors for cervicitis in
women with bacterial vaginosis, identified older age,
new male or female partner, recent oral sex and absence
of H2O2-producing lactobacilli. The loss of H2O2-
producing lactobacilli in conjunction with increase in
sialidases and glycosidases produced in bacterial vagino-
sis may break down the protective cervical mucus barrier
[58]. In keeping with this literature, the Center for
Disease Control and Prevention guidelines recommend
that bacterial vaginosis be treated if found in the presence
of cervicitis [12].
Ureaplasma urealyticum
U. urealyticum is commonly found in the genital tracts of
symptomatic and asymptomatic men and women, associ-
ated with lifetime number of sexual partners. U. urealy-
ticum is suggested as a pathogen associated with cervicitis
with an OR of 2.7 (P< 0.0133)) in study [33], adverse
pregnancy outcome [45,59] and postpartum sepsis
[45]. However there is little evidence of its role in
PID [45].
Herpes simplex virus, cytomegalovirus and adenovirus
HSV-1 and HSV-2 have been associated with cervicitis
[4,6,34]. Cervical HSV shedding is thought to be gener-
ally asymptomatic. Several studies suggest an associ-
ation between CMV and cervicitis [6,34,60,61]. CMV
accounted for 7.6% of cases of cervicitis in one large
cross-sectional study [34]. Another study of cervical
biopsies of HPV-associated cervical neoplasia identified
CMV DNA in 8.7% of specimens [61]. CMV shedding
has also been found to be significantly greater in HIV-
positive than HIV-negative women [62]. The develop-
ment of molecular diagnostic techniques, particularly
multiplex polymerase chain reaction (mPCR), will aid
in the detection of these viruses, which are also associ-
ated with significant congenital infection [63]. Adeno-
virus has been implicated in nongonococcal urethritis in
males [11], and it is thought to have a role in cervicitis
[64] but it is not well defined and is an area of potential
interest.
Trichomonas
Trichomonas is associated with cervical inflammation
[2,33,65,66] and increased risk of HIV transmission
[65]. Its reported contribution to the aetiology of cervi-
citis is highly variable, reflecting local prevalence, and it
is considered to be frequently under-diagnosed due to
the relatively low sensitivity of wet-mount microscopy.
New methods for Trichomonas detection, specifically
NAAT testing and the new rapid point-of-care (POC)
bedside immunochromographic tests, could help clarify
local prevalences [66]. Very little is published on cervi-
citis and yeast, but a negative association with cervicitis
has been suggested [33].
Management of cervicitis
In Australasia, standard empiric treatment for cervicitis
is azithromycin for affected women and their sexual
partners [13]. As the local heterosexual prevalence of
gonorrhoea is very low [3], concurrent treatment for
gonorrhoea is not routinely given empirically. Azithro-
mycin failure in 28% of men with M. genitalium-related
urethritis has been reported and occurred more fre-
quently when the M. genitalium originated from south-
east Asia, where there is emerging macrolide resistance
[11,67]. This has important treatment implications
when M. genitalium is associated with cervicitis. There
are reports of improved clearance rates of M. genitalium
with extended courses of azithromycin and moxifloxacin
[42,67].
Persistent cervicitis, despite ‘standard’ empirical treat-
ment is not infrequently encountered (M.J. Lusk and
P. Konecny, personal observation) and reported by others
[6,8,12]. The natural history of cervicitis is not defined,
nor is the benefit of further treatment for unresponsive
cases and their partners. Most STI guidelines suggest
gynaecological review to exclude underlying pathology
such as malignancy or the consideration of chemical
irritant or idiopathic causes. Ablative therapy of the cervix
has been used to treat chronic cervicitis [68], but there is a
paucity of literature concerning the rationale and effec-
tiveness of this intervention, which presumably relates to
the association between ectopy and cervicitis. Returning
to the concept that cervicitis may be an indicator of silent
PID, STI guidelines could perhaps give consideration to
recommending PID treatments for persistent cases of
cervicitis. The management of PID has recently been
reviewed and emphasis placed on achieving high rates of
clinical as well as microbiological cures [69].
Conclusion
In conclusion, cervicitis remains a condition yet to be
fully characterized. It is common, often asymptomatic
and may be associated with significant adverse outcomes
for women. Research in NSC is a particular area of need.
Wide variations of case definition, study populations and
methods for pathogen isolation hinder the ability to draw
conclusions on the aetiology, natural history and best
management of cervicitis on a population basis. Certainly
the evidence suggests it is a multifactorial condition. We
suggest future research should combine a microscopic
definition of >30PMNL/hpf, the more frequently cited
criterion, with at least one of the accepted clinical signs,
such as yellow mucopus.
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Urinary-based NAAT methods of STI testing have
revolutionized the process of STI testing, but ironically
without internal genital examination, the diagnosis of
cervicitis cannot be made. With the streamlining of
clinical services and, in some practices, the replacement
of genital examination with urinary NAAT testing,
particularly for asymptomatic screening, we risk over-
looking significant pathology in women with negative
results from STI screening tests. In the meantime
further research is needed to elucidate the contri-
bution of new putative aetiological agents, such as
M. genitalium and bacterial vaginosis, and their antibiotic
susceptibility patterns and noninfectious factors impli-
cated in the aetiology of cervicitis. This will improve
diagnosis and management of this condition and thus
ultimately improve health outcomes for women and their
partners.
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ABSTRACT
Objectives Trichomonas vaginalis (TV) has a low profile in
urban sexually transmitted infection (STI) clinics in many
developed countries. The objective of this study was to
determine the true prevalence of TV in an Australian
urban sexual health setting using sensitive molecular
diagnostic techniques.
Methods A cross-sectional study investigating the
aetiology of cervicitis in women attending two urban
sexual health clinics in Sydney, Australia, enrolled 356
consecutive eligible women from 2006 to 2008. The
diagnostic yield from the standard clinical practice of
discretionary high vaginal wet preparation microscopy in
women with suspicious vaginal discharge was compared
with universal use of nested PCR for TV of cervical
samples.
Results TV was detected by PCR in 17/356 women
(4.8%, 95% CI 2.8 to 7.5%), whereas only four cases
(1.1%, 95% CI 0.3 to 2.8%) were detected by
discretionary wet preparation microscopy. Eleven of the
17 women (p¼0.003) were of culturally and linguistically
diverse background. Additionally, cervicitis was found to
be significantly associated with TV, RR 1.66 (1.14 to
2.42), p¼0.034.
Conclusions Traditional TV-detection methods
underestimate TV prevalence in urban Australia. The TV
prevalence of 4.8% by PCR testing in this study exceeds
previously reported urban Australian TV rates of <1%.
An increase in trichomoniasis-associated adverse
reproductive outcomes and enhanced HIV transmission
poses a salient public health threat. Accordingly, TV
warrants a higher profile in urban STI clinic settings in
developed countries, and we suggest that priority be
given to development of standardised molecular TV
detection techniques and that these become part of
routine STI testing.
INTRODUCTION
Trichomonas vaginalis (TV) is a sexually transmitted
infection (STI) causing signiﬁcant morbidity
worldwide. Trichomonads are highly site-speciﬁc
protozoan parasites. In women, TV infects the
lower urogenital tract, causing superﬁcial vaginal
and cervical ulceration. Typical symptoms include
frothy yellow discharge, itch, odour, dyspareunia
and occasionally vaginal bleeding. Infection of the
urethra and paraurethral glands causes dysuria and
frequency.1 However, at least one-third of infected
women may be asymptomatic.2 Trichomoniasis has
been associated with premature rupture of
membranes,3 pelvic inﬂammatory disease (PID),4
cervicitis5 6 and enhanced risk of HIV transmission.7
Men may present with balanitis, urethral discharge
or dysuria, but again, high rates of asymptomatic
carriage have been reported. A recent US STI clinic
study detected TV in 72% of male partners of
infected females, and of these men, 77% were
asymptomatic.8 The duration of TV infection in
women may be prolonged for up to 3e5 years but
only about 4 months in men.9 The natural history
of TV infection is not well deﬁned.
Trichomoniasis is the most common curable STI.
In 1999, WHO estimated 174 million new cases per
year, more than double the number of Chlamydia
trachomatis cases and treble the cases of gonorrhoea.
The high TV prevalence worldwide is concentrated
in developing countries and socio-economically
disadvantaged groups, with a dramatic decline in
TV rates in some developed countries in the past
few decades.10 TV prevalence in urban Australia is
reportedly low based upon routine wet preparation
diagnostic methods.9 10 Australian rates of TV
peaked in the 1950s at 20e30% and rapidly declined
through the 1960s and 1970s to below 1% in 1990.10
This has been attributed to the combination of
widespread use of the Nitroimidazoles, and
increased surveillance through Papanicolaou
smears.9 10 This decline and the fact that TV is not
a notiﬁable disease in Australia have led to the
present situation where testing for TV has assumed
a very low priority in urban Australian settings. An
audit of commercial sex workers (CSW) undergoing
regular STI screening at a sexual health clinic in
Melbourne in 2003 reported a very low incidence of
TV at 0.11 per 100 person months.11 By contrast,
TV prevalence in indigenous Australian women, in
remote Northern Territory, was high at 25% in
a self-sampling PCR-method-based study.12 The
prevalence of TV by PCR among US women of
reproductive age was recently found to be 3.1%,
with an even lower prevalence of 1.3% in the
subgroup of non-Hispanic white women.13
We are conducting a prospective study investi-
gating the prevalence and aetiology of cervicitis
using molecular diagnostic techniques in women
attending two urban STI clinics in Sydney,
Australia. In this paper, we report the prevalence of
TV by PCR testing against traditional methods of
detection, and compare our ﬁndings with previous
data from other Australian urban STI clinics.
METHODS
This study was conducted in two urban Sydney
STI clinics from July 2006 to December 2008.
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Sydney and Illawarra Area Health Service Human Research
Ethics Committee and the Sydney South West Area Heath
Service Ethics Review Committee (Royal Prince Alfred Hospital
Zone).
Subject selection
Women were eligible for this study if they were 18 years or older,
had been sexually active in the previous 3 months and required
an internal examination. The parent cervicitis study protocol
excluded women if they had been previously enrolled, had clinical
PID, had received antibiotics or undergone gynaecological inter-
vention in the previous month, had an intrauterine contraceptive
device, were currently menstruating or pregnant, attending for
sexual assault or unsuitable for enrolment due to psychosocial ill
health or comprehension difﬁculties. Of a total of 957 consecu-
tive ﬁrst attendances, 561 women (58.6%) were ineligible, 40
(4.2%) declined, and 356 (37.2%) were enrolled. The most
common reasons for ineligibility included examination not
required (30.7%), antibiotics in previous month (14.2%), preg-
nancy (8.6%) and no sex in previous 3 months (8.3%). Women
with clinical PID comprised 3.1% of ineligible women. This
report is an interim analysis of 356 consecutive ﬁrst attendances
of women enrolled in the parent cervicitis study.
Sampling procedure
A sterile speculum was used to visualise the vagina and cervix. A
Gram stain was performed on all cervical and high vaginal swabs
(HVS). Due to the nature of the parent study, HVS for wet
preparation microscopy was discretionary based upon clinical
suspicion of TV infection, in keeping with usual clinical practice,
and so not performed for all women. The endocervix was
sampled in all women, with a sterile cotton swab (Copan,
Brescia, Italy) for Gram stain and bacterial agents. An additional
endocervical sterile cotton swab was taken and placed in viral
transport medium 199 (GIBCO Invitrogen, Grand Island,
New York) and stored at 708C for subsequent PCR testing for
TV by the method described below. Swabs from all women were
tested for TV by PCR.
Cervicitis was deﬁned as >30 polymorphonuclear cells per
high-powered ﬁeld (PMN/hpf) in at least three non-adjacent
ﬁelds of cervical mucus on Gram stain of the ﬁrst endocervical
swab. Bacterial vaginosis (BV) was deﬁned by Nugent score from
Gram stain of the HVS.
Nucleic acid extraction and PCR amplification
Swabs were suspended in 500 ml of viral transport medium
(above) before extraction of the total nucleic acid using a robotic
extraction machine (MagNaPure LC, Roche, Germany) applying
the Total NA protocol according to the manufacturer ’s instruc-
tions (Roche, Germany). Extracts were stored at 48C before
testing within 48 h of collection.
Detection of TVwas performed using a nested PCR. Brieﬂy, the
ﬁrst-round reaction comprised 10 ml of template in a 50 ml of PCR
reaction mixture containing 9 ml of nuclease-free water, 25 ml of
23 iScript reaction mix (BioRad, Sydney, Australia), 0.5 mM each
primer: TricV-OF (59 CTATTGTCGAACATTGGTCTTACCCTC
39) and TricV-OR (59 TCTGTGCCGTCTTCAAGTATGCCC
39)14 15 and 1 ml of iScript RTenzyme (BioRad). (This commercial
master mix is used in our laboratory for the ampliﬁcation of both
RNA and DNA templates). Cycling conditions were 508C for
30 min; denaturation at 958C for 15 min, then 35 cycles of 948C
for 45 s, 578C for 45 s and 728C for 1 min; a ﬁnal extension of
7 min at 728C; and a 48C hold. A second round reaction
comprised 2 ml of ﬁrst-round product included in a 50 ml reaction
mixture containing 18 ml of nuclease-free water, 25 ml of
Amplitaq gold PCR Master Mix (Applied Biosystems, Foster
City, California, USA) and 0.5 mM of each primer: TricV-IF
(59 CTCAGTTCGCAAAGGCAGTCCTTGA 39) and TricV-IR (59
GCTTGGAGAGGACATGAACTTCGGA 39).14 Cycling condi-
tions included denaturation and activation at 958C for 5 min, 33
cycles of: 948C for 20 s, 578C for 20 s, 728C for 20 s; a ﬁnal
extension at 728C for 10 min and a 48C hold. PCR products of
206 bp were expected for TV-positives and were visualised by gel
electrophoresis. Using positive controls from either culture-
proven or molecularly proven sources, sensitivity was assessed by
measuring the limit of detection (102 copies per reaction) of
plasmid constructs of the target sites as previously described14
and is estimated to be 95e98%. The speciﬁcity was determined
as follows: conﬁrmation by probe hybridisation following the
PCR ampliﬁcation, and DNA sequencing performed on PCR
products of the ﬁrst 10 TV positive samples from the study.
Nucleotide BLAST on NCBI site (for all 10 samples) conﬁrmed
that all DNA sequences produced from sequencing were TV. The
results from the above methods conﬁrmed that the assay has
100% speciﬁcity.
Analysis
We report the prevalence with 95% CI of TV by traditional
methods and PCR methods. Population characteristics of
women with and without TV were compared using c2 testing.
p Values <0.05 were considered statistically signiﬁcant. Data
were analysed with SAS software SAS Institute (Cary, North
Carolina).
RESULTS
Prevalence of TV by PCR testing was 17/356 (4.8%, 95% CI 2.8
to 7.5%). Clinical suspicion prompting discretionary wet-mount
preparation microscopy identiﬁed TV in only 4/356 women
(1.1%, 95% CI 0.3 to 2.8%). PCR identiﬁed a higher percentage
of women with TV (p¼0.0003).
Of the 17 women positive for TV by PCR testing, only 11 had
wet-preparation microscopy performed. The use of discretionary
wet preparation was not signiﬁcantly different in women with
and without TV by PCR (p¼0.498). Detection by Papanicolaou
(Pap) smear occurred in only two of the 11 Pap smears done in
women with TV. The mean age of the women with TV,
33.2 years, was not signiﬁcantly different from the mean age of
women without TV, 30.7 years (p¼0.221) (table 1). Signiﬁcantly,
11/17 women with TV (p¼0.003) were of culturally and
linguistically diverse background and identiﬁed consorts from
populations of higher TV prevalence overseas (Africa, China, Sri
Lanka, South America, Lebanon, Black American). Three women
identiﬁed rural or ‘bush’ Australian contacts. Five women were
CSW. No cases of TV were indigenous women. Six cases had BV,
and three had concurrent STIs (two with Chlamydia and one
with HIV and active genital herpes). Dysuria was signiﬁcantly
associated with women with TV (p¼0.014). Prevalence of
cervicitis in women without TV was 39%, compared with 65%
(11/17) in women with TV, giving a RR of cervicitis in the
presence of TV of 1.66 (95% CI 1.14 to 2.42) p¼0.034.
DISCUSSION
These data show that traditional methods of detection greatly
underestimate the prevalence of TV. We report a TV prevalence
of 4.8% by PCR testing, whereas clinical suspicion prompting
discretionary wet-preparation microscopy identiﬁed TV in only
4/356 women (1.1%) in the same study population. The lower
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case-detection rate by discretionary use of wet-preparation
microscopy (and Pap smear) observed here reﬂects the inade-
quacy of relying solely upon these methods for detecting TV.
Wet-mount microscopy has a sensitivity as low as 52%,16
depending on specimen handling, skill of the microscopist and
TV organism load in specimen. Additionally, wet-preparation
microscopy is not routinely performed, even in many STI clinic
settings and laboratories.8 17
These TV prevalence rates by PCR are higher than previously
reported rates of<1% in other urban Australian STI clinic studies,
sampling CSWs using traditional diagnostic methods.10 11 This
difference could signal a true rise in TV prevalence or be attrib-
uted to the more sensitive PCR diagnostic techniques employed
here as well as sampling a less clinically homogeneous, highly
screened population than those represented in previous litera-
ture.9 11 However, due to the relatively low population preva-
lence of TV, the positive predictive value of these PCR ﬁndings
may be reduced. On the other hand, these PCR data may
potentially underestimate the true prevalence due to the strict
inclusion criteria of the parent study protocol and retrospective
PCR testing of stored, frozen and thawed specimens. Cervical
specimens were used for this study, but the performance of
cervical and vaginal specimens for TV PCR testing has been
shown to be comparable.18
An important ﬁnding in our study was the high proportion (11/
17, p¼0.003) of women with TV who were of culturally and
linguistically diverse backgrounds. Urban society in Australia, as in
many other industrialised countries, is very culturally diverse with
a highly mobile population. Accordingly, sexual networks,
particularly of migrant and ﬁrst-generation Australians often
include consorts who come from or travel to populations with
higher TV prevalence. We found the symptom of dysuria to be
signiﬁcantly associated with women with TV, highlighting the
need for clinicians to consider the possibility of TVespecially in the
absence of other causes of dysuria. We did not ﬁnd any association
between TV and BV, although others have.8 BV may mask the
presence of TV. Standard BV treatment with nitroimidazoles will
effectively eradicate coexistent TV infection, but partners of
women with concomitant BV and TV will remain untreated,
potentially facilitating the persistence and spread of TV.
Cervicitis was associated with TV (RR 1.66, p¼0.034)
supporting the role of TV in the aetiology of cervicitis. Non-
gonococcal, non-chlamydial cervicitis or non-speciﬁc cervicitis
comprises a major proportion of reported cervicitis,5 6 and TV
has been recently recognised as an aetiological agent in this
condition.5 Molecular testing for TV in STI populations is likely
to shed further light on the aetiology of non-speciﬁc cervicitis in
women, a current area of research need.
Coinfection with another STI, including TV, remains a signif-
icant risk factor for HIV acquisition.7 Women increasingly carry
the burden of the HIV epidemic in many developing and
westernised countries.19 As many screening programmes are
targeting younger women, older groups of sexually active
women where TV predominates9 may be overlooked, potentially
contributing to the TV reservoir in the community. The recent
rise in gonorrhoea in women in some industrialised nations and
noted in our own region20 may indicate relaxation of safer sex
practices, possibly presaging a rise in STIs with re-establishment
in these sexually active populations and increased opportunity
for HIV transmission.
If not speciﬁcally sought, TV will not be detected. Presently
sensitive, standardised detection methods for TV are seldom
commercially available, relying on in-house laboratory molecular
methods. This, coupled with the low proﬁle of TV, has led to
infrequent uptake of any testing for TV in many clinical settings.
Our ﬁndings suggest that when sensitive diagnostic tests are
routinely or selectively applied, TV may be found to be more
prevalent than previously thought. These concerns echo those of
others2 7e9 16 21 that priority be given to developing standardised,
sensitive, cost-effective techniques for TV detection.
In summary, we report a higher than previously reported
prevalence of TV, by PCR testing, in an urban Australian STI
clinic population. We suggest that the current low proﬁle of TV
and the variable application of insensitive tests for case detection
have led to underdiagnosis of TV. In turn, this could facilitate
a re-emergence of TV, particularly in culturally diverse urban
populations. Trichomoniasis has the potential to impact signif-
icantly on reproductive health of women and increase HIV
transmission. Accordingly, TV warrants a higher proﬁle in urban
settings in developed countries. With this demonstration of
higher than expected TV prevalence, a call is justiﬁed for the
development and application of standardised PCR TV-detection
techniques to facilitate case-ﬁnding, surveillance and continued
control of this STI.
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Table 1 Characteristics of women with and without Trichomonas
vaginalis (TV) by PCR
Characteristic
Women with
TV n[17
Women without
TV N[339
p
Value*
Mean age (years) 33.4 30.7 0.221
Culturally and linguistically diversey 11 (65%) 104 (31%) 0.003
Condoms always 4 (24%) 75 (22%) 0.892
>1 partner last 3 months 6 (35%) 95 (28%) 0.516
Commercial sex workers 5 (29%) 58 (17%) 0.195
Concomitant STIz 2 (12%) 24 (7%) 0.469
Signs and symptoms
Dysuria 7 (41%) 59 (17%) 0.014
Vaginal discharge 11 (65%) 143 (42%) 0.067
Bacterial vaginosisx 6 (35%) 79 (23%) 0.258
*p Values <0.05 are statistically significant.
yDefined as women identifying at clinic registration as preferring a language other than
English, speaking a language other than English at home, or identifying a non-English ethnic
background.
zConcomitant chlamydia or gonorrhoea.
xDefined by Nugent score on Gram stain of high vaginal swab.
Key messages
< We report a higher than previously reported prevalence of
Trichomonas vaginalis (TV) of 4.8% by PCR methods in an
urban Australian sexually transmitted infection (STI) clinic
setting.
< TV is likely underdiagnosed in urban STI clinic settings using
only traditional methods of detection. This may presage re-
emergence with important Public Health consequences.
< We find TV is significantly associated with women of culturally
and linguistically diverse backgrounds, and cervicitis is
significantly associated with TV (RR 1.66, p¼0.034).
< TV warrants a higher profile. Priority should be given to the
development of standardised molecular TV detection tech-
niques for inclusion in routine STI testing.
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Mycoplasma genitalium is associated with cervicitis
and HIV infection in an urban Australian STI
clinic population
M J Lusk,1 P Konecny,1 Z W Naing,2 F L Garden,3 R G Cumming,3 W D Rawlinson4
ABSTRACT
Objectives To investigate the prevalence of the genital
mollicutes, Mycoplasma genitalium (MG), Mycoplasma
hominis (MH), Ureaplasma urealyticum (UU) and
Ureaplasma parvum (UP), and their associations with
cervicitis in a sexually transmitted infection (STI) clinic
population. Clinical correlates of MG infection were also
assessed.
Methods 527 women were enrolled in a cross-sectional
study at two STI clinics in Sydney between June 2006
and January 2010. Genital mollicutes were detected by
multiplex PCR testing of cervical swabs, and associations
with cervicitis were analysed. Cervicitis was defined as
>30 polymorphonuclear cells per high-power field in at
least three non-adjacent fields of cervical mucus on
Gram stain.
Results MG was found in 4.0% of women, MH in
17.1%, UU in 14.1%, and UP in 51.8%. MG was the only
mollicute associated with cervicitis (unadjusted
prevalence ratio (PR) 1.85, 95% CI 1.52 to 2.26,
p<0.0001), and this association remained after
adjustment for Chlamydia trachomatis (CT) infection
(adjusted PR 1.24 (95% CI 1.04 to 1.48), p¼0.02). MG
was significantly associated with women being HIV
positive (p¼0.03), but not with age, vaginal discharge,
commercial sex work, being of culturally and linguistically
diverse background, or concurrent CT infection. Two of
the 21 women with MG had ectopic pregnancies.
Conclusions The authors recommend wider application
of PCR testing for MG in STI services, particularly in
high-risk women and those with cervicitis or HIV
infection.
INTRODUCTION
Increasing evidence is emerging implicating Myco-
plasma genitalium (MG) as a genital tract patho-
gen.1e5 However, the potentially pathogenic roles
of other genital mollicutes, Mycoplasma hominis
(MH), Ureaplasma urealyticum (UU) and Ureaplasma
parvum (UP), are less well characterised.1 MG has
been associated with cervicitis1e3 endometritis1 4
and pelvic inﬂammatory disease.1 5
The objectives of this study were to determine
the population prevalence of MG, MH, UU and UP
and their associations with cervicitis, and to
examine clinical correlates of MG.
METHODS
A cross-sectional study was undertaken in two
urban Sydney sexually transmitted infection (STI)
clinics from June 2006 to January 2010. Ethics
approval was granted by South Eastern Sydney and
Illawarra Area Health Service human research
ethics committee and Sydney South West Area
Health Service ethics committee.
Participant selection
A total of 527 consecutive eligible consenting
women were enrolled, with 83% recruited from
a primary site. Both sites are part of a network of
public STI clinics in urban Sydney servicing the
same priority populations and are HIV referral
centres. Inclusion and exclusion criteria and sample
collection have previously been described.6 Of 570
eligible women, 527 consented (92.5%). All women
had cervical swabs tested for MG, MH, UU, UP and
Chlamydia trachomatis (CT). Cervicitis was deﬁned
as >30 polymorphonuclear cells per high-power
ﬁeld in at least three non-adjacent ﬁelds of cervical
mucus on Gram stain. Clinicians’ cervical Gram
stains for case deﬁnition of cervicitis were later read
by a single laboratory scientist blinded to clinical
diagnosis.
Nucleic acid extraction and PCR amplification
Specimens were extracted within 48 h of receipt,
stored, and subsequently tested in batches. Nucleic
acid extraction was carried out using a robotic
extraction machine (MagNAPure LC; Roche,
Mannheim, Germany) applying the ‘Total NA’
protocol.
Detection of the mollicutes MG, MH, UP and
UU involved a single-round multiplex PCR (mPCR)
(VDL06) followed by PCR ELISA. The VDL06
mPCR was carried out as described,6 except
reagents from the iScript One-Step RT-PCR kit
(BioRad, Hercules, California, USA) were used for
ampliﬁcation. The sensitivity of VDL06 mPCR has
been described previously.6 The speciﬁcity was
determined by DNA sequencing of the ﬁrst 10
positive samples of each mollicute from the study,
and resulted in 100% speciﬁcity. Chlamydia testing
was performed in a NATA-accredited diagnostic
laboratory, using a commercial assay (COBAS
Amplicor CT/NG multiplate ELISA; Roche)
following the manufacturer ’s instructions.
Statistical methods
Associations of mollicutes and CT with cervicitis
were estimated using prevalence ratios (PRs), 95%
CIs and p values. Given that the study was cross-
sectional and cervicitis is common, we calculated
PRs rather than ORs. Multivariate analysis in
logistic regression models involved forward selec-
tion including only covariates with p<0.05. MG
correlates were examined using c2 tests and t tests.
All analyses were performed with SAS V9.2.
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RESULTS
The prevalence of the mollicutes was: MG, 4.0%; MH, 17.1%;
UU, 14.1%; UP, 51.8%. CT prevalence was 5.7%. MG was the
only mollicute associated with cervicitis (unadjusted PR 1.85,
95% CI 1.52 to 2.26, p<0.0001), and this association remained
after adjustment for CT (adjusted PR 1.24 (95% CI 1.04 to 1.48),
p¼0.02) (table 1).
MG was signiﬁcantly associated with HIV positivity. Two of
the 21 women with MG were HIV positive (9.5%) compared
with 11 of 506 women without MG (2.2%) (p¼0.03). There was
no association between MG and age (p¼0.28), vaginal discharge
(p¼0.32), commercial sex work (p¼0.67), being culturally and
linguistically diverse (p¼0.95), or concurrent CT infection
(p¼0.44). Two of the 21 women with MG had an ectopic
pregnancy.
Mollicutes were found in 346/527 (65.7%) women, and, of
these, 95 (27.5%) had more than one species. UP occurred
signiﬁcantly more often as a single infection (72% of UP infec-
tions) (p<0.0001) in contrast with the other mollicutes, which
were more likely to coexist with other species.
The prevalence of cervicitis was 47.7%. Agreement between
the clinician and laboratory scientists’ Gram stain diagnosis of
cervicitis was 92.8% (k estimate 85.4%).
DISCUSSION
In this study of an STI clinic female population, the prevalence
of MG was 4.0%. This is similar to other high-risk populations:
6.3% in a Swedish STI population2 and 4.5% in a Norwegian STI
clinic setting,7 but lower than 8.7% in women having abortions
in New Zealand.8 Importantly, the prevalence of MG was
similar to that of Chlamydia, also noted in other STI clinic
populations.2 3 9
MG was the only mollicute signiﬁcantly associated with
cervicitis in this study. Evidence concerning the role of MG in
cervicitis is conﬂicting.1e3 10 Studies of associations of urea-
plasmas and MH with cervicitis are also inconclusive.1 The
prevalence of cervicitis in this study was high (47.7%), as noted
in other STI clinic populations.1 7
MGwas signiﬁcantly associated with HIV positivity (p¼0.03).
This association was also found in a study of West African
commercial sexworkers.3 AsHIV shedding is associatedwith high
MG organism burden,10 MG infection may facilitate HIV trans-
mission. We did not ﬁnd an association of MG with concurrent
CT infection, consistent with other studies,2 8 but not with
Huppert et al,9 who found an association in adolescent women.
Interestingly, two women with MG had ectopic pregnancies
within 1 month of study enrolment. As these data were not
speciﬁcally sought in all participants, we are unable to evaluate
the signiﬁcance of this. It may be a chance ﬁnding, but warrants
further investigation.
UP was very common (52%) and was usually found as a single
mollicute infection. This raises the possibility of a potential
probiotic effect of UP with respect to other mollicutes.
As this study involves a high-risk population, its applicability
to general populations is limited. In addition, sample size was
too small to detect weak associations. Strengths of the study
include robust case deﬁnition for cervicitis and high participa-
tion rate in a consecutive series of women.
In conclusion, we found that MG was the only mollicute
species signiﬁcantly associated with cervicitis, and MG was
associated with HIV positivity. We recommend wider applica-
tion of PCR testing for MG in STI services.
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We aim to characterize sexual behavioral aspects of heterosexualNeisseria gonorrhoea (NG) acquisition in two Sexually Transmitted
Diseases clinics in Sydney, Australia, in 2008–2012. Of 167 NG cases, 102 were heterosexually acquired with a trend of increasing
NG prevalence in heterosexuals from 1.1% (95% CI 0.6–2.1) in 2008 to 3.0% (95% CI 2.0–4.0) in 2012 (𝑃 = 0.027). Of heterosexual
male cases, unprotected fellatio was the likely sexual activity for NG acquisition in 21/69 (30.4%) and commercial sex work (CSW)
contact the likely source in 28/69 (40.6%). NG prevalence overall in CSW (2.2%) was not significantly higher than in non-CSW
(1.2%) (𝑃 = 0.15), but in 2012 there was a significant increase in NG prevalence in CSW (8.6%) compared to non-CSW (1.6%)
(𝑃 < 0.001). Pharyngeal NG was found in 9/33 (27.3%) female cases. Decreased susceptibility to ceftriaxone (MIC ≥ 0.03mg/L)
occurred in 2.5% NG isolates, none heterosexually acquired. All were azithromycin susceptible. A significant trend of increasing
prevalence of heterosexual gonorrhoea in an urban Australian STD clinic setting is reported. We advocate maintenance of NG
screening in women, including pharyngeal screening in all women with partner change who report fellatio, as pharyngeal NGmay
be an important reservoir for heterosexual transmission. Outreach to CSW should be enhanced.
1. Introduction
Latest surveillance indicates rising rates of Neisseria gonor-
rhoea (NG) in New South Wales, Australia [1]. The risk of
HIV transmission is significantly enhanced by coinfection
with NG [2, 3], and so the control of NG particularly in
light of increasing minimum inhibitory concentration (MIC)
values to ceftriaxone is a major public health concern [4, 5].
The predominance of gonorrhoea amongst Australian urban
men who have sex with men (MSM) is well documented
[1, 6] but heterosexual gonorrhoea in urban settings is less
well characterised. NG is a notifiable disease in Australia but
data is only collected by age, sex, and region of diagnosis
and so heterosexual trends are poorly defined. Trends of
increasing prevalence of heterosexually acquired NG and
acquisition from fellatio and commercial sex worker (CSW)
contact were noted in our suburban STD services in 2009,
prompting this investigation specifically aimed at examining
sexual behavioral aspects of heterosexual NG acquisition.
2. Methods
A case series was conducted from patient records at two
STD services in South Eastern Sydney over a 5-year period,
January 1, 2008 to December 31, 2012. Data was collected
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Table 1: Summary of heterosexual patients and NG cases 2008–2012.
2008 2009 2010 2011 2012 Overall
No. hetero patients (male and female) 875 1009 1102 1041 1091 5118
No. hetero male patients 473 529 577 539 599 2717
No. hetero female patients 402 480 525 502 492 2401
Total NG cases 18 35 27 33 54 167
Total hetero NG 10 26 13 20 33 102
Hetero male NG 5 19 11 13 21 69
Hetero female NG 5 7 2 7 12 33
Prevalence of NG in heterosexuals (%)∗ 1.14 2.58 1.18 1.92 3.02 2.0
No. female CSW 50 63 76 75 58 322
Mean age (yrs) hetero males with NG∗∗ 32.4 33.1 38.2 44.3 37.4 37.3
Mean age (yrs) hetero female with NG∗∗∗ 32.4 39.0 44.0 25.7 32.8 33.2
∗A significant trend of increasing NG prevalence in heterosexuals was noted over the 5 year period (𝑃 = 0.027).
∗∗No significant age trend in heterosexual male NG cases (𝑃 = 0.122).
∗∗∗No significant age trend in heterosexual female cases (𝑃 = 0.387).
prospectively from late 2009 when the study started but
retrospectively prior to this. These clinics operate in a cultur-
ally diverse suburban environment and offer free services by
triage to high risk patients defined by “priority populations”
specified in the 2010–2013 NSW Sexually Transmitted Infec-
tion (STI) strategy [7] (i.e., MSM, youth, CSW, multipart-
nered heterosexuals, intravenous drug users, HIV positive,
indigenous) and other symptomatic patients, contacts of
STDs, or those referred by General Practitioners (GPs).
NG cases were identified from the clinic database. All NG
cases were included whether detected by routine screening
or testing in symptomatic patients. Heterosexual acquisition
was defined as sexual activity not involving any same sex
contact in the preceding 12 months. Heterosexual patient
numbers were derived from total client numbers, minus
MSM and women who have sex with women (WSW). Likely
acquisition source and activity was identified from detailed
sexual histories, which routinely seek information on the
nature and timing of recent sexual contacts including number
and sex of consorts, type of sexual contact (oral, vaginal,
anal, insertive/receptive), and condom use for each activity.
In deciding the likely transmission mode and source of NG,
we took into account onset of symptoms and NG disease
incubation time.
Receipt of oral sex (fellatio) was considered the likely
route of NG infection when this activity occurred in isolation
without a condom or if this occurred concurrently with
vaginal or anal sex where a condom was used for the latter
activities but not for oral sex. A female commercial sex
worker was defined as a woman who stated she was currently
engaged in sex work. Local contact was defined as sexual
contact with a person in Australia.
Clinic policy states that all symptomatic patients are
tested for NG in the relevant anatomical site. MSM are
screened for NG in the rectum, urine, and throat, CSW are
screened in the throat and cervix or urine, heterosexual men
in the urine, and heterosexual women in the cervix or urine.
Cases diagnosed by PCR are also cultured where possible, in
order to ascertain antimicrobial susceptibility data. NG was
treated during the study with ceftriaxone 250mg IMI, and
this was increased to 500mg IMI from early 2010 in keeping
with local recommendations. Cefixime is not available in
Australia.
NG was cultured on selective media of lysed horse
blood agar containing vancomycin, colistin, nystatin, and
trimethoprim (VCNT) inhibitors. Antimicrobial suscepti-
bility testing was performed prospectively at the Neisseria
Reference Laboratory, Randwick, Sydney, a WHO Collab-
orating Centre for STD, using published methodology [8].
Decreased susceptibility of NG to ceftriaxone in extragenital
sites was reported when the MIC value was ≥0.03mg/L
and ≥0.06mg/L in genital sites [8]. All samples positive for
NG using Nucleic Acid Amplification Techniques (NAAT)
(Roche Amplicor PCR from study commencement to June
2011 and then from July 2011 by Roche Cobas 4800) were
confirmed by supplementary assays targeting porA and opa
genes as required by the National Testing Guidelines [9].
Proportions were compared using Chi-Square tests and
trends identified using a Mantel-Haenszel Chi-Square test
with SAS (version 9.2; SAS Institute Inc., Cary, NC, USA).
Ethics approval was granted by the South Eastern
Illawarra Area Health Service Ethics Committee.
3. Results
During the study 6164 patients were seen of which 5118
(83.0%) were classified as heterosexual and 1046 (17.0%)
MSM or WSW, with approximately equal numbers of male
(53.1%) and female (46.9%) heterosexual patients (Table 1).
There were 167 cases of NG, 102 (61.1%) heterosexually
acquired (overall prevalence 2.0%) and 65 (38.9%) MSM
acquired (overall prevalence 6.9%). Over the 5-year period
there was a significant trend of increasing NG prevalence in
heterosexuals rising from 1.1% (95% CI 0.6–2.1) in 2008 to
3.0% (95% CI 2.0–4.0) in 2012 (𝑃 = 0.027).
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Of heterosexual cases, 69 were males and 33 were females
(M : F ratio 2.1 : 1). 67/69 (97.1%) of heterosexual males and
25/33 (75.8%) of females had genital symptoms.
Receipt of unprotected fellatio was the likely source of
acquisition for 21/69 (30.4%) of heterosexual males (11/21
CSW related and 10/21 non-CSW related). Commercial sex
work (CSW) contact was the probable NG source for 28/69
(40.6%) of heterosexual males (18 CSW contacts local, and 10
whilst overseas). Only 7/33 (21.2%) of female cases reported
current CSW. Importantly, NG prevalence during the study
overall in CSW (2.2%) was not significantly higher than
in non-CSW (1.2%) (𝑃 = 0.15), but in 2012 there was a
significant increase in NG prevalence in CSW seen (8.6%)
compared to non-CSW (1.6%), 𝑃 < 0.001.
Of female cases, 31/33 (93.9%) reported unprotected vagi-
nal sex. Pharyngeal NG was found in 9/33 (27.3%) women, 5
of these CSW. NG was acquired locally in 24/33 (72.7%) of
females and 47/69 (68.1%) of heterosexual males.
137/167 (82%) of NG cases were diagnosed by positive
culture and 30/167 (18%) by positive PCR alone. Antimi-
crobial susceptibility data was available in 122/137 (89%)
of NG cases diagnosed by culture. Decreased susceptibility
to ceftriaxone was reported in 3/122 (2.5%), two pharyn-
geal and one rectal isolate all MSM related isolates, none
heterosexually acquired. Of the 122 isolates with antibiotic
susceptibility data, 55/122 (45.1%) were MSM related and
67/122 (54.9%) were heterosexually related. All NG isolates
were azithromycin susceptible.
4. Discussion
This study found an increasing prevalence of heterosexual
gonorrhoea in an urban Australian setting from 2008 to 2012,
a trend which may be contributing significantly to rising
NG notifications in Australia. At our services heterosexual
acquisition accounted for 61.0% (102/167) of NG cases. The
male : female ratio in heterosexual cases of 2.1 : 1 is compara-
ble to the overall national Australian surveillance ratio of 2 : 1
[10]. The overall study male : female ratio including the MSM
cases was 4.0 : 1, which is in marked contrast to our South
East Sydney local health district reported ratio of 8 : 1 where
NG detection predominates in the large MSM population
[1, 10].This reflects the lower proportion ofMSMattendances
at our clinics (25.8%) compared to inner city services. The
persistence of the 2 : 1male : female case ratio in heterosexuals
is interesting. Factors contributing to thismale predominance
in heterosexual NG case detection might include increased
likelihood of symptomatic disease and therefore detection
in males (and more asymptomatic disease in females), lack
of pharyngeal screening in females, suboptimal screening of
CSW and high risk females, and possibly some misclassifica-
tion of “heterosexual” acquisition. Enhanced surveillance of
NG might help to clarify this enigma.
Receipt of unprotected fellatio was the likely sexual
activity resulting in NG acquisition for 30% of heterosexual
men. Additionally the number of heterosexual male NG
cases due to fellatio may be underestimated in this study
if receipt of unprotected oral sex occurred in conjunction
with unprotected vaginal or anal sex. The pharyngeal NG
reservoir in MSM is well recognized [11, 12], but this reser-
voir could also be important in all women with partner
change who practice fellatio, not just CSW. This theory is
supported by the high transmission rate in heterosexual men
receiving fellatio and noting that equal numbers of fellatio-
related transmissions occurred inmen reporting contact with
CSW and non-CSW females. Oral sex is frequent amongst
heterosexuals and is typically unprotected. This combined
with lack of awareness of the associated STD transmission
risk, common perception that oral sex is not sex [13] and
infrequent pharyngeal screening in women, may facilitate
heterosexual NG transmission via this route. We isolated
pharyngeal NG from 27% of female cases (by culture), but
this is likely to be an underestimate due to clinic policy at the
time of only undertaking pharyngeal screening in CSW and
MSM. Increased uptake ofmore sensitiveNAAT testing in the
pharynx [14] is also likely to improve female NG detection.
Our findings in both men and women suggest that an NG
pharyngeal reservoir in women may be a common source
of NG infection for heterosexual males. A recent UK study
[15] also suggested that the pharynx may be an important
NG reservoir in heterosexual womenwith a similar finding of
30% of female NG cases being pharyngeal.We found that NG
infections in heterosexual menwere almost always associated
with genital symptoms (97.1%) but women less commonly so
(75.8%). Hence, asymptomatic screening in women may be
particularly important. Accordingly, our clinic guideline has
changed to recommend the maintenance of NG screening in
heterosexual women with additional pharyngeal NG screen-
ing in those women reporting partner change and fellatio.
As female cases generally reported unprotected vaginal sex
(93.9%), condom use is also reiterated.
CSW in Australia have low rates of STDs reflecting good
condom use [16]. However, a recent study of CSWs providing
fellatio in Sydney [17] found that Cantonese speaking women
were significantly less likely to use condoms for this service
thanThai-speaking and English-speaking CSW.Additionally,
women who do not identify as being CSW (e.g., working in
massage) may be less likely to engage in safe sex, including
safe oral sex [17]. Our study found that 40% of heterosexual
males reported CSW contact but only 21% of female cases
were CSW, an inconsistency which could reflect suboptimal
testing rates and outreach to CSW in our population. Impor-
tantly NG prevalence in female CSW overall was no different
from that in female non-CSW, except for the significant rise
noted in 2012. Of concern, however, was the finding that
2/3 of the NG infections related to CSW contact occurred
locally in Sydney, the rest acquired from overseas contacts.
This would suggest a need to enhance local educational and
testing services available to women engaged in CSW.
Three quarters of all infections were acquired from
local contact, reflecting the increasing local heterosexual NG
prevalence noted in this study and from local surveillance [1].
Numbers of NG cases rose in 2012 which is also in keeping
with the rise in local NG prevalence.
Antimicrobial susceptibility data was available for 89%
of cultured isolates. Decreased susceptibility to ceftriaxone
occurred in 3/122 (2.5%) isolates, all MSM related cases
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from extragenital sites. No decreased susceptibility was noted
in heterosexually acquired isolates but numbers are too
small to speculate on the significance of any difference in
antibiotic susceptibilities between these populations at this
time, but this should be the subject of ongoing monitoring
and surveillance to inform treatment recommendations in
these different populations. The finding of 3 isolates with
decreased susceptibility to ceftriaxone is consistent with the
right shift in MIC values to ceftriaxone reported locally
[4] and globally [5, 18] and cause for concern for disease
control in the absence of viable treatment alternatives if
resistance to ceftriaxone develops. All isolates were sensitive
to azithromycin. We recommend that cases positive by PCR
should also be cultured where possible for purposes of mon-
itoring NG isolate susceptibility. The widespread supplanting
of culture methods with PCR has the advantages of greater
sensitivity and no fuss specimen transport, but at the cost
of antimicrobial surveillance. STD services are best placed to
maintain this NG antimicrobial resistance surveillance role.
This study is limited by small numbers, reliance on patient
sexual histories, and its partially retrospective nature in two
triaged STD clinic populations within the same local health
district. Inevitably some definitions particularly relating to
transactional sex can become blurred and sexual histories are
reliant on patient recall and propensity to disclose the exact
nature of the contact. Some cases were unwilling or unable to
identify the likely source of the infection. Clinical judgment
was applied to determine the likely source of infection based
on disease incubation, onset of symptoms, and detailed
recent sexual history. Triage processes were unchanged over
the study period and priority population groups remained
relatively stable. Importantly antibiotic resistance testing was
prospective and performed in a reference laboratory, aWHO
Collaborating Centre for STD.
5. Conclusion
A significant trend of increasing prevalence of heterosexual
gonorrhoea in an urban Australian STD clinic setting is
reported. This study suggests that the pharynx may be
an important reservoir for heterosexual NG transmission,
and we advocate maintenance of NG screening in women,
particularly inclusion of pharyngeal screening in women
with partner change who practice fellatio. Case detection,
enhanced surveillance, and health promotion are pivotal
to NG control. Health promotion efforts should include
messages concerning STD transmission risks associated with
oral sex in heterosexuals, andwe recommend enhancedCSW
engagement with education and STD testing opportunities.
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